Printed Abstracts Only

PAO-1
Two cases of Fanconi-Bickel syndrome - first report from China
Zhe Su; Hua-mei Ma; Pi-mei Zheng
The First Affiliated Hospital of Sun Yat-Sen University, Pediatric Department, Guangzhou, China

Background: Fanconi-Bickel syndrome (FBS) is a rare autosomal recessive disorder of carbohydrate metabolism caused by mutations in Glut2. To date there is no case has been reported from China.

Objective and hypotheses: To summarize the clinical characteristics of FBS by reviewing the 2 cases and published literature.

Methods: We reported the first two cases of FBS in China. We summarized the clinical characteristics of FBS by reviewing the 2 cases and published literature.

Results: The both cases presented similar manifestations as reported, including severe short stature, hypoglycemia, hepatomegaly secondary to glycogen accumulation, severe glycuorenia secondary to proximal renal tubular dysfunction. And more points may help to differentiate FBS and type I glycogen storage disease (GSD I) including glucose intolerance with normal lactic acid and uric acid, possible and slightly glucose response to glucagon stimulation without accumulation of lactic acid, severe symptoms of hypophosphatemia and rickets, and metabolic acidosis caused by type II renal tubular acidosis. After receiving symptomatic treatment both children presented catch-up growth.

Conclusions: FBS is a rare inherited disease caused by mutations in Glut2. It should be carefully differentiated from GSD I and diabetes mellitus in clinical practice. Symptomatic treatment can be helpful.

PAO-2
Final height outcome of boys with central precocious puberty treated with gonadotropin-releasing hormone analogue
Pi-mei Zheng; Hua-mei Ma; Qiu-l Chen; Zhe Su
First Affiliated Hospital of Sun Yat-Sen University, Pediatric Department, Guangzhou, China

Background: Data on the final height outcome of boys with central precocious puberty treated with gonadotropin-releasing hormone analogues (GnRHa) are far less than those in girls.

Objective and hypotheses: To report the final adult height of 20 boys with central precocious puberty treated with gonadotropin-releasing hormone analogue (GnRHa).

Methods: Twenty boys with central precocious puberty treated with GnRHa at a dose of 60–80 μg/kg every 4 weeks for (20.5 +/- 6.7) months. At the beginning of therapy, mean chronological age and bone age was (11.2 +/- 1.0) y and (13.0 +/- 0.4) y, respectively. GnRHa was discontinued when the boys reached the chronological age and bone age of (13.2 +/- 1.1) y and (13.7 +/- 0.6) y, respectively. At the conclusion of the study, all the boys had been followed up for (3.3 +/- 1.5) yrs and had achieved adult height. Comparisons were made among their final adult height (FAH), target height (THt), predicted adult height (PAH) at the start and the end of GnRHa treatment (PAHi and PAHe).

Results: Final height was similar to the target height ([168.6 +/- 5.6]cm versus [167.8 +/- 4.6]cm) with no significant difference from the predicted adult height (PAH) ([169.8 +/- 6.0]cm versus [169.8 +/- 6.0]cm) based on the Bayley-Pinneau method, using a table for average bone age at the beginning of GnRH analogue therapy. Predicted adult height (PAH) at discontinuation of GnRHa therapy was significantly higher than predicted adult height at the beginning of GnRHa analogue therapy ([172.5 +/- 7.6]cm versus[168.6 +/- 5.6]cm, P<0.05). Ninety percent (90.0%) of the boys reached target height range (FAH/>=THt-1SD). The height gain in comparison with predicted adult height before the start of treatment was (-1.2 +/- 3.3) cm, with the residual growth capacity of (10.6 +/- 4.3)cm.

Conclusions: GnRHa treatment can improve final height into the range of target height in boys with central precocious puberty.

PAO-3
Prevalence of impaired glucose tolerance and insulin resistance among obese children and adolescents
Robabeh Ghergherehchi; Nazanin Hazhir; Ali Tabrizi
Tabriz University of Medical Sciences, Pediatric Endocrin, Tabriz, Islamic Republic of Iran

Background: Obesity is one of the most important nutritional disorders in the world which has an obvious relationship with the incidence of metabolic diseases. Obesity prevalence has increased among children and adolescents during recent decades, leading to a rise in Type 2 diabetes mellitus (DM II) prevalence in these two age brackets. Hence, the aim of this study was to assess impaired glucose tolerance and insulin resistance, and gather metabolic findings in obese children and adolescents.

Methods: We studied 110 obese children and adolescents (body mass index, 95th percentile for age and gender) 4–18 years of age referred to the endocrine clinic of the Children’s Hospital at Tabriz University in a descriptive cross-sectional study. Fasting glucose, insulin, and lipid profile in all subjects were determined. Oral glucose tolerance test after eating 1.75 g/kg glucose was performed. Homeostatic model assessment was used to estimate insulin resistance.

Results: Impaired glucose tolerance and insulin resistance prevalence in 68 obese adolescents was 14.7% and 31.8%, respectively. Impaired glucose tolerance was not seen in 23.8% of 42 obese children. No case of DM II was seen. There was a significant statistical difference in glucose (P = 0.003) and insulin (P , 0.001) level at minute 120 in individuals with impaired glucose tolerance compared to obese children and adolescents without impaired glucose tolerance. Rate of insulin resistance in patients with impaired glucose tolerance was greater and had a significant statistical difference (P = 0.03).

Conclusions: Obesity has a close relationship with increased risk of impaired glucose tolerance and insulin resistance in children and adolescents. Oral glucose tolerance test, unlike fasting glucose test, is a benefit test to predict impaired glucose tolerance. With prompt identification and treatment of obese children with impaired glucose tolerance, we can prevent it from progression towards DM II.

50th Annual Meeting of the ESPE
Horm Res 2011;76(suppl 2) 263
Introduction: In this study, we investigated the changes of serum levels of Free T4 and T3, T3 resin uptake (T3RU) and TSH in epileptic children during chronic treatment with anti-epileptic drugs (carbamazepine, Primidone, phenobarbital and valproate) and 3 months later than prescription.

Material and method: This study consisted of four case-series comparisons, was accomplished on 115 (in 4 same groups) epileptic children who were involved 37 girls and 78 boys with ages between 2 months up to 15 years (mean: 62.06 ± 44.97 months), who were taking either phenobarbital (n=29), PRM(n=28), CBZ (n=29), or VPA (n=29) for at least 3 months were evaluated T3, T3 resin uptake (T3RU), T4 and thyroid-stimulating hormone (TSH) levels in start and end of study.

Results: All patients were in euthyroid state, there were no clinical findings or laboratory results of hypothyroidism. In collation with thyroid hormones be-

Conclusions: Thyroid function should be evaluated intermittently in epileptic children using AEDs specially in long term prescriptions.

Background: The birth brain size - body size ratio has been related to fetal-neonatal stress.

Methods: 78 NBWs 1) free of diabetes mellitus (DM)/life-threatening disease, 2) free of mother with DM and 3) with all of the following variables could be not completely explained by preterm birth (PT) and intrauterine growth retardation (SGA).

Results: Table 1 shows t value (t), partial correlation coefficient (r) and significance level (p) of partial correlations of BRW with IB2/IB3x-ln, IB2/IB3y-ln and IB2/IB3z-ln as outcome and, as predictors, either 1) BRW, SEX, PT and SGA, or 2) BRW, SEX, PT, NBBW and PNA (Table 1A), or 2) BRW, SEX, PT, NBBW and PNA (Table 1B).

Conclusions: A direct BRW relation to IG1 was observed in studied NBWs after controls including PT and SGA, which could be in part explained by peripheral, i.e., not BRW-related, birth size.

Table 1. vs. A) IB2/IB3x-ln A) IB2/IB3y-ln A) IB2/IB3z-ln # B) IB2/IB3x-ln B) IB2/IB3y-ln B) IB2/IB3z-ln
BRW t/p 2.505/ 0.283a 2.812/ 0.315b 2.211/ 0.252a // 0.059/ 0.007ns 0.790/ 0.486c 0.301/ 0.035ms
R2/p 0.285c 0.459c 0.302c // 0.375c 0.486c 0.347c

Significances: a, p<.05; b, p<.01; c, p<.001; ns, not significant.

Table 1. vs. A) IB2/IB3x-ln A) IB2/IB3y-ln A) IB2/IB3z-ln # B) IB2/IB3x-ln B) IB2/IB3y-ln B) IB2/IB3z-ln
BRW t/p 2.489/ -281a 2.483/ -281a 2.946/ -281a // -0.733/ -0.665b -0.397/ -0.781ns -0.375/ -0.781ns -0.047/ -0.471ns
R2/p 0.405c 0.394c // 0.035c 0.425c 0.463c

Significances: a, p<.005; b, p<.005; c, p<.001; ns, not significant.

Conclusions: Inverse BRW relations to IB2/IB3 in studied NBWs after controls including PT and SGA could be in part explained by not BRW-related birth size.
Edema has been accepted as an uncommon complication occurring after initiating of insulin therapy in the absence of heart, liver or renal disease. In newly diagnosed type 1 diabetic children and adolescents insulin-induced edema should be considered after the initiation of insulin therapy.

Case report: A 13 year old boy was admitted with a one month history of polyuria, polydipsia, enuresis nocturna and also weight loss developed within last fifteen days. On admission, physical examination was normal except the mild dehydration. He had elevated blood glucose levels, 342 mg/dl and an elevated glycosylated hemoglobin A1c concentration of 11.5%. He had ke-}

PAO-7

**Insulin oedema in a newly diagnosed type 1 diabetic adolescent**

_Tolga Altug Pan; Meltem Ugrap; Adnan Narci; Özlem Güraşkin; Gülay Demircin; Faruk Alpay_

‘Ayon Kocatepe University Faculty Medicine, Pediatric Endocrinology, Afyonkarahisar, Turkey; ‘Ayon Kocatepe University Faculty Medicine, Pediatric Gastroenterology, Afyonkarahisar, Turkey; ‘Ayon Kocatepe University Faculty Medicine, Pediatric Surgery, Afyonkarahisar, Turkey; ‘Ayon Kocatepe University Faculty Medicine, Pediatrics, Afyon, Turkey; ‘Ayon Kocatepe University Faculty Medicine, Pediatric Nephrology, Afyonkarahisar, Turkey

50th Annual Meeting of the ESPE

examinations were normal. Doppler ultrasound findings of the lower leg arteries and veins were normal. After four days, the edema subsided spontaneously in parallel with a decrease in daily insulin doses, at a dose of 0.9 units/kg/day.

Discussion: Insulin edema is a poorly understood phenomenon, which is a rare complication of insulin therapy. Probably it is an underestimated complication, since most of the cases are mild. Here we reported a newly diagnosed type 1 diabetes case who developed insulin edema, in order to make physicians be aware of that rare complication. In most of the cases no therapy is needed and spontaneous resolution of the edema has been mentioned, as was the case in our patients.
Results: The study revealed that according to the glucometer’s readings the minimum glycemia level was 6.72±1.31 mmol/l; CGMS displayed 3.46±0.44 mmol/l (p <0.001). The maximum glycemia level was 14.93±1.15 mmol/l (glucometer) and 18.18±1.48 mmol/l (CGMS) (p < 0.01). The mean glycemia level was 9.76 mmol/l (glucometer) and 10.8 µmol/l (CGMS).

Conclusions: CGMS is able to reflect the adequate ratio of the hyper- hypoglycemia and normoglycemia and helps to reveal the most serious latent hypoglycemias which are difficult to detect with the glucometer. CGMS helps to detect the actual glycemia variability in patients. CGMS shows more accurate results in the mean glycemia measuring and improves glycemic control quality.

PAO-10

FTO-risk alleles had no impact on body composition and parameters of metabolism before and after a lifestyle intervention programme in obese children and adolescents

Stefan Ehrhard¹, Jessica Schum¹, Gunnar Blumenstock¹, Karin Weber¹; Roland Schweizer², Michael B. Ranke¹; Gerhard Binder¹;
¹University Children’s Hospital Tuebingen, Pediatric Endocrinology and Diabetes, Tuebingen, Germany; ²Eberhard-Karls-University Tuebingen, Department of Medical Biometry, Tuebingen, Germany

Background: Variants in the FTO (fat mass and obesity associated) gene are associated with early onset and severe obesity.

Objective and hypotheses: To investigate the impact of variants of the FTO gene (rs1421085, rs17817449, rs9939609) in obese children before and after lifestyle intervention.

Methods: 75 overweight children (40 male, mean BMI 30.4 ± 5.5 kg/m²; mean age 12.6 ± 2.6 years). Measurements: Genotyping by means of a TaqMan SNP genotyping assay. Lean and fat mass were determined by means of DXA. The lifestyle intervention program consisted of an increase in physical activity from one to two hours per day including all daily life activities and fitness training; nutritional recommendations based on the ‘Optimized Mixed Diet for German Children and Adolescents’ of the Research Institute of Child Nutrition, Dortmund, Germany.

Results: For the whole study population, the 6-month lifestyle intervention resulted in a significant improvement (before intervention minus time 6 months; mean ± SD) in BMI-SDS (0.10 ± 0.17, p < 0.001), HOMA (1.41 ± 3.19, p<0.001) and relative fat-mass-SDS (0.09 ± 0.23, p=0.005). Before and after lifestyle intervention, there was no significant difference between heterozygote (n=52) and homozygote (n=21) carriers of the FTO gene in terms of BMI, body composition, and the metabolic profile (Insulin, HOMA, lipids, liver function tests).

Conclusions: Variants in the FTO gene are common in obese children. However, they seem to have no impact on body composition and metabolism before and after lifestyle intervention.

PAO-11

Hypovitaminosis D in a population of foreign adopted or migrant children in Italy

Salvatore Seminario¹, Marta Genaro²; Laura Nanni³; Fiorella Galluzzo³; Luisa Galli; Giuseppina Veneruso; Perla Scalini³
¹University of Florence, Department of Sciences for Woman and Child’s Health, Florence, Italy

Background: Rickets vitamin D-dependent is highly prevalent in developing nations; however, the prevalence of hypovitaminosis D is underestimated in developed nations.

Objective and hypotheses: To compare serum level of 25(OH)D in a population of Italian healthy children versus a population of adopted or migrant foreign children.

Results: The study revealed that according to the glucometer’s readings the minimum glycemia level was 6.72±1.31 mmol/l; CGMS displayed 3.46±0.44 mmol/l (p <0.001). The maximum glycemia level was 14.93±1.15 mmol/l (glucometer) and 18.18±1.48 mmol/l (CGMS) (p < 0.01). The mean glycemia level was 9.76 mmol/l (glucometer) and 10.8 µmol/l (CGMS). According to the CGMS results the patients were in the normoglycemia conditions during the 73% of the whole research period, hyperglycemia was registered at 24.69%; and hypoglycemia was registered at 3.47%. The readings of the regular glucometer showed normoglycemia at the 52% of the whole period, hyperglycemia at the 48%; hypoglycemia wasn’t revealed. The initial HbA1C level was 7.95%; after the three month it decreased to 7.41%(p > 0.05). The lack of accuracy may be caused by the limited sampling.

Conclusions: CGMS is able to reflect the adequate ratio of the hyper- hypoglycemia and normoglycemia and helps to reveal the most serious latent hypoglycemias which are difficult to detect with the glucometer. CGMS helps to detect the actual glycemia variability in patients. CGMS shows more accurate results in the mean glycemia measuring and improves glycemic control quality.

PAO-12

Parental consanguinity among parents of infants with congenital hypothyroidism in Hamedan

Zahra Razei
Hamedan University of Medical Sciences, Paediatric Endocrinology, Hamedan, Islamic Republic of Iran

Introduction: Congenital hypothyroidism is inadequate thyroid hormone production in newborn infants. This can occur because of an anatomic defect in the gland, an inborn error of thyroid metabolism, or iodine deficiency. It is the most common congenital endocrine disorder. According to published studies the incidence of congenital hypothyroidism (CH) is high among Iranian population. The purpose of this study was to determine rate of consanguinity among parents of infants with congenital hypothyroidism.

Methods and materials: This descriptive study was conducted in infant diagnosed to have congenital hypothyroidism, between 1385-1389. All infants with biochemically confirmed CH (low T4, and TSH- 10IU/mL in venous blood were enrolled in this study. A detailed record of the required information was made. The data was manually extracted and displayed in a descriptive manner. p-value less than 0.05 was defined as statistically significant.

Results: The study population consisted of 150 infants with CH (72(47%) females and 78(53%) males. Of the neonates with congenital hypothyroidism 28% had relative parents and in 72%, parents were not relative. In Control group, 20 neonats (14%) had relative parents and 86% parents were not relative. The difference between two groups was significant p=0.005. There were no significant differences in sex ratio seasonally, order of birth and mean age of mother at delivery of infant with congenital hypothyroidism and control group (p=0.05).

Conclusion: The results of this study suggest infant of consanguineous parents are at greater risk for of congenital hypothyroidism than the rest of population.

PAO-13

Bone health and physical activity in Danish children, an intervention study

Malene Heidemann¹; Steffen Husby¹; Anders Schou¹; Niels Wedderkopp¹; Christian Malgaard²
¹Institute of Clinical Research, SDU, Department of Paediatric Research Unit, Odense, Denmark; ²H. C. Andersen's Children Hospital, Odense University Hospital, Odense, Denmark; ³Hospital Lillebaest, Spine Center of Southern Denmark, Middelfart, Denmark

Background: Peak bone mass is an important determinant of adult risk for osteoporosis. Factors, which determine bone mineral density (BMD) and bone mineral content (BMC) in children, are not fully understood. Studies indicate that both genetic factors and lifestyle, such as diet and physical activity during early childhood can contribute to bone mass development.

Methods: Group 1 included 121 healthy children born in Italy or living in Italy since at least 1 year (78 females and 43 females, mean age 9.5±4.1 years). Group 2 included 168 adopted or migrant children living in Italy since less than 1 year (62 females, 106 males, mean age 5.45±3.1 years); the geographical area of Sub-Saharan Africa (n=29), Latin America (n=36), Eastern Europe (n=37), Russia (n=24), Southeast Asia (n=25), Indian subcontinent (n=17).

Results: In group 1 mean serum level of 25(OH)D was 25.3±11.1 ng/mL; 34.7% of children was vitamin-D deficient and 39.6% was insufficient. In group 2 mean serum level of 25(OH)D was 29.0±17.9 ng/mL (significantly higher compared to group 1, P=0.04); 29.8% of children was vitamin-D deficient and 29.8% was insufficient. The subgroup from Southeast Asia had better levels of 25(OH)D (40.2±24.3 ng/mL) compared to the other subgroups. Comparing group 1 versus group 2 without subgroup from Southeast Asia (n=143), mean 25(OH)D 27.0±15.9 ng/mL), we found no significant differences (P=0.05).

Conclusions: Hypovitaminosis D is highly prevalent in both Italian (74.3%) and adopted or migrant children (59.6%); if we exclude subgroup from Southeast Asia the prevalence in group 2 raises to 65.7%. We have no explanation for the higher levels of 25(OH)D found in this subgroup (Philippines, Cambodia and Vietnam).
Objective and hypotheses: The aim of the study is to assess the effect of physical activity on BMD, BMC and bone area (BA) in healthy Danish children. The study also aims to evaluate the relationship between fracture risk and BMD.

Method: The study is a three year controlled intervention study from August 2008 to February 2011. 684 children participated. Anthropometrics was registered every four month. X-ray of the left hand-wrist was taken at baseline and after the intervention for assessment of bone age. The children’s level of physical activity was recorded by accelerometers. Information about fractures was received through questionnaires and SMS-track.

Results and perspectives: Preliminary analysis has revealed, that the children in the two groups were similar regarding to anthropometrics, motor performance and aerobic fitness at baseline. Results from the DXA scans will be correlated to fracture risk and the two groups will be compared regarding BMD, BMC and BA values.

Conclusions: The data collection has just been completed and the results will be processed through the following months.

PAO-15

A peculiar cognitive and behavioural phenotype as the first clue to suspect Klinefelter syndrome in prepubertal males

Maria Francesca Messina; Fortunato Lombardo; Valentina Comito; Tommaso Aversa; Danila Pecoraro; Mariella Valenzise; Filippo De Luca University of Messina, Department of Pediatrics, Messina, Italy

Background: Klinefelter syndrome (KS) is the most frequent chromosomal aneuploidy with a prevalence of 1 in 700 males and, although the classical clinical picture is well-known and easily recognizable, most patients remain undiagnosed. The rate of diagnosis is extremely low in childhood and only 10% of cases are identified before puberty because the classical signs and symptoms of androgen deficiency appear only latter in adolescence. A common element, often underappreciated, in these young boys is the peculiar cognitive and behavioural pattern.

Case report: We describe two patients who were diagnosed in prepubertal age, respectively at 7.1 and 10 years, due to a peculiar neurocognitive profile. Both of them showed on WISC III low-normal scores, i.e. FSIQ, PIQ and VIQ ranging between 80 and 85 and a behavioural profile characterized by immaturity, insecurity, shyness and low-self esteem, learning disabilities and academic difficulties. On clinical examination both of them showed a height taller than target height and a progressive growth acceleration between 5 and 7 years, and from the pubertal point of view they had pubertal testicular volume (< 2 cc) and one of them had hypoplastic ischrcum with monolateral cryptorchidism. Hormonal profile confirmed normal prepubertal basal levels of gonadotropins.

Conclusions: We believe that to achieve the goal of an early diagnosis in KS, it is necessary to increase the medical awareness of the disease and in particular to augment paediatricians’ knowledge that in prepubertal age pathognomonic endocrinological features of KS are often lacking but a peculiar cognitive and behavioural pattern is always present, especially when accurately searched.
PAO-17

Thrombocytopenia in a girl with idiopathic central precocious puberty treated with long-term gonadotropin hormone agonists (GnRHa)

Marina Krsteva-Konstantinova; Aleksandra Janchevska; Zoran Gucev
University Children's Hospital Skopje, Endocrinology and Genetics, Skopje, Macedonia, FYrom

Background: Central precocious puberty (CPP) is a frequent endocrine problem in childhood. The idiopathic and organic etiology of CPP are most commonly treated with GnRH agonists. They have been considered in many studies to be safe and effective.

Case report: We present a 7 year old girl with idiopathic CPP diagnosed by standard GnRH testing. She developed severe thrombocytopenia during GnRH treatment. The familial history showed that the mother has been treated 8 years for infertility. The pregnancy was controlled and uneventful. At the time of diagnosis her weight was at the 75th percentile and she was 130.5 cm tall on the 97th percentile. The Tanner stage was B3, A1, P1. The bone age was advanced to 8.5 years. Before the treatment she was otherwise healthy.

All laboratory evaluations were normal from blood count to thyroid function and brain imaging techniques. After receiving her 9th monthly depot therapy of GnRH agonist, triplorelin acetate, 3.75 mg i.m., she developed bleeding

Methods:

Objective and hypotheses:

Background:

Objective and hypotheses:

Results:

Conclusions:

To our knowledge, thrombocytopenia has not been yet reported in children receiving GnRH agonist treatment. This may represent a possible serious adverse effect which needs further investigation.

PAO-18

Peripheral blood karyotype poorly represents tissue mosaicism determined by FISH and QF-PCR - a case report

Dóra Tóth1; Irén Halbrich2; Bálint Nagy3; Zsuzsa Tóth1; Zsolt Jórdás2; Andrea Luczay1
1 Semmelweis University, 2nd Department of Pediatrics, Budapest, Hungary; 2 Semmelweis University, 1st Department of Obstetrics and Gynecology, Budapest, Hungary; 3Bethesda Children's Hospital, Department of Surgery, Budapest, Hungary

Background: Cytogenetic analysis in disorders of sexual differentiation is routinely performed on peripheral blood lymphocytes. The presence of Y chromosome material in the gonads is of major interest because of the risk of gonadoblastoma development. However, there is a lack of evidence whether the gonadal karyotype is congruent with lymphocyte karyotype.

Patient and methods: A three-week-old boy with normal male genitals presented with left inguinal hernia and cryptorchidism. The inguinal hernia surgery revealed an unusual anatomic situation. His free testosterone was normal (23.21 pg/ml). Peripheral blood karyotype was mos 45,X[25]/46,X,i(Y)(p10), ish idic(Y)(q11)(DXZ1++)[Y][6]. An SRY duplication was detected by FISH.

Histological examination found an immature testis on the left, a dysgenetic gonad on the right side and a uterus-like organ. Based on the different degree of differentiation of the two gonads and the normal hormone production we hypothesized that the mosaicism -namely the ratio of Y chromosome- may vary from loci to loci, moreover in some tissues might be significantly different from that of the peripheral lymphocytes. To test this hypothesis blood, gonad and subcutaneous fibroblast samples were analyzed by FISH and QF-PCR.

Results: The X:Y ratio was normal in the tests and nearly 2:1 in the blood, fibroblast and a dysgenetic gonad samples by QF-PCR. However, FISH analysis in the tests have found one X centromere in 60% and presence of different mosaic SRY+ cell lines (with single or double SRY signals) in 40% of cells (nuc ish(DXZ1+)(SRY-)[201]/(DXZ1+)(SRY+)[88]/(DXZ1+)(SRY++)[52]/(DXZ1-)(SRY+)[12]).

Conclusions: Our case underlines that peripheral blood lymphocyte karyotype might not provide a reliable representation of specific tissue karyotypes. Future studies may prove whether Y chromosome material present in the gonads would be completely absent or undetected in lymphocytes. Peripheral blood is an easy and reliable source of material for cytogenetic analysis, however, the interpretation of test results might require caution.

PAO-19

Complete catch-up growth in a neglected case of hypoaldosteronism a year after starting therapy

Noura Athemaid1; Ashraf Soliman; Amal Sabt; Ahmed Elawwa
Hamad Hospital, Pediatric, Doha, Qatar

Background: Early growth impairment may be a Sequel of untreated hypoaldosteronism in infants.

Objective and hypotheses: To study the growth pattern of an infant with neglected hypoaldosteronism after treatment for 3 years.

Methods: This boy presented at the age of one year, with recurrent vomiting and poor growth. He was a product of full-term pregnancy and normal vaginal delivery. Birth weight = 3.1Kg, length = 50 cm. His parents were first-degree cousins. He had five sisters and one brother, all were healthy. He was on formula feeds and started weaning at six months of age, with good appetite and normal bowel motion. He showed delayed gross motor milestones (can sit but can not stand at 1 y) with normal other developmental parameters. Examination revealed fair general condition, with mild dehydration with no pallor, jaundice, dysmorphic features or pigmentary changes. Vital signs including blood pressure were normal. His weight = 6Kg, length = 67.5cm (LSDS = -3), HC= 41.5cm (all <5th centile). The rest of exam was unrevealing.

Results:

Conclusions: Our case underlines that peripheral blood lymphocyte karyotype might not provide a reliable representation of specific tissue karyotypes. Future studies may prove whether Y chromosome material present in the gonads would be completely absent or undetected in lymphocytes. Peripheral blood is an easy and reliable source of material for cytogenetic analysis, however, the interpretation of test results might require caution.

Linear growth before and after treatment

Printed Abstracts Only
Methods: 58 children with DMT1 were included into this research and divided depending on gender and pubertal stage.

Objective and hypotheses: The study aim was to assess nutritional stereotyping during the first year of life. Complete catch-up of growth was achieved during the first year of treatment.

Conclusions: Hypoaldosteronism may present with severe growth retardation during the first year of life. Complete catch-up of growth was achieved during the first year of treatment.

PAO-21

Do we need to change the policy of hydrocortisone administration by emergency personnel?

Rebezkah Pryce

Abertawe Bro Morgannwg Healthboard, Department of Paediatrics, Swansea, United Kingdom

Background: An 8 year old male with congenital hypopituitarism requiring hydrocortisone, growth hormone and thyroxine replacement had an episode of unresponsiveness whilst at school. There was a health care plan in place with appropriate advice suggesting an oral dose of hydrocortisone and if the patient remained unwell to call an ambulance so that intramuscular hydrocortisone could be administered. The patient was brought to hospital where it was evident that the ambulance team were unable to administer intramuscular hydrocortisone as the diagnosis was not that of Addison’s disease.

Objective and hypotheses: To review the pre hospital management of adrenal crisis.

Methods: The paediatric population of Swansea with conditions that require long term steroid dependence.

Results: There are currently 13 paediatric patients in Swansea requiring hydrocortisone administration, none of whom have Addison’s disease as the underlying diagnosis. All Ambulance crew carry hydrocortisone in their emergency equipment. However current guidelines (1) state this can only be administered in the case of Addisonian crisis. This is interpreted to mean that if the diagnosis is not Addison’s disease then Hydrocortisone is not administered. None of our patients would have the necessary medication administered by the ambulance crew if they presented in an adrenal crisis. This represents a clinical risk causing a delay in administration of potentially life saving medication. This risk currently applies across Wales and the rest of the UK as all ambulance crew follow these guidelines and are advised not to deviate away from it.

Conclusions: A significant proportion of paediatric patients requiring long term hydrocortisone replacement do not have Addison’s disease as the underlying cause and would not be given the appropriate resuscitation medication in the UK. It is important that this is recognised so that future guidelines can be amended. In the meantime, patients can be registered with the ambulance authorities so there is an alert that hydrocortisone may need to be administered.

PAO-22

Diabetes influence on nutritional stereotype and children’s quality of life

Ekaterina Lepetilo; Anjelika Solnceva; Liudmila Viazava

Belarusian State Medical University, Pediatrics, Mirak, Belarus

Background: Diabetes mellitus type 1 (DMT1) can influence on life quality and emotional stability in children.

Objective and hypotheses: The study aim was to assess nutritional stereotype’s influence on emotional status and life quality in children with DMT1 depending on gender and pubertal stage.

Methods: 58 children with DMT1 were included into this research and divided to 4 groups depending on gender and pubertal stage. Group A (n=14) and B (n=15) included early pubertal boys at age 10,1±2,1 years and girls (10,1±2,1 years) respectively. Group C (n=14) and D (n=15) ~ late pubertal boys at age 15,1±2,2 years and girls (15,1±2,2 years) equally. Patients were interviewed by self-report questionnaires (Diagnostic Interview for psychological disturbances in childhood and adolescence (DIPS-K)) with point estimation. All foodstuffs were divided into 3 groups: allowed, with the limited use and prohibited. Questions about fast food using were separated from other. Glycosylated haemoglobin (HbA1c), daily usual glycemia, insulin doses were also estimated. All patients got insulin therapy in intensive regimen. Statistical analysis were performed by using T-test (p<0,05).

Results: Forbidden products increasingly used for food in groups A and B (p<0,05). Useful products prevailed in groups C and D (p=0,05). 20% children from A and B groups used fast-food in everyday life, 11% - during weekends; 50% and 17% from group C, 8% and 0% from group D respectively.

Conclusions: Fast-food consumption frequency in late pubertal boys higher than in other groups. Intensity of life quality’s dissatisfaction and anxiety about the future relate from the disease duration.

PAO-23

Values of levels of IGF-1, IGFBP-3 and urinary GH to diagnose of short stature

Said Ismailov1; Barno Nazarova2

1Center of Endocrinology, Sugery, Tashkent, Uzbekistan; 2Center of Endocrinology, Pediatric Endocrinology, Tashkent, Uzbekistan

Background: Levels of IGF-1, IGFBP-3 and also urinary GH (uGH) are recognized by markers of GH deficiency and have diagnostic value in various variants of short stature.

Objective and hypotheses: To define differences of IGF-1, IGFBP-3 and uGH values in various variants of short stature.

Methods: We have examined 147 subjects (85 boys and 62 girls), aged 3-18 yrs (mean age 11±3,9yr.) with short stature and 20 healthy children (10 boys and 10 girl). Serum levels of IGF-1, IGFBP-3 and uGH were measured by IRMA (Immunotech, Beckman Coulter).

Results: The obtained data of laboratory researches of levels of IGF-1, IGFBP-3 and uGH are given in the table. GH excretion and basal levels of IGF-1 and IGFBP-3 were lower in growth hormone deficiency, hypothyroidism and raised in case of familial short stature in compare with healthy children.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total No. (%)</th>
<th>urinary GH, ng/ml</th>
<th>IGF-1, ng/ml</th>
<th>IGFBP-3, ng/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth hormone deficiency</td>
<td>53(36,0%)</td>
<td>0,6±0,84*</td>
<td>97,9±66,9*</td>
<td>1849,0±876,2</td>
</tr>
<tr>
<td>Constitutional growth delay</td>
<td>20 (13,6%)</td>
<td>1,4±0,9*</td>
<td>222,9±92,2***</td>
<td>3217,0±584,6***</td>
</tr>
<tr>
<td>Familial short stature</td>
<td>15 (10,2%)</td>
<td>2,3±1,2***</td>
<td>242,2±38,4***</td>
<td>3916,0±49,0***</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>15 (10,2%)</td>
<td>0,9±0,8*</td>
<td>135,7±25,4**</td>
<td>3100,0±125,4**</td>
</tr>
<tr>
<td>Genetic syndromes</td>
<td>15 (10,2%)</td>
<td>1,2±0,7**</td>
<td>53,3±48,8**</td>
<td>1308,0±266,9</td>
</tr>
<tr>
<td>Other medical causes</td>
<td>14 (9,6%)</td>
<td>1,4±0,8**</td>
<td>187,0±36,4**</td>
<td>2591,0±516,7</td>
</tr>
<tr>
<td>Turner syndrome</td>
<td>9(6,1%)</td>
<td>1,4±0,16***</td>
<td>69,3±7,35***</td>
<td>1728,4±68,5</td>
</tr>
<tr>
<td>Skeletal dysplasia</td>
<td>6 (4,1%)</td>
<td>1,63±0,9***</td>
<td>128,9±101,0***</td>
<td>2430,0±169,7</td>
</tr>
<tr>
<td>Healthy children</td>
<td>20</td>
<td>7,5±2,5</td>
<td>414,0±212,1</td>
<td>1925,0±500,1</td>
</tr>
</tbody>
</table>

P - differences between group of healthy children:* p<0,001; ** p<0,01; *** p<0,05.

Conclusions: Complex measurement of levels of IGF-1, IGFBP-3 and uGH allows to improve the diagnoses of endocrine variants of short stature.
Descriptive study on growth of small for gestational age (SGA) babies in a multi-ethnic population

Sharon Lim
Broomfield Hospital, Paediatric, Chelmsford, United Kingdom

Background: The childhood population under study is approximately 200,000 with an annual birth rate of approximately 11,000.

Objective: In this prospective observational study, the aim was to collect data on parental ethnicity, educational attainments, social habits, medical history and aetiology of SGA babies till the first birthday.

Methods: SGA babies were defined as birth weight or length less than the third percentile for gestation. Measurements were converted to SD scores. Mothers of SGA babies were interviewed by one of the authors using a standardised questionnaire. Babies were measured using a stadiometer and weighed using digital weighing scales.

Results: 24 mothers were interviewed. Growth data was available for all babies except 1 final measurement. Only 5 out of 24 mothers were Caucasian, 14 were Asian, 3 were mixed and 1 was African. Mean maternal age was 31 (range 21 - 40yrs). 2 admitted to smoking before and during pregnancy. 10 admitted to alcohol intake prior to getting pregnant, with 3 continuing to drink in pregnancy. Birth weight SDS ranged between -2.7 to -1.3, mean -1.8, weight SDS at 1 year ranged between -2.2 to 1.1, mean -0.7 (see chart).

Conclusions: It was possible but difficult to study this largely multiethnic group of families (hence the small numbers). Data obtained can be used in future to compare with other populations and with the comparisons, possible factors may be identified to be more strongly linked to having a SGA baby.

Serum IGF-1 and IGFBP-3 levels in central precocious puberty girls with gonadotropin releasing hormone agonist (GnRHa) treatment

Kyung Hee Yi¹; Eun Young Kim²
Wonkwang University Sanbon Medical Center, Pediatrics, Gunpo, Gyeonggi province, Republic of Korea; °Chosun University School of Medicine, Pediatrics, Gwangju, Republic of Korea

Purpose: To investigate changes of serum IGF-1 and IGFBP-3 levels during one year gonadotropin releasing hormone agonist (GnRHa) treatment in central precocious puberty (CPP) girls.

Methods: From 2007 through 2009, twenty six girls were enrolled in this study. They were diagnosed as central precocious puberty and were treated with GnRHa (Leuprolide acetate) for one year. Height, bone age, IGF-1, IGFBP-3 were evaluated every 6months.

Results: From 2007 through 2009, twenty six girls were enrolled in this study. They were diagnosed as central precocious puberty and were treated with GnRHa (Leuprolide acetate) for one year. Height, bone age, IGF-1, IGFBP-3 were evaluated every 6months.

Albright hereditary osteodystrophy phenotype and 2q37: a familial case report

Cécile Etoubleau¹; Fanny Laftargue¹; Sandrine Perine²; Florence Compagni¹; Cécile Laroche-Raynaud¹; Anne Lienhardt-Roussie³; Catherine Verdy³; Zehra Ayancı⁴; Ece Böber⁵; Feyza Darendellievi⁶; Firdavs Bas⁷; Korcan Demir⁸; Pinar Isguven⁹; Erdal Ada²; Oya Ercan¹⁰; Merih Berberoglu¹; Sukran Darcan¹; Omer Faruk Tarım¹; Banu Kuckemre Aydınlı¹; Zeynep Sikiali¹; Demira Gokser¹; Oltay Evliyagilı¹; Sule Can¹; Zehra Ayancı¹⁰; Dökuz Eylül University, Department of Pediatric Endocrinology, İzmir, Turkey; ¹Istanbul University, Istanbul Faculty of Medicine, Department of Pediatric Endocrinology, Istanbul, Turkey; ²Goztepe Education and Investigation Hospital, Department of Pediatric Endocrinology, Istanbul, Turkey; ³Bakırköy Maternity and Children Education Hospital, Department of Pediatric Endocrinology, Istanbul, Turkey; ⁴Dr. Sami Ulus Women Health, Children’s Education and Research Hospital, Department of Pediatric Endocrinology, Ankara, Turkey

Background: Determinants of first-year response to growth hormone (GH) are not well established in children with brain tumor.

Objective and hypotheses: To retrospectively analyze first-year response to GH in children with brain tumor registered in KIGS (Pfizer International Growth Database) Turkey.

Methods: Among 53 eligible patients, 9 were excluded due to a follow-up period of under 9 months and 7 due to lack of relevant data. Remaining patients were divided into two as Group 1 (change in height SD score <0.5, n=15) and Group 2 (change in height SD score >0.5, n=22), which were compared regarding clinical and laboratory variables. Correlation analysis, receiver operating characteristic (ROC) curve, and logistic regression analysis were used to further assess the association of follow-up variables with the degree of height gain.

Results: Thirty seven cases [M/F: 17/20; median (interquartile range) age 11.8 (8.9-13.7); ratio of pubertal patients, 28%] were included in the study. Majority of the patients were suffering from craniopharyngioma (n=15, 41%) or medulloblastoma (n=12, 32%). Median (interquartile range) value for height SD score at the start of treatment was 2.83 (-4.01 – -1.93) and duration of follow-up 2.7 years (1.35-4.93). Higher age and height SD scores and greater number of cranial tumors distant from pituitary/hypothalamic area were found in Group 2. Age (r=-0.462, p=0.004) and height SD scores (r=-0.419, p=0.01) at the start of GH were moderately negatively correlated with first-year response. ROC curve analyses provided cut-off levels for age (>9.75 years) and height (>3 SD score) for prediction of poor first-year response. Risk of poor first-year response increased 2.9 times per 1 SD score increase in height and 1.6 times per 1 year increase in age.

Conclusions: Poor response to GH treatment in children with brain tumor is associated with some clinical variables, which might serve to make treatment modifications.

Albright hereditary osteodystrophy phenotype and 2q37: a familial case report

Cécile Etoubleau¹; Fanny Laftargue¹; Sandrine Perine²; Florence Compagni¹; Cécile Laroche-Raynaud¹; Anne Lienhardt-Roussie³; Catherine Verdy³; Zehra Ayancı¹⁰

Background: We report on one case of pseudopseudohypoparathyroidism related to SALL1 deletion. MC presents an Albright Hereditary Osteodystrophy phenotype including short stature, obesity, mental retardation, brachydactyly and mild facial dysmorphic features. Plasma calcium, phosphate, parathyroid hormone (PTH) levels and Gsα activity were normal. The chromosomal analysis showed an unbalanced (2;10) translocation inherited from his mother that led to monosomy for the distal 2q and trisomy for the distal...
Objective: To study the percentage of patients with Type 1 DM that presents initially with DKA as this is a good indicator of public health knowledge about diabetes in the pediatric age group.

Method: A retrospective study to evaluate charts of patients seen regularly in Aseer Diabetes Center (ADC) over a period of 10 years from 1st Jan 2000 till 31 Dec 2009 whether they present initially in DKA or not.

Result: A total of 614 patients with Type 1 DM were registered. Among them 487 patients with completed data, 228 patients were seen in DKA as initial presentation.

Results:

A total of 614 patients with Type 1 DM were registered. Among them 487 patients with completed data, 228 patients were seen in DKA as initial presentation.

Conclusions:

We demonstrated novel ethnic- and gender-based inequities in the evaluation of referred short children. We found that the current evaluation of short stature in our area does not comply with existing guidelines.
PAO-32

Growth and weight-regulation disorders in children are not commonly associated with mutations of the ghrelin and GH secretagenous receptor (GHSR) genes

Ora Hees¹; Gadir Elias¹; Tal Almagor¹; Osnat Admoni¹; Morad Khayati¹; Stavit Saley-Allon¹; Yarden Tenenbaum-Rakover¹

¹Ha'Emek Medical Center, Pediatric Endocrine Unit, Afula, Israel;
²Ha'Emek Medical Center, Genetic Institute, Afula, Israel

Background: Ghrelin and its receptor, growth hormone secretagenous receptor, GHSR, play a major role in appetite control and growth regulation. To date, only four confirmed mutations in the GHSR gene have been identified in children with obesity and short stature, while no such mutations have been found in the ghrelin gene.

Objective and hypotheses: In the current study, we tested the hypothesis that mutations in ghrelin or GHSR will result in subjects being either over or underweight, and exhibiting abnormal growth.

Methods: Ninety-five subjects (37F:58M) were enrolled with FTT (10 pts), GHD (45 pts), ISS (18 pts) or obesity (22 pts). Both ghrelin and GHSR genes were sequenced.

Results: Seven different sequence changes were identified (66.3%) in GHSR, two of them novel and five described previously. None of the sequence changes identified in the GHSR gene changed the sequence of the encoded protein. The prevalence of these sequence changes did not differ between the subgroups. One previously described sequence change, Leu72Met, within the preproghrelin/ghrelin gene was identified in two patients (2%), one with FTT and the other with obesity and partial GHD. This sequence change, which had been identified previously in obese women, is located on exon 2 outside the coding region of the mature ghrelin.

Conclusions: Our results suggest that mutations of the ghrelin and GHSR genes are not commonly associated with growth and weight-regulation disorders in children.

PAO-33

The relationship between initial BMI and BMI change during 1-year of GnRH agonist therapy in girls with idiopathic central precocious puberty

JuYoung Yoon; Sei Won Yang; Young Ah Lee; Min Jae Kang; Sinni Kim; Jeun Lee; Choong Ho Shin

Seoul National University Children’s Hospital, Department of Pediatrics, Seoul, Republic of Korea

Background: Childhood obesity is associated with early pubertal development, and early sexual maturation is associated with increased prevalence of obesity. Above-average BMI is frequent at diagnosis of central precocious puberty (CPP).

Objective and hypotheses: The purpose of this study is to evaluate the relationship between initial BMI and BMI after 1 year of GnRH agonist (GnRHa) therapy in girls with idiopathic CPP. We also compare the group in which BMI-standard deviation score (BMI-SDS) increased after treatment with the group in which BMI-SDS remained the same or decreased.

Methods: The subjects were ninety-nine CPP girls treated with GnRHa for more than 1 yr. We investigated chronologic age (CA), bone age (BA), BA advancement (BA-CA), height, HT-standard deviation score (HT-SDS), BMI, BMI-SDS, predicted adult height (PAH), PAH-SDS before initiation of GnRHa treatment and 1 yr later.

Results: There was no difference in initial CA, BA, BA-CA, HT-SDS, target height between normal BMI group and overweight/obesity group. BMI-SDS increased more in normal BMI group than in overweight/obesity group (0.2 vs -0.1, P<0.004), and initial BMI and delta BMI-SDS showed negative relationship (R2=0.251, P<0.001). PAH-SDS increased less in normal BMI group than in overweight/obesity group (0.3 vs 0.7, P<0.02), but there was no linear relationship between initial BMI and PAH-SDS. Delta BA, delta BA-CA, delta HT-SDS also was not different between normal BMI group and overweight/obesity group. Comparing pts. in whom BMI-SDS increased or remained or the same after treatment with those whose BMI-SDS decreased, there was no difference in delta BA, delta HT-SDS, delta PAH-SDS. Delta BMI-SDS was related only with initial BMI SD, and showed no relationship with CA, BA, BA-CA.

Conclusions: In CPP girls treated with GnRHa for 1 year, BMI SDS increased in those with normal BMI. Delta BMI-SDS had negative relationship with initial BMI-SDS, but was not influenced by other factors such as initial CA, initial BA, initial BA-CA, initial HT-SDS, initial PAH-SDS, target height, drug dosage.

PAO-34

A case of salt-wasting and virilizing form of congenital adrenal hyperplasia in a patient with male phenotype and 46,XX karyotype

Maia Rekhviashvili¹; Mariam Balakhadze¹; Revaz Morgoshia¹; Rolf Peter Willig²

¹JSC “Vere XXI”, Department of Physical and Sexual Development of Children and Adolescents, Tbilisi, Georgia; ²Endokrinologikum Hamburg, Pediatrics, Hamburg, Germany

Background: In congenital adrenal hyperplasia (CAH) with 21-hydroxylase or 11β-hydroxylase deficiency, futile trophic hormone stimulation results in excess sex hormone precursors. Androgen predominance in these forms of CAH leads to virilization of affected females in utero.

Objective and hypotheses: We describe a patient with virilizing and salt-wasting form of CAH.

Methods: A case report.

Results: Patient 7.2 years old boy. The complaints were: Delay of physical and sexual development (unorchia), pubic hair since the age of 2 years. Anamnesis to the postnatal period: the child was frequently hospitalized due to intensive vomiting, diarrhea and weight loss. The patient was on symptomatic treatment. Auxology: HSDS 1.22. Sexual development stage P3 A1 G2; Testes not palpable. Bone age by Greulich and Pyle 10.5 years. Genetical research: karyotype - 46XX; Laboratory research: 17OH Prog 50 ug/l, Potassium 4.1 mmol/l, Sodium - 136 mmol/l, LH - 0.1 IU/l, FSH 2.8 IU/l, Estradiol 10 ng/l, Androstenedion 0.7 ug/l, ACTH 133 ng/l, Renin 241 ng/l. Abdominal MRI: In the pelvic cavity on both sides ovary like structur, with the size: 0.8X1.33 cm. At the posterior side of the urinary blade tubular mass with the size 2X7.7 mm (apparently vagina). The conclusion of children’s psychologist: The psychologic development of the child corresponds to male. Therapy: Hydrocortisone 15mg/day, Fludrocortisone 1 mg/day, Cyproterone 10 mg/day. By substitutional therapy hormone concentration in the blood came down to the normal range and puberty stopped. The condition of the patient was explained to the parents and to an ethical committee for the decision, to raise the patient as a girl or as a boy by gender reassignment surgery (extirpation of uterus and ovaries).

Conclusions: Continued excessive adrenal sex steroids in untreated CAH patient causes several problems which may reveal not only physical, but also psychological deviations.

PAO-35

A hypothyroidal harymatoma associated with precocious puberty

Mariam Balakhadze¹; Maia Rekhviashvili¹; Revaz Morgoshia¹; Rolf Peter Willig²

¹JSC “Vere XXI”, Department of Physical and Sexual Development of Children and Adolescents, Tbilisi, Georgia; ²Endokrinologikum Hamburg, Pediatrics, Hamburg, Germany

Background: Gonadotropin-releasing hormone (GnRH) dependent, or central precocious puberty (CPP) results from early onset of pubertal hypothalamic-pituitary-gonadal activity. This occurs as a consequence of physiologic gonadotropin stimulation emanating from the GnRH secretion of hypothalamic origin. Both boys and girls with an organic etiology of CPP are more likely to present at a younger age, than those with idiopathic etiology.

Objective and hypotheses: We describe a child with hypothyroidic harymatoma associated with precocious puberty on Triptorelin treatment.

Methods: A prismatic case report.

Results: We report 1 year 9 months old girl. Complaints: premature puberty. Sexual development stage: Tanner 3 (B3, P3, A2, Me at the age of 8 months). Anamnesis: from the age of 2 weeks till today vaginal discharge (white), at the age of 3 months pubic hair appeared, at the age of 6 months breast de-
Development has started, at the age of 8 months menarche occurred. Auxology: Height: 92.7 cm; Weight: 17.8 kg; HSDS: 2.35; Bone age by Greulich and Pyle: 4 years; Gynaecological Ultrasonography: Uterus: 23.6X17X26 mm; Endometrium thickness 4 mm; Ovaries: dex - 23X11 mm with cystic insertion 11X6 mm; sin - 14X9 mm with cystic insertion 2.5 mm; Adrenal Ultrasonography:. Without pathology. Cerebral MRI: Disontogenic neof ormation of the hypothalamic area (Harmathoma). Hormonal research: FSH 9.6 IU/L (N < 1); LH 1.70 mIU/ml (N > 0.1); Estradiol 77 pg/ml (N < 15); Therapy: GnRH agonist – Triptorelin (Dosage 3.75 mg every 4 weeks). By the therapy hormone concentration in blood came to the normal range 0.06 mIU/ml (LH) and 0.19 mIU/L (FSH), patient had no menstruation since the beginning of the treatment. The puberty has stopped.

**Conclusions:** CNS abnormalities causing CPP include redundant or excessive hypothalamic tissue (hypothalamic hamartoma). Treatment by suppression of gonadotropin secretion with Gonadotropin-releasing hormone agonist (GnRHa) is an appropriate and efficacious treatment of CPP.

**Methods:**
Complementary tests TSH 1.98µU/mL, FSH 51.6 U/L, LH 33.2 U/L, Estradiol 13.3 pg/mL. Testosterone total 10.41 ng/mL, SHBG 52.92 nmol/L, DHEAS 174 mcg/dL, Free Testosterone 19.3 17 OHP 1.64 ng/mL, Karyotype: (400 bands): 47.XXY[28]/45,X[2].

Genital Echography: small size uterus (40x20x6 mm) and gonads (15 x 5 mm) without follicles Lineal endometrium. LHRH Test: positive response for testosterone

Ginecologic exploration through laparoscopy: Uterus and Fallopian tubes were normal. Left ovary compatible with testicle; with a similar form between fimbriaes in right side. Tissues biopsy: Compatible with testicular tissue. Karyotype of gonadal biopsy 47 XXY

Evolution: Quick estrogenization (etimilestradiol VO and combined proges-
teron). 6 months after quirurgry, there was a reduction of basal testosterone, partial reduction of body hair, telarche development grade III and a substantial improvement of patient’ self-esteem. Clitoromegaly is lower too.

**Results:**
- The pubertal status and the standard deviation score for height
- Evaluation of short stature. Laboratory test index of blood were measured.
- The average age in the 6 patients was 13.36 years (11-18 years).
- Two patients, at onset of clinical diabetes, presented with an asymptomatic glycosuria and four with polydipsia, polyuria, weight loss and ketoadiposis. Serum ferritin was in the range of 4800-7148ug/L; Fasting blood glucose was in the range of 8.9-43.8mmol/L, HbA1c was in the range of 8.9-16.8%.
- 2 patients were detected high insulin level (>20µU/L), suggesting insulin resistance. 4 cases of ketoadiposis were detected insulin level <2mU/L, C peptide mean 24pmol/L, suggesting lack of insulin secretion. Pancreas MRI showed the signal to reduce, which was related with iron deposition. The pubertal stage of 6 patients was in Tanner 1 to Tanner 2. 6 patients were all short stature, 4 cases of hyposyroidism, 2 cases of GHDI. Mild liver function abnormalities (2 cases) and abnormal heart function (1 case) were detected. All patients treated with transfusion, deferoxamine, exercise, diet control, Glucobay and insulin. Comprehensive therapy was good.

**Conclusions:**
Despite therapy with deferoxamine to treat iron overload, the risk of secondary endocrine dysfunction remained high. Diabetes in patients of beta-thalassemia major were often accompanied by other endocrine organ damaged, which occurs with iron deposition. The pathogenesis of diabetes in beta-thalassemia major may be similar to the development of type 2 diabetes. Early diabetes, it was insulin resistance, and finally lack of insulin secretion induced to insulin dependent diabetes mellitus.

**Objective:** The aim of this study was investigation of clinical features, patho-
genesis, laboratory examination and early treatment of diabetes mellitus in patients with beta-thalassemia major.

**Methods:** Diabetes mellitus was observed in 6 of 53 patients with beta-thal-
assemia major. In this retrospective analysis study, patients were examined to determine their pubertal status and the standard deviation score for height for evaluation of short stature. Laboratory test index of blood were measured.

**Results:** The average age in the 6 patients was 13.36 years (11-18 years).

**Conclusions:** Despite therapy with deferoxamine to treat iron overload, the risk of secondary endocrine dysfunction remained high. Diabetes in patients of beta-thalassemia major were often accompanied by other endocrine organs damaged, which occurs with iron deposition. The pathogenesis of diabetes in beta-thalassemia major may be similar to the development of type 2 diabetes. Early diabetes, it was insulin resistance, and finally lack of insulin secretion induced to insulin dependent diabetes mellitus.

**Introduction:** The craniopharyngioma is a cystic tumor, calcified, squamous-
epithelial origin in the slow growth. Internationally, the incidence is 0.5-
2/100.0. Mortality/morbidity: survival varies by age group, with a excellent prognosis in patients aged less than 20 years (99% at 5 years).

**Clinical:** The most common presenting symptoms are headache (55 - 86%), endocrine dysfunction (66-90%) and visual disturbances (37 - 68%). Endo-
ctrine abnormalities are found in 80 to 90% of craniopharyngiomas. In fact,
in 39% of patients shows impairment of 3-axis pituitary in 28% of 2 or more
axes in 11% of 1 or more and 22% no axis compromise. [5]. The most fre-
quent response is that of a GH deficiency present in more than 75% of cases,
followed by a gonadotropine deficiency in 40% of cases and a ACTH and
TSH deficiency in 25%. Despite craniohypophyrgias are usually of signific-
ant size already at diagnosis, the pituitary stalk is rarely interrupted, for
which only 20% of patients presents hyperprolactinemia resulting from the
compression pedicle.

Our experience: In 25 children (16 males and 9 females) whose age at diag-
nosis was between 0.35 and 13.30 years with an average of 6.65 years (SD
3.04). Location of craniohypophyrgia. Suprasellar 8 Sellar suprasellar 8
Saddle 3 3rd ventricle 1 Suprasellar diencefal 1 Suprasellar þ 3rd ventricle
1 Chi semic 2 3rd ventricle 1 Retrosachial 1 Suprasellar 1 Suprasellar ret-
rosachial 1 Total 25 Apto-aendoce abnormalities at diagnosis. Growth
retardation 4/25 (16%) Precocious puberty, 1/25 (4%) Delayed puberty 1/
25 (4%) PU/PD 1/25 (4%) Overweight / obesity 5/25 (20%) Gigantism 1/
25 (4%) Endocrine abnormalities detected after treatment. Diabetes insipids
20 (80%) Precocious puberty 2 (8%) Hypoparadrenalism 18 (72%)

Conclusion:
- High incidence of short stature and / or = 2
- High incidence of obesity hyperphagia
- marked hyperphagia (binge eating) with difficulty in controlling appetite.
- Increased behavioral and psycho-social.

PAO-40
Prevalence of subclinical hypothyroidism in child cancer survivors and efficacy of
levothyroxine treatment
Shinichiro Sano; Yuichi Nakagawa; Toshiki Nakanishi; Rie Matsuishi;
Elieicho Satake; Yasuko Fujisawa; Eiko Nagata; Takehiko Ohzeki
Hamamatsu University School of Medicine, Pediatrics, Hamamatsu, Japan

Background and objective: Child cancer survivors (CCS) have some com-
plications. Although hypothyroidism in CCS has been well reported, little is
known about subclinical hypothyroidism (SCH). The aim of this study was
to investigate the prevalence of SCH and efficacy of levothyroxine (LT4)
supplementation in CCS with SCH.

Methods: Twenty CCS were divided into two groups. The chemo group
(n=8) was treated with chemotherapy alone and the radiated group (n=12)
received radiotherapy plus radiotherapy. Control group was healthy chil-
dren who showed short stature but normal hypothalamic-pituitary and thyroid
function. TSH, FT3, and FT4 were measured in all patients. TRH stimulating
test was performed only in the patients who were diagnosed with SCH. The
definition of SCH is TSH > 5 µIU/ml, while FT3 and FT4 are within nor-
mal range. Lipid profile and QOL were evaluated after 2 or 3 month of LT4
supplementation in theses patients.

Results: No patients in the chemo group showed SCH. Four patients in the
radiotherapy group (33%) were diagnosed with SCH. They received radiotherapy
both in spine and brain. Their TRH stimulating test showed hyperresponse
and persistence of high levels of TSH. Their cholesterol levels were signifi-
cantly higher than those of the chemo group. Mild dose of LT4 administration
improved their lipid profile and QOL.

Conclusions: High prevalence of SCH was seen in CCS with radiotherapy.
Our findings suggest that irradiation of spine plus brain is high risk of SCH.
Mild dose of LT4 can improve the lipid profile and QOL in SCH patients.

PAO-41
Adenohypophysitis in a boy with pan-sinusitis
and meningitis
Mariella Valenzione; Malgorzata Wasniewska; Francesca Granata;
Sabrina Carole; Maria Rosaria Velletri; Filippo De Luca
1University of Messina, Department of Pediatrics, Messina, Italy;
2University of Messina, Department of Neurosciences, Psychiatry and
Anaesthesiology, Messina, Italy

Background: Although hypophysitis is usually thought as a primary process,
it may occur secondarily in relation to infections or other processes such as
Langerhans cell histiocytosis, Crohn disease.

Case report: We report the case of a 15-year-old boy who was admitted to
our Clinic due to headache, fever, visual disturbances and rigor nucalis. A 3D-
CT showed pansinusitis whereas CSF showed a pleiocytosis (500 cell/mm3);
therefore, broad spectrum antibiotics therapy were administered. After 5 days
headache, fever, rigor nucalis were resolved, but diplopia persisted. MRI
demonstrated diffuse pansinusitis and extension of inflammation and infec-
tion into the adjacent cavernous sinuses and pituitary gland that, after gado-
linium, presented asymmetrical enlargement in size. Basal concentrations of
plasma ACTH, cortisol, PRL, FSH, LH, testosterone were very low; also TSH
appeared very low but thyroid hormones were still within the normal limits.
Anti-pituitary antibody was also negative. Corticosteroid treatment (1 mg/kg/
die) was administrated for six months and after two months of discontinuation
endocrinological investigations were repeated. There were normal responses
of FSH and LH to appropriate stimuli, normal levels of T, ACTH, cortisol,
TSH, FT4. Only GH secretion after stimulation tests appeared subnormal
(Peak 3.71 ng/ml). Follow-up MRI showed that the pituitary had reduced in
size.

Conclusion: On the basis of our case we may conclude that: a) pansinusitis
may occur secondarily in relation to infections or other processes such as
Langerhans cell histiocytosis, Crohn disease.

PAO-39
Is the level of anti TPO antibodies predictive for the course of Hashimoto thyroiditis?
Ana Ostojić; Jovana Obrenovic; Silvija Sajić; Ana Stankovic; Vera Zdravković
1University of Belgrade, Medical School, Belgrade, Serbia; 2University
Childrens Hospital, Endocrinology, Belgrade, Serbia

Background: Hashimoto’s thyroiditis (HT), characterized by the presence
of high serum thyroid auto-antibody titers and goiter, is one of the most common
types of thyroiditis in children and adolescents. It is associated with a wide
spectrum of thyroid functions, ranging from euthyroidism to overt hypo-
thyroidism, with a variable clinical course.

Objective and hypotheses: To assess the thyroid hormone status during the
long-term follow-up and to establish the prognosis of children and adoles-
cents with HT.

Methods: We evaluated thyroid function (TF) in 77 children with HT. The
patients were assessed at presentation and then followed up at 6-12 months
intervals. We divided them according to the level of anti TPO antibodies into
2 groups: up to 10 fold elevated and above that level.

Results:

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>5-19, mean 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>19/58</td>
</tr>
<tr>
<td>Puberty (no/yes)</td>
<td>8/69</td>
</tr>
<tr>
<td>TSH (high/normal)</td>
<td>28/49</td>
</tr>
</tbody>
</table>

Follow up period was 0.5 to 10, mean 1.9 years. We compared TF in 2 groups
of patients and did not find that level of anti TPO antibodies was predictive.

Conclusions: In our group of patients we noticed female predominance, most
patients were in puberty and majority of them are still euthyroid in follow up.
We were not able to establish the connection between the level of anti TPO
antibodies and thyroid function.
**PAO-42**

**Adrenal agenesis secondary to DAX 1 mutation in a newborn**

Ignacio Diez-Lopez1; Ainhoa Sarasua Miranda1; Enrique Gonzalez Molina2; Mercedes Martinez Ayucar3; Amaia Rodriguez Estevez4; Luis Castaño Gonzalez5; Txaigorritxu Hospital, Paediatric Endocrinology Unit, Vitoria, Spain; Txaigorritxu Hospital, Newborn Unit, Vitoria, Spain; Cruces Hospital, Paediatric Endocrinology Unit, Bilbao, Spain; Cruces Hospital, Paediatric Research Laboratory, Bilbao, Spain

**Background:** Agenesis or hypoplasia of adrenal glands associated to alterations of Gen DAX-1 (crom X) are a very unusual clinical subject, and could be accompanied of other hormonal and genetic alterations. We present a clinical case, supported with images.

**Objective and hypotheses:** Male newborn with breathing distress and very important hyper-pigmentation. Mother 35 years healthy first birth. Father healthy. No consanguinity. Prenatal ecography normal. Negative serology. 41 GA prenatal monitoring normal.

**Methods:** Weight 3880 G (>2 SDS) Height 56,5 cm (<2 SDS) CP 37 cm Hypotonic, with labial sub cyanosis and general hyper pigmentation, Silverman score 3-4/10. Normo configured genitalia, except hypopigmentation. Apgar 2/6/8. Requires RCP type II

**Results:** Laboratory: pH 7.26, CO2H 19,4; EB -6. Sodium 119 mEq/L, potassium 7.3 mEq/L, PCR 23,8 mg/dl after 24 hours/life Cultivates: Negative. Cortisol 2,86 mcg/dl. DHEA-S 8,32 mcg/dl (32-431), 17OP 3,73 ng/ml (0,4-3,3). ACTH 1,129,1 pg/mL (5-77), cholesterol 177 mg/dl (50-170), Norepinefrin: 5 mcg/24 horas (12 mcg/L) Epheminefrin: < 1 mcg/24 horas (<2 mcg/L) Dopamine: 65 mcg/dl (163 mcg/L). Abdominal ultrasound and MRI: There is no sign of adrenal glands. Genetic study; 46 XY (DAX-1 +) at index case, father not affected, mother 46 XX*, (null/DAX –1).

**Conclusions:** After Hydro-electrolytic correction and treatment with hydrocortisone, the values of Na/K were normal. We use supplementary dose of sodium too. After 3 months, the levels of ACTH were normal. Up to date (18 months age), patient is asymptomatic. His psychomotor and somatometric development is according to his age. Bone-age equivalent and the hyper-pigmentation has disappeared.

**PAO-43**

**Bone mineral density and turnover in patients with idiopathic hypogonadotropic hypogonadism**

Eeva-Maria Laitinen; Johanna Tommiska; Kirsi Vaaralahti; Tanelli Raivo; Helsinki University Central Hospital, Hospital for Children and Adolescents, and, University of Helsinki, Institute of Biomedicine/Physiology, Helsinki, Finland

**Background:** Patients with idiopathic hypogonadotropic hypogonadism (IHH) may have reduced peak bone mass in early adulthood, and increased risk for osteoporosis despite long-term hormonal replacement therapy (HRT).

**Objective and hypotheses:** We investigated markers of short-term bone turnover, and the relationship between HRT history and bone mineral density (BMD) in patients with IHH.

**Methods:** 33 subjects (24 men, 9 women; mean age 39.8 yrs, range 24.0—69.1) with IHH (Kallmann Syndrome or nonmosmic IHH), were physically examined and measured for circulating PINP, ICTP, and sex hormone levels. 26 subjects underwent DEXA for BMD of lumbar spine, hip, femoral neck, and whole body.

**Results:** In men, serum PINP correlated with ICTP (R=0.61; p=0.002), but these markers correlated neither with circulating T, nor with serum E levels in women.

**Conclusions:** Treatment history had a clear impact on bone health in men: lumbar spine (LBMĐ, mean Z-score -2.0 SD, range -4.1—1.4) was reduced in subjects with inadequate HRT (n=7, including those with long (>5 years) treatment pauses) as compared to those with a history of adequate HRT (n=11; LBMĐ: -0.5 SD, -2.4—0.7) (p=0.037).

The overall duration of treatment pause (range 0.15—30 yrs) correlated negatively with lumbar and femoral neck Z-scores (R=0.42 and -0.61; p=0.039 and 0.001, respectively).

**PAO-44**

**Two cases with HDR syndrome (hypoparathyroidism, sensorineural deafness and renal disease)**

Mehmet Keskin1; Yilmaz Kor1; Ali Yalcin1; Hatice Uygur2; Ozlem Keskin1; Deniz Kor1

1Gaziantep University, Faculty of Medicine, Pediatric Endocrinology and Metabolism, Gaziantep, Turkey; 2Gaziantep University, Faculty of Medicine, Pediatrics, Gaziantep, Turkey

**Background:** HDR syndrome (hypoparathyroidism, sensorineural deafness and renal disease) was first reported by Barakat et al. described two brothers with steroid-resistant nephrosis with progressive renal failure, sensorineural deafness and hypoparathyroidism in 1977. Autosomal dominant disorder that is caused by mutations of the GATA3 gene, which is located on chromosome 10p15, has been identified recently. GATA3 is expressed in the developing parathyroid glands, inner ears and kidneys, together with thymus and central nervous system.

**Objective and hypotheses:** The patients with symptoms of hypocalcemia must be evaluated carefully.

**Results:** Hypoparathyroidism, sensorineural deafness and renal anomaly were diagnosed in our two patients with symptoms of hypocalcemia.

**Conclusion:** These cases are reported because of HDR syndrome is a very rare condition and the history of deafness in patients with hypocalcaemia for understanding of this syndrome.

**PAO-45**

**Effects of growth hormone on muscle strength, tone and mobility of children with Prader-Willi syndrome**

Shadab Salehpour1; Omid Aryan2; Farzaneh Rohani3

1Shaheed Beheshti University of Medical Sciences, Pediatric Surgery Research Center, Pediatric Endocrinology, Tehran, Islamic Republic of Iran; 2Special Medical Center, Molecular Genetics, Tehran, Islamic Republic of Iran; 3Tehran University of Medical Sciences, Pediatric Endocrinology, Tehran, Islamic Republic of Iran

**Background:** Prader-Willi syndrome (PWS) is a genetic syndrome presenting with severe hypotonia and decreased agility. Growth hormone (GH) which is often used in these cases to treat short stature and obesity, seems to have some improvement in hypotonia, physical strength, activity, and locomotor developmental ability.

**Objective:** The aim of this study is to find the growth hormone effect on the agility and strength of these patients.

**Material and methods:** In a prospective, randomized controlled clinical trial, at an out-patient pediatric endocrine clinic in Tehran, 21 PWS children (12 boys and 9 girls, 4 to 9 years old) were divided either in GH-treated or control groups and followed for two years. Agility run, sit ups, weight lifting, and inspiratory and expiratory strengths were considered as the main outcome measures.

**Results:** All the outcome measures of the GH treated group showed a significant improvement compared to those of the control (p<0.01).

**Conclusions:** GH causes a significant improvement in agility and strength of PWS children.
Background: Mutations of the CYP17A1 gene result in 46,XY disorder of sex development, hypertension, hypokalemia and absent pubertal development. It is a rare, autosomal recessive form of congenital adrenal hyperplasia (CAH).

Objective and hypotheses: Usually, most patients are detected rather late as adolescents due to lack of puberty or hypertension.

Methods: We report about a neonate born to a 40 year old woman, 1st para, 1st gravida. Amniocentesis revealed a fetus with a 46,XY karyotype. At 20 weeks of gestation the development of male external genitalia was missing. Further molecular testing excluded an androgen receptor and SRY gene mutation. A phenotypically female child was born at 41st week of gestation. Gonads were palpable in the labia majora.

Results: Postpartal ultrasound revealed testes in both labia majora, absence of uterus and normal adrenal glands. Screening for 21-hydroxylase-deficiency was normal. Multisteroid analysis in serum showed reduced basal glucocorticoid, testosterone and androstenedione levels at the age of two weeks. The urinary steroid metabolome – assessed by GC-MS - showed excessive excretion of 17-desoxy-steroids, decreased glucocorticoid metabolites and absent C19-steroids. Such a metabolic constellation proves 17-alpha-hydroxylase-deficiency. Molecular analysis identified a novel mutation of the CYP17A1 gene: c.896T>A (p.1299N) in exon 5. Substitution with hydrocortisone was started at a moderate dose to prevent hypertension. The child is growing well so far.

Conclusion: Herein we report the unusually early diagnosis of a newborn with the rare CAH form of 17-alpha-hydroxylase-deficiency allowing installation of early treatment.

Background: Central precocious puberty (CPP) is less common in boys than in girls. There is little data available on the long-term safety and efficacy of GnRH agonists in Korean boys with idiopathic central precocious puberty and early puberty.

Methods: This study included nine boys with CPP and 13 boys with early puberty who were evaluated after two years of treatment.

Results: Of the 187 subjects, 66 (35.3%) had GH deficiency, while 121 (64.7%) were categorized as having idiopathic short stature. Reliability was assessed and GH results appropriately interpreted for all subjects undergoing GH stimulation testing. Also, higher BMI is associated with lower GH secretion. BMI should be measured and to analyze the reproducibility of GH stimulation test.

Conclusion: There is little data available on the long-term safety and efficacy of GnRH agonists in Korean boys with idiopathic central precocious puberty and early puberty.

Background: The diagnosis of growth hormone (GH) deficiency is based on a reduced peak GH response to provocative tests. However, the provocative tests are poorly reproducible and GH secretion is regulated by physiological parameters, such as body weight and puberty. The aim of this study was to assess the influence of BMI on growth hormone response to provocative testing and to analyze the reproducibility of GH stimulation test.

Methods: Clinical data was collected retrospectively by chart review from the Pediatric Endocrine Unit at Ajou University Hospital. A total of 187 subjects with short stature who completed a GH stimulation testing between 2003 and 2009 were included in the study.

Results: Of the 187 subjects, 66 (35.3%) had GH deficiency, while 121 (64.7%) were categorized as having idiopathic short stature. Reliability was calculated for 48 patients with ISS who underwent the GH stimulation test twice. A GH response ≥10 ng/ml after retesting was found in 39 (81.3%) patients and a GH response <10 ng/ml was found in 9 (18.7%) patients. In a stepwise multivariate analysis, BMI was a significantly independent predictor of peak GH. Elevated BMI was negatively associated with peak plasma GH levels.

Conclusions: The lack of reliability of GH values in response to pharmacological stimuli should be taken into account in the diagnosis of GH deficiency. Also, higher BMI is associated with lower GH secretion. BMI should be measured and GH results appropriately interpreted for all subjects undergoing GH stimulation testing.
PAO-49

Medullary thyroid carcinoma in two children from a family with multiple endocrine neoplasia 2a syndrome - a case report

Gordana Stanicic1; Lavinia La Grasta Sabolic2; Marija Pozgaj Sepec2; Maja Radman3
1University Hospital, Department of Pediatrics, Zagreb, Croatia; 2University Hospital “Sestre milosrdnice”, Department of Pediatrics, Zagreb, Croatia; 3University Hospital Center Split, Department of internal medicine, Split, Croatia

Introduction: All carriers of a point mutations in the RET proto-oncogene with multiple endocrine neoplasia type 2A (MEN2A) develop medullary thyroid carcinoma (MTC), while 50% and 30% of patients develop pheochromocytoma and hyperparathyroidism. MTC tends to disseminate early. It is chemo- and radio-resistant and remains the cause of death in 15-20% of MEN2A patients. Consequently, early prophylactic total thyroidectomy is performed in all MEN2A patients.

Case report: A 32-yr-old father presented with bilateral pheochromocytoma, MTC and parathyroid adenoma. Genetic analysis revealed a point mutation in codon 634 of exon 11 of the RET proto-oncogene. Genetic testing confirmed that both siblings were carriers of the same mutation. In a 10-y-2-mo old son ultrasound of the neck disclosed nodules in both thyroid lobes and enlarged paratracheal and left jugular lymph nodes. Laboratory examination revealed high calcitonin concentrations (437 pg/ml), while serum calcium and PTH levels were on the upper limit of normal values. In a 7-y-10-mo old daughter serum calcium level was slightly elevated (20.7 pg/ml), and plasma calcium and PTH levels were normal. On ultrasonography, a nodule in a right thyroid lobe, enlargement of the left jugular and right submandibular lymph nodes were observed. Both children underwent total thyroidectomy with neck dissection. Pathological examination showed bilateral MTC in a boy and MTC of the right thyroid lobe in a girl, with no lymph node metastatic disease. Laboratory examination showed no pheochromocytoma in siblings. After surgery both children began with thyroid replacement therapy. Due to the permanent hypocalcemia in a boy, in treatment with calcium-carbonate and calcitriol was initiated. Eighteen months after thyroidectomy, the children are doing well.

Conclusions: At present, genetic testing and prophylactic total thyroidectomy prevents the development of an invasive MTC in MEN2A patients. However, the risk of permanent hypoparathyroidism and the issue of thyroid replacement therapy remain a concern.

PAO-50

A case of adenral hypoplasia congenita caused by DAX1 deletion

Eun Young Kim-Kook1; Yang Jib Kang2; Hyun Wook Shin3; Han-Wook Yoo4
1Kwangju Christian Hospital, Pediatrics, Gwangju, Republic of Korea; 2Asan Medical Center, Pediatrics, Seoul, Republic of Korea

Background: Adrenal hypoplasia congenita caused by DAX1 (Dosage sensitive sex reversal-Adrenal hypoplasia congenita critical region on the X chromosome gene-1) mutation, is a rare disorder and presents usually acute severe adrenal insufficiency in the neonatal period and hypogonadotropic hypogonadism. Because DAX1 is located on Xq21, the mutation affects primarily boys (X-linked). Associated with deletion of DAX1, the Duchenne muscular dystrophy, mental retardation-IL1RAPL1, glycerol kinase and ornithine transcarbamylase genes may also be deleted as part of a contiguous gene syndrome.

Case: We report an 1 month old male patient presenting with weight loss, dehydreadration, lethargy, poor feeding, and hypercentrogenation. The first laboratory investigation showed hypoglycemia (121 mg/dl), hyperkalemia (7.8 mg/dl), high ACHT (342 pg/ml), and high renin (246 ng/ml/hr), so he was diagnosed with primary adrenal insufficiency (PAI). To reveal the cause of PA, further investigations were performed and showed normal 17-OH, VLCFA, and negative adrenal Ab. On abdominal CT, adrenal hypoplasia was detected. DAX1 gene analysis using PCR presented complete deletion and contiguous genes (glycerol kinase and IL1RAPL1) were also deleted. He showed clinical improvement after glucocorticoid and mineralocorticoid treatment, but at present (12months of age), shows mild motor developmental delay.

Conclusion: DAX1 mutation analysis should be considered in males with adrenal hypoplasia congenita.

PAO-51

Comparison of the efficacy of multiple daily insulin injection therapy and flexible intensive insulin therapy in children with type 1 diabetes mellitus

Gurul Gulecoglu1; Oplem Sangur1; Bumin Dundar1
1Hacettepe University, Department of Pediatrics, Ankara, Turkey; 2Hacettepe University, Department of Pediatric Endocrinology, Ankara, Turkey

Objective: To compare the effects of multiple daily insulin injection therapy (MDI) and flexible intensive insulin therapy (FIIT) on metabolic parameters and quality of life in children with type 1 Diabetes Mellitus (DM).

Method: Twenty eight patients who were followed regularly at least 1 year in our Pediatric Endocrinology outpatient clinic and being treated with MDI (three doses of pre-meal insulin aspart and a single daily dose of basal detemir/glargine insulin) were included in the study. All the patients were evaluated for HbA1c, BMI-SDS, hypoglycemia, mean fasting plasma glucose (FPG) levels, lipid profile, total daily insulin requirement and quality of life (QOL) before and after the 6 months of FIIT. Treatment periods of MDI and FIIT were compared. The Medical Outcomes Survey Short Form-36 (SF-36) was performed in order to assess QOL.

Results: Mean age of the patients was 12.9 ± 2.59 years old. The mean HbA1c and FPG levels of the patients during MDI treatment were found significantly decreased after switched to FIIT (p<0.001 and p=0.024). Insulin requirement, frequency of hypoglycemia, total cholesterol, low density lipo-protein (LDL), triglyceride levels, HDL levels and BMI-SDS of the patients was not significantly decreased with FIIT (p>0.05).

Conclusion: HbA1c and mean FPG levels significantly decrease with FIIT without causing significant difference in insulin requirement and frequency of hypoglycemia and lipid profiles. FIIT also improves mental health and is a reasonable choice in treatment of pediatric Type 1 DM patients.

PAO-52

Suspicious reflections and a solitary nodule in Hashimoto thyroiditis: finally carcinoma

D Mul1; J Kievit2
1Haga teaching Hospital / Juliana Children’s Hospital, Pediatric endocrinology, The Hague, Netherlands; 2Leiden University Medical Center, Surgery (section Endocrine/Head & Neck), Leiden, Netherlands

Background: There is controversial literature on the association between Hashimoto thyroiditis (HT) and the incidence and course of papillary thyroid carcinoma (PTC) in children.

Case report: Our patient was first seen as a young girl at age 14 with a clinical picture of HT with positive antiTPO antibodies. Ultrasound revealed an inhomogeneous pattern in the left lobe with many reflections, mimicking microcalcifications, and Tc-99m-pertechnetate scan was inconclusive. Fine needle aspiration (FNA) suggested a benign etiology with lymphocytic thyroiditis. One year later, the patient complained of a swollen neck and the thyroid gland was found to have increased in size. Ultrasound showed a 2 cm hypervascular solitary nodule in the left lobe near the isthmus. FNA again showed an HT picture. The risk for malignancy, given these repeated negative biopsies, was low and no surgical intervention was performed. Three months later the patient returned. On holiday abroad she had fallen ill and was seen at a hospital outpatient department. Complaints of further diameter increase of the thyroid led to another ultrasound of the neck disclosed nodules in both thyroid lobes and enlarged paratracheal and left jugular lymph nodes. Laboratory examination revealed nodular abnormalities making could guide clinical decisions in children with HT presenting with nodular abnormalities.

50th Annual Meeting of the ESPE

Horm Res 2011;76(suppl 2)

277
and cell types in the blood.

Hypothalamus, the pituitary gland and the adrenal glands; thus how well a major part of the neuroendocrine system, involving the interactions of the Central mechanisms:

young people with CKD.

With vulnerable body systems, thus leading to long-term adapting/ coping in

- and stresses under normal circumstances. Anxiety is a common psychologi-

people with CKD would be expected to cope adequately with daily events

The majority of young people with CKD are expected to cope adequately with daily events

weakness, glucose intolerance, reduced bone density; all leading to reduced cardiovascular dysfunction, anaemia, malnutrition, muscle wasting, muscle weakness, glucose intolerance, reduced bone density, all leading to reduced coping, well-being and overall quality of life.

Conclusions: In children without overt GHD, a higher BMI SDS may have negative correlation with the peak GH level. Therefore, we can take BMI SDS into consideration when analyzing the results of growth hormone provocation test.

Background: Obesity and other related factors are known to suppress the secretion of growth hormone. But the influence of obesity on the peak GH level of provocation test is still controversial in children without growth hormone deficiency (GHD).

Objective and hypotheses: This study aims to evaluate the influence of obesity on the peak GH level of provocation test in children without GHD.

Methods: The subjects were patients who were admitted to Seoul National University Children's Hospital and got provocation tests done due to short stature from January 2000 to July 2010. Their medical records were retrospectively reviewed, and patients with obvious growth hormone deficiency were excluded. The main outcome measure was peak GH level of provocation test, and the height, weight, and serum IGF-1 levels were also recorded.

Results: Simple logistic regression analysis showed that body mass index, standard deviation score (BMI SDS) had negative correlation with natural log value (Ln) of peak GH level (P=0.004), but gender, age, pubertal status, Ln IGF-1 had no correlation, respectively. In multiple logistic regression analysis, BMI SDS (P=0.042) and age (P=0.017) were suggested to be significant predictors of Ln peak GH level.

Conclusions: In children without overt GHD, a higher BMI SDS may have negative correlation with the peak GH level. Therefore, we can take BMI SDS into consideration when analyzing the results of growth hormone provocation test.

Background: The study of coping with Chronic Kidney Disease (CKD) in young people is a unique and challenging task because their circumstances are quite divergent from their adult counterparts. The aim of this article is to use a combination of retrospective and present literature to inform discussion linking psychology, immune and neuroendocrine systems to recognize a deeper perspective on coping in young people facing CKD.

CKD in children and young people: CKD is a chronic illness and it is irreversible. Coupled with its devastating effects, CKD is associated with cardiovascular dysfunction, anaemia, malnutrition, muscle wasting, muscle weakness, glucose intolerance, reduced bone density, all leading to reduced coping, well-being and overall quality of life.

Coping strategies (psychological and physiological): The majority of young people with CKD would be expected to cope adequately with daily events and stresses under normal circumstances. Anxiety is a common psychological pattern of children/ young people with CKD. Physiologically, due to the influence of internal conditioning factors, what might generally be called ‘a normally well-tolerated degree of stress’ can become chronic for individuals with vulnerable body systems, thus leading to long-term adapting/ coping in young people with CKD.

Central mechanisms: The hypothalamic-pituitary-adrenal (HPA) axis is a major part of the neuroendocrine system, involving the interactions of the hypothalamus, the pituitary gland and the adrenal glands; thus how well a young individual with CKD copes may be related to stress hormone levels and cell types in the blood.

Conclusions: Overall, an integrated PNI approach is desirable to better understand coping. The immune system has a ‘means’ to signal and ready the body to respond to stressful challenges enabling it to cope. Understanding coping in children/ young people with CKD should not be restricted to psychological/ psychosocial research.

Background: The reproductive health is frequently associated with thyroid disorders.

Objective: To study of mammary glands (breasts) condition in adolescent girls with autoimmune thyroiditis (AT).

Population and methods: The study included 30 girls (aged 15-18 yrs) with AT (group I) and 30 girls without thyroid diseases (control group). AT was diagnosed on the basis of thyroid peroxidase antibodies level and typical picture of thyroid ultrasound. Mammary glands (MG) disease (mastopathy or dysplasia) was diagnosed on the basis of signs and typical picture of MG ultrasound. Statistical analysis was performed using Mann-Whitney Test.

Results: Thyroid function was normal in all these girls. TSH levels in girls of group I and control group were 2.9±0.9 and 1.7±0.5 µIU/L respectively. The investigation shows that only 2 girls without AT and all girls (100%) with AT had MG diseases. Among the patients with MG disease the diffuse fibrous dysplasia was found in 26 (87%) in group I and 2 girls – in control group. The cystic diffuse dysplasia was diagnosed only in girls with AT (in 2 patients). The study demonstrated that all adolescents with AT and MG disease had cyclic (premenstrual) mastalgia, 27% girls – persistent mastalgia and 45% girls – cyclic and persistent mastalgia. The investigation shows that only 2 girls with MG disease of in control group had premenstrual mastalgia.

Conclusions: This study has shown a high frequency of mastopathy (38%) among the examined adolescent girls with AT. The AT is risk factor for the mastopathy and the indication for observation and examination of MG.

Diabetic cardiac autonomous neuropathy (DCAN) – is one of chronic complications of diabetes mellitus (DM) which indicates the unfavorable prognosis of disease.

Objective: To study the possibilities of apparatus programmed test in diagnostics of DCAN in children. Population and methods. There were examined 49 children with DMT1, at the age from 7 to 16 yrs. 12 children have had the diabetes type 1 (group I); 8 from II group (group II). To diagnose DCAN there was used cardiac vegetative test by means of apparatus programmed complex «VNS - spectrum» (Neurosoft), with program analysis «Poly-spectrum». The evaluation of cardiac rhythm variability (5 cardiac vascular tests on Ewing) was used as the basis of investigation. Each one is estimated from 0 to 2 points.

Results: In all patients of I group there was revealed compensation of carbohydrate metabolism; subcompensation in 6 patients of II group and in 5 patients of III group; uncompensation in 10 patients of II group and in 7 patients of III group. DCAN of I degree (5-7 points) was revealed in 20 children with DM: 4 patients of I group; 8 – of II group, 8 – III group. DCAN of 2 degree (8 – 10 points) was revealed in 5 children with DM: 1 from I group; 4 from II group. There was detected the correlation of DCAN with the age of children at the debut of the disease, duration of the disease, degree of compensation.

Conclusions: Cardiac vegetative test allows to diagnose DCAN in children and administer the treatment at early stage, when there is no irreversible death of the nerve fibre.
PAO-58

Failure to thrive and the diencephalic syndrome
Yvonne Yiuan Lim, Cindy Wei Li Ho, Kah Yin Loke
National University Health System, Paediatrics, Singapore, Singapore

Background: Diencephalic syndrome is a rare condition which typically presents with severe failure to thrive despite preservation of normal linear growth. This is associated with tumours involving the hypothalamus and/or optic chiasma, with the majority being astrocytoma.

Objective and hypotheses/method: We describe 3 patients seen at our centre who were diagnosed with diencephalic syndrome over the past 20 years.

Results: Initial differential diagnoses for failure to thrive included celiac disease, generalized lipodystrophy and Russell Silver syndrome in one patient who was short. Only one patient presented with nystagmus, which suggested an intracranial pathology. After extensive workup for failure to thrive, Computed Tomography of the brain eventually revealed the presence of a suprasellar tumour in all 3 patients, which were subsequently confirmed to be inoperable hypothalamic astrocytomas. The age of diagnosis ranged from 9 to 18 months old. There was one death, with the other two patients demonstrating a more protracted course. The child who died presented at the earliest age and had the largest tumour which recurred within 1 month of surgery, suggesting a more aggressive course. Of the other two patients who have survived into adulthood, one underwent cranial irradiation before the age of 5 years, and suffered the consequences of late onset endocrinopathies and mental retardation. Both surviving patients have reached adulthood, with minimal increase in tumour size, suggesting a more indolent course. In diencephalic syndrome, the overall mortality rate is 55% with death ranging from 8 months to 13 years.

Conclusions: Diencephalic syndrome must always be considered in any child with failure to thrive from no other apparent reason. This peculiar syndrome provides a unique model of partial growth hormone resistance (elevated growth hormone levels) with normal linear growth, and suggests that there are hypothalamic-pituitary factors in the feedback mechanisms of appetite regulation and metabolism.

PAO-59

Profile of iron metabolism in pediatric age: clinical and epidemiological impact on our environment
Javier Caballero1; Alicia Romero2; María Aguilar2
Eva L van Donkelaar3; Virginia Moreno2; Ramón Cañete2
1IMIBIC, Hospital Reina Sofia, Universidad de Córdoba, Clinical Analysis Service, Córdoba, Spain; 2IMIBIC, Hospital Reina Sofia, Universidad de Córdoba, Pediatric Endocrinology Unit, Córdoba, Spain; 3University of Maastricht, Faculty of Health, Medicine and Life Sciences, Maastricht, Netherlands

Introduction: Iron deficiency is a significant public health problem in terms of epidemiology and potential comorbidities. Its prevalence and easy diagnosis and treatment, put into question the relevance of performing screening programs or targeted screening in high risk populations or suspected cases.

Objectives: Determine our environment and the existence of iron deficiency or iron-deficiency anemia in children previously diagnosed between 2 months and 11 years, analyzing their clinical implications.

Material and methods: Cross-sectional study in a sample of 900 children seen in primary care. They have no diagnosis or suspicion of iron deficiency or anaemia. Simple systematic sampling was conducted to recruit 30 children. We included cases of iron deficiency disease. The history collected: age, gender, background neonatal (birth weight, gestational age, type of delivery, neonatal period, feeding (breast milk or formula), vaccinations, previous admissions and intercurrent). We determined weight, height and body mass index. It was performed a blood analysis which included cell count and iron, ferritin and transferrin in serum levels. Descriptive statistics was carried out, showing frequency distribution.

Results: We found 46.6% of cases of iron deficiency disease. Of the latter, we observed more frequently in men (83%) and predominant age group (53.3%) fell between 12-26 months. It was also observed more frequently in cases of low birth weight and/or exclusive feeding of formula.

Conclusions: Iron deficiency anemia is a common disease in our environment. Our largest case series was in children under 36 months, which disagrees with results of other authors. To obtain guidance on the diagnosis and etiology, sufficient medical history, physical examination and a small number of laboratory tests. Based on the foregoing, we propose the establishment of a hypothetical program of mass screening of iron deficiency or anemia in children, assessing their potential economic impact on the public health system in terms of cost-effectiveness.

PAO-60

Implications of bone metabolism in pediatric patients with inflammatory bowel disease
Caballero Javier1; María Aguilar2; Alicia Romero2; Virginia Moreno2; Eva L van Donkelaar3; Ramón Cañete2
1IMIBIC, Hospital Reina Sofia, Universidad de Córdoba, Clinical Analysis Service, Córdoba, Spain; 2IMIBIC, Hospital Reina Sofia, Universidad de Córdoba, Pediatric Endocrinology Unit, Córdoba, Spain; 3Maastricht University, Faculty of Health, Medicine and Life Sciences, Maastricht, Netherlands

Introduction: Alterations of bone metabolism in patients with inflammatory bowel disease (IBD) have a high prevalence. Among the known factors leading to this comorbidity are: corticosteroid therapy, the activity of IBD and duration of symptoms and lifestyle.

Objectives: To study the potential impact of IBD in mineral metabolism in pediatric patients, evaluating clinical, biochemical, densitometric and radiographic parameters.

Material and methods: Cross-sectional study in children with IBD. We collected anthropometric and clinical data (cumulative dose of corticosteroids, index of IBD activity, nutrition survey and lifestyles). It was carried out a blood analysis. It included CBC and serum biochemical study on the levels of glucose, urea, creatinine, sodium, potassium, calcium, phosphorus, alkaline phosphatase, urate, magnesium, PTH, osteocalcin, TSH, T4, CRP, albumin, prealbumin, total protein, total cholesterol, HDL-cholesterol, triglycerides, iron, ferritin, transferrin, orosomucoid and C-telopeptide. The urine analysis included: glucose, urea, creatinine, ions, calcium, inorganic phosphate, total protein, microalbuminuria and urate. We performed bone densitometry (DEXA) of spine and hand-wrist radiograph. Multiple linear regression was performed in successive steps, using as dependent variable bone mineral density (BMD) quantified by the z score value obtained from the DEXA.

Results: Preliminarily there are 8 patients (4 boys and 4 girls) aged between 3 and 17. About 25% had a BMD below the normal range for age and sex. Another 25%, an IBD activity index higher. About 37.5 had increased CRP. The C-telopeptide was increased all cases. There was only one case of overweight. We found a significant relationship (p <0.02) between BMD and IBD activity index.

Conclusions: The index of activity of the IBD had a negative impact on BMD of the child. Iatrogenic corticosteroid did not result in a detriment of the BMD of pediatric patients and so we propose to prioritize good rate control IBD activity. The C-telopeptide is consistently high in children with IBD.

PAO-61

Gonadal mosaicism 45X/46XY resulting in a Turner phenotype with mixed gonadal dysgenesis: a report of two cases
Cristina Dumitrescu1; Lavinia Viga1; Camelia Procopciuc1; Andrea Caragea-Thopelo1; Florentina Dinu2; Oana Popa2
1"C I Parhon" National Endocrinology Institute, Bucharest, Romania; 2"C I Parhon" National Endocrinology Institute, Hormonology Laboratory, Bucharest, Romania; "Grigore Alexandrescu" Paediatrics Hospital, Surgical Department, Bucharest, Romania

Background: Mixed gonadal dysgenesis is regarded as the most common manifestation of 45X/46XY mosaicism associated with a wide spectrum of phenotypic manifestations.

Objective and hypotheses: We describe two cases with a Turner phenotype associated with mixed gonadal dysgenesis. One of the two cases presents a mosaicism 45X/46XY and one a 46XY caryotype.

Methods: We describe a 16 year old girl who presented with short stature and pubertal delay. She had female external genitalia, an urethral opening on the posterior vaginal wall and some clinical features of Turner syndrome (widely spaced nipples, cubitus valgus, low hairline, multiple nevi). Endocrine studies showed levels of sex hormones consistent with primary gonadal failure. The
pelvic ultrasound revealed the presence of an uterus. At laparotomy a uterus, fallopian tubes and small gonad-like tissue masses in the region of the Fallopian fimbria were found. Histological analysis revealed no organized testicular or ovarian morphology, fallopian tubes on the right side and epididymis on the left side. The second case is a 10 year old girl presenting with features of Turner syndrome (broad chest, mouth abnormalities, cubitus valgus), short stature, and primary gonadal failure. The pelvic ultrasound reveals the presence of an uterus, fallopian tubes with streak gonads.

Results: In the first case G-bandning analysis of blood lymphocytes confirmed a 46XY karyotype while in the second there was a mosaicism 45XO/46XY. FISH analysis for the eventual presence of isodicentric Y chromosome, as well as gene sequencing for SRY, SOX9, AMH and AR were in progress.

Conclusions: Comprehensive cytogenetic, endocrine, histological and molecular studies on the gonads are further needed in order to explain the causality between the genetic profile and the phenotype in these two particular cases.

PAO-62
The experience of recombinant growth hormone treatment in a secondary endocrine referral centre in Saudi Arabia
Suzanne Elkholy, Sulaiman AlMuhaidm
King Fahad Military Medical Complex, Paediatrics, Dhahr, Saudi Arabia

Background: King Fahad Military Medical Complex is a secondary referral centre for paediatric endocrinology for the eastern province in Saudi Arabia. Recombinant Growth Hormone has been used for many years as a treatment option for children and young adults with many endocrine disorders mainly short stature resulting from growth hormone deficiency or insufficiency.

Objective and hypotheses: The aim of the present study is to evaluate the use of R-GH treatment use, indication, dose, effect on height as well as effect of discontinuation of treatment due to compliance or lack of supply issues.

Methods: We have identified over 50 patients who are receiving R-GH and performed a retrospective chart review to assess the effect of treatment of GH.

Conclusions: Most patients were diagnosed with growth hormone deficiency followed by children with Turner syndrome, then other genetic disorders, and ideopathic short stature. Doses used were generally less than recommended followed by children with Turner syndrome, then other genetic disorders, and ideopathic short stature. Doses used were generally less than recommended.

PAO-63
Rapid increase of serum TSH level in an infant on amiodarone treatment: a case report
Aleksandr Peet; Vallo Tillmann
Children’s Clinic of Tartu University, Department of Paediatrics, University of Tartu, Tartu, Estonia

Background: Amiodarone is widely used as an effective and relatively safe anti-arrhythmic drug. Amiodarone-induced hypothroidism is well described and close monitoring of thyroid function in all patients receiving amiodarone is recommended. For the first control of serum TSH level is usually recommended 10 to 60 days after starting the treatment.

Objective and hypotheses: We present a case of term infant who rapidly developed increased TSH level after starting amiodarone treatment.

Results: Male infant from normal pregnancy and uneventful delivery was born from 40 gestational week with the birth weight of 3210 g. Supraventricular tachyarrhythmia, severe combined congenital heart diseases (constriction of aorta, ventricular septal defect, and foramen ovale apertum), and congestive heart failure were diagnosed at the first day of life. In order to control frequent episodes of supraventricular tachycardia paroxysms, treatment with amiodarone was introduced over 50 patients who are receiving R-GH and performed a retrospective chart review to assess the effect of treatment of GH.

Conclusions: Most patients were diagnosed with growth hormone deficiency followed by children with Turner syndrome, then other genetic disorders, and ideopathic short stature. Doses used were generally less than recommended followed by children with Turner syndrome, then other genetic disorders, and ideopathic short stature. Doses used were generally less than recommended.

PAO-69
A case of Liddle’s syndrome in an 8-year old girl with argininosuccinic acidemia and childhood absence epilepsy
Jan Marquard; Thomas Meissner
University Hospital Duesseldorf, Department of General Pediatrics, Duesseldorf, Germany

Background: Liddle’s syndrome, also called pseudohyppokalemia, is a rare autosomal dominant disorder caused by an activating mutation of the renal epithelial sodium channel. Affected patients typically show hypertension, hypokalemia and metabolic alcalosis.

Case report: We report on an 8-year old girl with argininosuccinic academia and childhood absence epilepsy who developed arterial hypertension. Initial diagnosis was a workup showed a slight hypokalemia, serum aldosteronae was not capable of measuring. 24-hour urinary potassium excretion, serum creatinine, arterial blood gas analysis, blood catecholamines and steroid levels, abdominal and renal ultrasound, electrocardiogram and renal magnetic resonance angiography were without pathological findings. The family history was unremarkable. An essential hypertension was assumed and the girl was treated with propranolol which failed to control the elevated blood pressure as well as the combination of captopril and spironolactone. Additionally, the girl developed a metabolic alkalosis, hypokalemia worsened. Serum and urine aldosteronae levels as well as plasma renin activity were abnormally low. Liddle’s syndrome was suspected and treatment with amiloride was started. After 4 weeks of uncomplicated treatment blood pressure returned to normal levels and blood gas analysis was in a normal range. Gene-sequencing for liddles’s syndrome was negative.

Discussion: Despite a negative gene-sequencing for liddle’s syndrome (molecular detection rate around 40%) the diagnosis could be established by typical laboratory findings and a good response to amiloride. Neither argininosuccinic academia nor childhood absence epilepsy seems to be related to liddle’s syndrome since there are no comparable reports in literature. In retrospect the initial slight hypokalemia in combination with hypertension was already indicative for liddle’s syndrome but in fact the clinical course provided the diagnosis.

Conclusion: Children with hypertension and lack of therapeutic response to first-line antihypertensive agents should be worked up for secondary causes.

PAO-65
Side effect profile of diazoxide in children with congenital hyperinsulinism. A retrospective study
Jan Marquard; Laura Huberman; Thomas Meissner
University Hospital Duesseldorf, Department of General Pediatrics, Duesseldorf, Germany

Background: Diazoxide is the first-line drug for long-term treatment of congenital hyperinsulinism (CHI). However, the use of diazoxide is often limited by side effects, e.g. hypertrichosis, fluid retention and feeding problems. To precisely determine the frequency of major side effects of diazoxide in children with CHI.

Patients and methods: Interviews on side effects were performed with the parents of CHI patients who received diazoxide. In addition, patients’ records were retrospectively searched for side effects of diazoxide.

Results: So far we identified 24 patients (13 female, 11 male) with CHI who are or had been treated with diazoxide. Preliminary data shows that 92% of them developed hypertrichosis. The treatment of 16 patients is still ongoing, for 25% of these patients hypertrichosis has been regressive in the course of the treatment. In 8 cases the diazoxide treatment has ended because of remission of the disease. In all of these cases hypertrichosis regressed completely. Hypertrichosis was most distinctive along the spine (48%) followed...
by the face (30%) and the extremities (13%). In 54% of patients feeding difficulties were reported during the diazoxide treatment, 40% of them had a verifiable weight loss. 37% of the patients developed edema, nearly all of them had facial edema. Tachycardia was rarely reported (4%), hyperuricemia and leucopenia were not reported during diazoxide treatment.

Conclusions: The most common reported side effects of diazoxide in patients with CHI are hypertrichosis (92%) followed by feeding problems (54%) and facial edema (3%).

Background: The term ambiguous genitalia or indeterminate sex is a terminology that parents fear to hear. This is most devastating within the African continent where being in the 21st century the sex of a child is of utmost importance. Fortunately this disorder is uncommon. Classifying the cases into different groups is formidable especially when investigative support is minimal.

Objective: To determine the prevalence of ambiguous genitalia, categorize patients, the mean length of time for completion of investigation and therapy outcome.

Methodology: This is a review of all patients referred with ambiguous genitalia to the clinic over 13 years. Assessment criteria were based on clinical presentation, hormonal and biochemical estimations, sonogram of the abdomen, genitogram and karyotype / baccal smear. Stimulation with human chorionic gonadotropin (hCG) and ACTH (adrenocortical hormone) stimulation tests were performed as required.

Results: Reviewed were 44 out of 245 patients with endocrine disorders (1997 to 2010) who had ambiguous genitalia. They were categorized as genetic females with virilisation or FPH (15, 34 %) all were due to congenital adrenal hyperplasia (CAH), Genetic males overvirilized (4, 9%) Genetic males undervirilized or MPH (11, 25%), Microgenitalism with severe chordee 3, 6.8%, microgenitalism with micropenis and cryptorchidism (5, 11%), true hermaphroditism (2, 4.5%) and the syndromic form of ambiguous genitalia (1, 2.2%). Age at presentation ranged from 48hrs to 10 years. Mean length of time for investigation 9 months while 75% had appropriate therapy.

Conclusions: Ambiguous genitalia appear very rare when compared to similar collections for the length of time of review. This may be an invalid conclusion due to the inadequate health delivery service, referral system and or older age presentation. Finance seems to be a big constraint to management. The obvious indeterminate external genitalia in females with CAH may account for higher percentage amongst cohorts.

**PAO-66**

**Ambiguous genitalia – a 15 years overview**

Adobla Oduvicole; Rolli Nwoodo; Elizabeth Ebrechi Ogunusi; Chris Bode; James Rentier

Lagos University Teaching Hospital, Paediatrics, Surulere, Lagos, Nigeria

**Background:** The term ambiguous genitalia or indeterminate sex is a terminology that parents fear to hear. This is most devastating within the African continent where being in the 21st century the sex of a child is of utmost importance. Fortunately this disorder is uncommon. Classifying the cases into different groups is formidable especially when investigative support is minimal.

**Objective:** To determine the prevalence of ambiguous genitalia, categorize patients, the mean length of time for completion of investigation and therapy outcome.

**Methodology:** This is a review of all patients referred with ambiguous genitalia to the clinic over 13 years. Assessment criteria were based on clinical presentation, hormonal and biochemical estimations, sonogram of the abdomen, genitogram and karyotype / baccal smear. Stimulation with human chorionic gonadotropin (hCG) and ACTH (adrenocortical hormone) stimulation tests were performed as required.

**Results:** Reviewed were 44 out of 245 patients with endocrine disorders (1997 to 2010) who had ambiguous genitalia. They were categorized as genetic females with virilisation or FPH (15, 34 %) all were due to congenital adrenal hyperplasia (CAH), Genetic males overvirilized (4, 9%) Genetic males undervirilized or MPH (11, 25%), Microgenitalism with severe chordee 3, 6.8%, microgenitalism with micropenis and cryptorchidism (5, 11%), true hermaphroditism (2, 4.5%) and the syndromic form of ambiguous genitalia (1, 2.2%). Age at presentation ranged from 48hrs to 10 years. Mean length of time for investigation 9 months while 75% had appropriate therapy.

**Conclusions:** Ambiguous genitalia appear very rare when compared to similar collections for the length of time of review. This may be an invalid conclusion due to the inadequate health delivery service, referral system and or older age presentation. Finance seems to be a big constraint to management. The obvious indeterminate external genitalia in females with CAH may account for higher percentage amongst cohorts.

**PAO-67**

**Characteristics and prevalence of non-classical congenital adrenal hyperplasia with a v281l mutation in patients with premature pubarche**

Senay Savas Erdeve1; Merih Berberoglu1; Nuket Yurur Kutlay2; Zeynep Siklar1; Bulent Hachimdoglugi1; Aijan Tukun1; Gonul Ocal1

1Ankara University School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology, Ankara, Turkey; 2Ankara University School of Medicine, Department of Medical Genetics, Ankara, Turkey

**Background:** The frequency of NCCAH with V281L among children presenting with premature pubarche (PP) is variable.

**Objective and hypotheses:** To determine the prevalence, clinical and laboratory characteristics of NCCAH with the V281L mutation in patients with PP. Methods: The study group was composed of 159 unrelated patients with PP. ACTH stimulation test was performed in 14 of the 159 patients with PP who had basal 17-OHP levels >2 mg/ml. Patients whose stimulated 17-OHP level on the ACTH test was >10 ng/ml underwent a mutational analysis of the CYP21 gene, and those with the mutation were considered to have NCCAH.

**Results:** NCCAH was defined in nine (5.7%) among 159 patients with PP and all of them had the V281L mutation. The gender distribution showed a similarity between NCCAH and patients with idiopathic PP (IP). When compared with the IPP group, the NCCAH group had higher bone age and BA-chronological age ratio. However, chronological age, age at pubic hair onset, height, height standard deviation score, parental adjusted deficit in height, weight, and body mass index (BMI) were similar in both groups. All nine patients whose peak 17-OHP levels in the ACTH stimulation test were >10 ng/ml had the CYP21P2 gene mutation. Four of them were homozygote and four of them were heterozygote. Other one patient was compound heterozygote for the V281L mutation and the f2 splice mutation . The one of the patients with V281L heterozygous mutation developed true precocious puberty and the other one patient had rapid progressive early puberty and developed polycystic ovary syndrome.

**Conclusions:** ACTH stimulated > 17-OHP 10 ng/ml in PP patients is load star to mutation analysis and heterozygote patients should be followed for clinical and biological hyperandrogenism up to completion of the whole gen sequence.

**PAO-68**

**Continuous subcutaneous insulin infusion (CSI): a successful mode of therapy for neonatal diabetes (experience in Qatar)**

Fawziya Alkhalaf; Maryam Al Ali; Ashraf Tawfeq; Mohamoud Zyyoud; Noura Alhemaidi; Amal Sabt; Ahmed Alawa

Hamad Medical Corporation, Pediatric, Doha, Qatar

**Background:** Neonatal diabetes is defined as persistent hyperglycemia occurring in the first months of life that lasts more than two weeks and requires insulin for management.

**Objective and hypotheses:** Although pediatricians face numerous difficulties in managing insulin therapy at this age, very few data are available on possible methods of insulin delivery in neonatal diabetes.

**Methods:** We report our experience over 3 years of continuous subcutaneous insulin infusion (CSI) in cases of neonatal diabetes requiring insulin therapy (n = 5). Two neonates were negative for ABCCR,-ve KCNJ11, two had pancreateatic agenesis and one has Wolcott-Rallison syndrome. CSI therapy in neonatal diabetes allows easy adaptation of insulin delivery, closely following the current feeding regimen (a basal infusion needed with very minimal dose; preprandial boluses being started with intermittent bottle feeding).

**Results:** Management using very small insulin doses (e.g. bolus = 0.20 U and basal rate = 0.02 U/h) was required and was only possible after insulin dilution (5-10 U/ml) and is more accurate with CSI than with using syringes. CSI allows easy delivery of such small doses without dilution errors. CSI achieved good glycemic control for all neonates (mean HbA1c = 8 %) with few hypoglycemic events; which are particularly frequent and dangerous at this age. Neonates tolerated the subcutaneous infusion lines well without any local side effects.

**Conclusions:** During the neonatal period, and under the supervision of an experienced team, CSI is safe, more physiological, accurate and easy to manage than using syringes or pens.

**PAO-69**

**Complete catch-up growth in a case of Johanson Blizzard syndrome with severe postnatal growth retardation**

Amal Sabt; Ashraf Solliman; Noura Alhemaidi; Ahmed Elawwa; Nadra Abdelmajed

Hamad Medical Center, Pediatrics, Doha, Qatar

**Background:** Patients with Johanson Blizzard syndrome (JBS) have significant postnatal growth retardation.

**Objective and hypotheses:** We report the growth pattern of a boy with the JBS who was born with at term with aplasia of the alae nasi and severe congenital sensori-neural deafness.

**Case:** At the age of 1.5 years the boy presented with features of JBS and severe postnatal growth failure and apparent severe mental retardation.

**Results:** Investigations revealed mild pancreatic exocrine insufficiency and oral Pancrex V (lipase) was initiated. Despite some improvement in weight, his linear growth was still slow. At 2 years of age, endocrine evaluation proved growth hormone deficiency (glucagon test) with low IGF-I level, primary hypothyroidism (low free T4 and high TSH) and cortisol deficiency. MRI of the brain, showed hypoplastic pituitary gland. The child was started on human growth hormone.

50th Annual Meeting of the ESPE

Horm Res 2011;76(suppl 2) 281
growth hormone (GH), L-thyroxine and hydrocortisone replacement. Marked improvement of linear growth occurred with complete catch-up to his mid-parental height SDS occurred in 2 years. He maintained normal linear growth during the following 3 years.

**Conclusions:** Our case represents the first report of complete catch-up growth in a case of Johansen blizzard syndrome after severe postnatal growth retardation during infancy.

**Figure:** Linear Growth JB6 on Therapy

**PAO-70**

**Pediatric Graves ophthalmopathy in association with thyroid autoantibodies**

Dae Kyun Koh1; Won Kyung Cho2; Min Ho Jung2; Byung Kyu Suh2; So Hyun Park1

1The Catholic University of Korea, Pediatrics, Seoul, Republic of Korea; 2The Catholic University of Korea, Pediatric endocrinology, Seoul, Republic of Korea

**Background:** As pediatric Graves disease is an uncommon condition, Graves ophthalmopathy should be more unusual. Graves ophthalmopathy has been reported to be associated with high titers of thyroid autoantibodies. Nevertheless, studies on children are not abundant.

**Objective and hypotheses:** We aimed to compare the thyroid autoantibody levels in Graves disease patients with ophthalmopathy to those in patients without ophthalmopathy.

**Methods:** The subjects were 60 patients under the age of 18 years diagnosed with Graves disease from January 2000 to December 2010 at the Catholic University Saint Vincent Hospital. We reviewed the medical records retrospectively.

**Results:** Among them, 20 patients associated with Graves ophthalmopathy (33.3%) were compared with 40 patients without ophthalmopathy (66.7%). TSH Receptor antibody levels were higher in patients with ophthalmopathy than in patients without it (111.25±140.50 U/L vs 57.52±103.08 U/L, p = 0.024), and the percentage of elevated anti-microsomal antibody level was also higher in patients with ophthalmopathy (80 % vs 45 %, p=0.013).

**Conclusions:** Pediatric Graves ophthalmopathy was associated with high titers of thyroid autoantibodies in our study. Nevertheless, large-scale studies with more patients are required.

**PAO-71**

**Intestinal malabsorption and dark skin caused elevated parathormone levels**

Rolfe Peter Willig1; Nunu Mitskevich2

1Endokrinologikum Hamburg, Pediatrics, Hamburg, Germany; 2Tbilisi State University, Immunology and Microbiology, Tbilisi, Georgia

**Background:** Hyperparathyroidism is a rare finding in children. It is a typical sign of vitamin D-deficiency caused by different reasons. It may also be due to calcium wasting syndromes, and it can rarely be induced by adenomas of the parathyroid glands and in parathormone receptor mutations (pseudohypoparathyroidism).

**Objective and hypotheses:** To show how celiac disease can mimic hyperparathyroidism followed by rheumatic complaints.

**Patient:** A 12-year old Gambian girl living in north Europe was developing abdominal and joint pain. Serum analysis revealed low serum-calcium, significantly elevated parathormone and decreased vitamin D. Immigrant rickets was assumed. Because of abdominal pain and iron deficiency, lamblisis was ruled out. Celiac disease was demonstrated by gliadin- and tissue transglutaminase-antibodies as well as by intestinal mucosa biopsy. Despite of a gluten-free diet the joint pains persisted. They were declared by rheumatologists to be caused by a chronic juvenile arthritis (sister disease of celiac disease). However, there were no positive inflammation signals and no clear elevated rheuma-immunology.

**Follow up:** Gluten-free diet and additional treatment with calcium and active vitamin D did not stop increasing parathormone levels, did not stop abdominal and joint pain, and did not stop increment of positive celiac disease antibodies. Assuming compliance problems the patient was then treated with vitamin D injections, which caused decreasing parathormone levels and vanishing joint pain.

**Conclusion:** Celiac disease can cause intestinal rickets with elevated parathormone levels mimicking chronic juvenile arthritis, if gluten-free diet is not strictly performed by compliance problems. Parenteral supply of depot-vitamin D is the therapy of choice in these patients exhibiting normalization of parathormone and vitamin D25 levels with disappearance of rheumatoid joint pain.

**PAO-72**

**Pituitary hyperplasia in primary hypothyroidism**

Roberto Franzese1; Maria Bellizz1; Vittoria Casu2; Umberto Rozzanigo2; Riccardo Failo2; Annunziata Di Palma1

1S.Chiara Hospital of Trento, Pediatrics Unit, Trento, Italy; 2S.Chiara Hospital of Trento, Diagnostic Imaging Unit, Trento, Italy

**Background:** Despite recent progress in imaging techniques, it is not possible to distinguish between TSH-producing macroadenoma and hyperplasia of pituitary thyrotroph cells on CT and MR scans. In such cases, repeat MRI after therapy with thyroxine may provide a definitive diagnosis and eliminate unnecessary surgery.

**Objective and hypotheses:** We describe an example of reactive pituitary hyperplasia from primary hypothyroidism that mimicked a pituitary macroadenoma in a child.

**Case report:** A 10 year old boy presented with occipital headache over the last three months and height growth arrest. Cranial Magnetic Resonance Imaging (MRI) detected an intrasellar and suprasellar pituitary mass. Endocrine evaluation revealed a severe primary hypothyroidism (TSH 589 mU/L, free T4 1.5 pmol/L), mild hyperprolactinemia (1.23 nmol/L) and low IGF-1 (8.6 nmol/L). Thyroid ultrasound showed normal thyroid size with markedly heterogeneous echo texture and hypo-echoic areas. Thyroid peroxidase and thyroglobulin antibodies were high. The patient was started on levothyroxine at 30 mcg daily, without any improvement of the mass effect.

**Conclusions:** Primary hyperplasia should be considered in the differential diagnosis of solid mass lesions of the pituitary gland. Examination of thyroid function in patients with sellar and suprasellar masses revealed by MRI may avoid unnecessary operations which can cause irreversible complications.

**PAO-73**

**Familial non autoimmune hyperthyroidism- a family**

Gül Yesiltepe Mutlu; Filiz Mine Cizmecioglu; Sukru Hatun; Elif Orzu

Kocaeli University, Pediatric Endocrinology and Diabet, Kocaeli, Turkey

**Objective:** Familial nonautoimmune hyperthyroidism which is inherited autosomal dominant, that caused by activating mutations of the thyrotopin receptor gene (TSHR). Recent studies have shown that FNAH, toxic adenoma and sporadic congenital hyperthyroidism are in fact facets of the same disease, genetic hyperthyroidism due to TSHR mutations.

Printed Abstracts Only
Methods: Case 1: Eleven-year-old male patient was admitted to our clinic with complaints of a neck swelling, weight loss, irritability, sweating. In his physical examination his weight and height were in the normal range, cardiac rate was 100/min above the upper limit. Thyroid examination revealed grade 2 goiter. The patient’s laboratory examination: TSH:0.199IU/ml (0.5-4.8), free T4:1.23ng/ml(0.8-2.3), free T3:4.92pg/ml(2-4), anti-TPO:175IU/ml, anti-TG:21.6IU/ml(0-134), anti-TSH receptor was negative. Imaging of the thyroid gland both thyroid glands and isthmus thickness increased, 3mm colloid nodule was seen in right lobe. The patient’s mother also had goiter with hyperthyroidism which was resistant to treatment so radioactive iodine treatment was applied. Also autoantibody and anti-TSH receptor were found negative in mother.

Case 2: Ten-year-old female patient was admitted because of goiter with his (case1 ) older brother. Beside intolerance the heat, she had no symptom. In her physical examination her weight and height were in the normal range, cardiac rate was 104/min above the upper limit. The patient had grade 2 goiter whose laboratory examination: TSH:0.3uIU/ml (0.5-4.8), free T4:1.43ng/dl (0.8-2.3), free T3: 4.66pg/ml (2-4), anti-TPO:12.8 IU/ml(0-134), anti-TG:19.7 IU/ml (0-134) and anti-TSH receptor was negative. Imaging of both thyroid glands and isthmus thickness increased TSHR gene mutations were sent for genetic analysis because of known two-generation family affected and hyperthyroidism no autoimmunity.

Result: TSHR activating mutations as the cause of subclinical hyperthyroidism may be more common and should be considered in the differential diagnosis especially if familial.

POA-74
The effect of long term sandostatin treatment in a child with hypothalamic obesity
Merith Berberoglu; Bulent Hacihambalioglu; Zeynep Siklar; Senay Savas Erdeve; Gomul Ocal
Ankara University School of Medicine, Pediatric Endocrinology, Ankara, Turkey

Background: Hypothalamic obesity is one of the most important effects of central nervous system damage. Generally lifestyle modification and diet are ineffective to treat the hypothalamic obesity. Sandostatin has been trying in pediatric hypothalamic obesity with short period in a few study. The results were promising but some are inconclusive.

Objective and hypotheses: To evaluate sandostatin treatment a case with morbid hypothalamic obesity.

Methods: A 5.1 year old male patient admitted to our clinic with complaint of visual disturbances and cephalgia. Extended evaluation revealed diagnosis of cranioopharyngeoma. After neurosurgical intervention, he had developed multiflu hypophyseal hormone deficiency (TSH, GH, LH, FSH, ADH deficiency) and was given apropriate replacement therapy. Growth was normal despite GH deficiency, and no GH therapy was introduced. Intractable obesity as BMI increased from 19.3 kg/m2 to 45.4 kg/m2 within 2 years was developed. The attempts to reduce heigth gain were unsuccessful. Sandostatin was introduced to patient and he treated for 2 years (5 mcg/kg/day in dose in the first year, 10 mcg/kg/day in the second year). First year of sandostatin treatment, decrease of weight gain gain, even loss of weight occurred (A BMI: -2.3 kg/m2/year). Second year of therapy, the response was the not the same that only stabilisation of weight was achieved. No side effect was seen related to sandostatin treatment.

Results: In this case report, sandostatin treatment was safe but not as effective as expected, especially in second year of therapy.

Conclusions: But that result can not be generalised because consist of one patient. More hypothalamic obese children should be evaluated to conclude the effectiveness of sandostatin treatment.

POA-75
TNF-A and others inflammatory molecules in overweight children
Maria Cristina Bazán1; Teresa Carrizio2; Maria Prado2; Elsa Diaz2; Maria Fonio2; Adela Agregu2
1University National of Tucuman, Medicine Faculty, Tucuman, Argentina; 2University National of Tucuman, Biochemical Faculty, Tucuman, Argentina

Background: Childhood obesity is associated with obesity later in life for adults, and it constitutes a major risk factor for cardiovascular disease and diabetes. The obese adipose tissue expresses an increased quantity of proinflammatory proteins such as the TNF-a.

Objective and hypotheses: The objective of this study was to evaluate the levels of TNF-a and others proinflammatory molecules in an overweight infant-juvenile population and their relationship with clinical and laboratory variables. Twenty overweight children and 20 control children were studied. Children in both groups were between 8-13 years old, and each child had his/her waist circumference (WC) measured and body mass index (BMI) calculated. The inclusion criteria for the overweight group was a BMI of >85th percentile for age and sex. In both groups was determined: fasting glucose level (glucose-oxygen); plasmonic insulin (ECLIA); plasma fibrinogen (Clauss); TNF (ELISA); Immunonobutidymetric (Enzyme immunoassay); TNF-a (ELISA); lipid profile (enzymatic); erythrocytate sedimentation rate and HOMA index. The data were analyzed with the SPSS 15.0 program for Windows. The Spearman’s rank correlation coefficient was used to measure statistical dependence between the variables.

Results: The TNF-a levels were higher in overweight children [15.4(13.2-24.0) vs. 12.7(11.2-14.8) pg/ml; p= 0.03]. Also the levels of fibrinogen (Fg), plasma insulin, HOMA index, uCRP and triglycerides were statistically higher than in the control group. The TNF-a was positively correlated with the waist circumference.

Conclusions: The high TNF-a, uCRP and fibrinogen levels confirm a proinflammatory state associated with abdominal obesity in the studied population.
PAO-77

The first documented case of Wolcott-Rallison syndrome in Serbia
Tatjana Miletkovic1; Sladiana Todorovic1; Dragana Zdravkovic1; Anke Pyper2; Andrea Naefel2; Jayne Houghton2; Sian Ellard2; Katarina Mitrovic1
1Mother and Child Healthcare Institute of Serbia, Endocrinology, Belgrade, Serbia; 2Klinik fur Kinder und Jugendmedizin, Endocrinology, Dresden, Germany; 3Peninsula Medical School, Universities of Exeter and Plymouth, Genetic laboratory, Exeter, United Kingdom

Background: Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disease. Its main characteristic is permanent neonatal diabetes mellitus (PNMD) associated with skeletal epiphysseal dysplasia. The obesity epidemic has reached children in Europe, including Greece. National epidemiological data and trend monitoring are of extreme importance in order to be able to provide a burden to this epidemic.

Clinical report: The female infant was born from unrelated parents. Pregnancy was uneventful and delivery was at term. Birth weight was 2100 g (below 5th centile) and length was 48 cm. At 3 months of age, the diagnosis of NDM was established and insulin treatment was introduced. From the very beginning, diabetes was difficult to control. At the age of 1.5 year she was admitted to the hospital for vomiting, edema and hepatomegaly. Laboratory workup showed extremely high levels of liver enzymes. This episode of hepatitis resolved spontaneously within 4 weeks. By that time, she was also diagnosed a hypothyroidism and was started on L-thyroxine. Eight months later, when investigated for steatorrhoea, pancreatic hypoplasia was found on abdominal ultrasound. After exocrine pancreatic insufficiency has been confirmed, therapy with pancreatic enzymes was initiated. At the age of 2.6 years an episode of liver failure (requiring hospitalization) reappeared. She had seizures soon after and was put on Phenobarbital. The etiology of seizures was unrevealed. Mutation analysis of the EIF2AK3 gene showed that the child is homozygous for a nonsense mutation, R902X, in exon 13. This result confirmed the diagnosis of WRS. After the diagnosis had been established skeletal X-ray was performed. It revealed multiple epiphyseal-methaphyseal dysplasia affecting long bones, vertebrae and pelvis.

Conclusions: WRS is a very rare disease. However, it should be considered in any child with NMD and associated disorders, especially if skeletal changes are detected. Detection of WRS in our patient delayed since genetic testing had not been performed at the time of making the diagnosis of NDM and hypothyroidism. Although genetic diagnosis of WRS does not alter therapeutic approach, it might help in predicting the outcome, as well as offering informed genetic counseling.

PAO-79

Prevalence of obesity and overweight in the primary school children and their relationship with some lifestyle factors, Iran, 2010
Shahla Vaziri Esfarjani1; Samin Vae1; Maryam Razzaghy-Azar2
1Jondi-Shapour University of Medical Sciences, Social Medicine, Ahvaz, Islamic Republic of Iran; 2Tehran University of Medical Sciences, Pediatric Endocrinology and Metabolism, Tehran, Islamic Republic of Iran

Background: Currently obesity is a major health problem throughout the world and a risk factor of many chronic diseases such as cardiovascular disease, hypertension, diabetes mellitus and cancer. Prevalence of obesity and overweight has been rapidly increased in both children and adults. Most of the obese children (80%) will be obese in adulthood.

Objective and hypotheses: The aim of this study presents the prevalence of childhood overweight, obesity and their relationship with factors which focused on watching TV, using the computer or playing video games, fast foods consumption, breast feeding and birth weight.

Methods: In this cross sectional study 960 (480 male and 480 female) primary school children aged 6-12 years old were selected by a two stage cluster sampling method. Height and weight were measured by the standard methods. Additionally BMI was calculated based on the weight, height and obesity; overweight were defined based on the BMI scores using CDC chart. Obesity, overweight and normal weight were defined as BMI<85th percentile and BMI=85-95th 15>BMI=85th respectively. The other data were collected by questionnaire that completed by parents. Data were analyzed by using chi square and fisher exact test(ANOVA).

Results: According to our findings 11.9% of the subjects were overweight and 6% were obese. The results have shown a positive significant relationship between BMI and the mean time of watching TV, using computer or playing video games and fast food consumption during childhood (p<0.0001). There was no relationship between BMI and gender, birth weight and breast feeding.

Conclusions: In this study the prevalence of overweight and obesity was compared to the same study in the last seven years which showed increasing in this community. Several studies have shown breast feeding is a protective factor for obesity, but this study has shown fast foods consumption, the mean time of watching TV and using computer or playing video games during childhood in spite of breast feeding in infancy period can be more effective on obesity.

PAO-80

Growth patterns in 100 short children receiving GH therapy – a retrospective study
Cristina Dumitrescu1; Corina Chirita2; Camelia Procopciuc2; Anda Dumitrescu3
1National Institute of Endocrinology, Pediatric Endocrinology, Bucharest, Romania; 2Anina Specialty Medical Services, Endocrinology, Bucharest, Romania; 3National Institute of Endocrinology, Radiology, Bucharest, Romania

Background: The obesity epidemic has reached children in Europe, including Greece. National epidemiological data and trend monitoring are of extreme importance in order to be able to provide a burden to this epidemic.

Objective and hypotheses: The aim of the present study was to review all available data published the last decade on objectively measured weight status (1-12 years old) according to the International Obesity Task Force Criteria, 2001-December 2010, reporting the prevalence of childhood obesity (ages 2-11 girls with Turner syndrome, mean age 8.2 yrs +/- 3; group 3 - 17 children born SGA, 8 girls and 9 boys, mean age 7.8 yrs +/-3.4; group 4 - 14 children with idiopathic short stature: 5 girls and 9 boys, mean age 7.4 yrs +/- 3.2. The SDs for height and growth velocity (GV) were calculated using the Prader standards from 1988 and statistical relevance was calculated using test.
Results: In group 1, the average height was -3.1 SD +/- 1SD (between -6.1 and -1.5 SD). In the first year, the height gain was of 0.8 SD with an average GV of 3.9 SD (0.6 cm/year). In the second and third years of treatment the height gain and GV were 0.9 SD and 3.3 SD (8.5 cm/year) respectively 0.4 SD and 2.3 SD (7.4cm/year). In group 2 the initial growth deficit was -2.7 SD +/-1.2 SD (between -5.0 and -1.1 SD), with a gain of 0.5 SD in one year. The GV was 2.5 SD – 8.6 cm/year (p=0.02 compared with the 1st group) but dropped to 1.2 SD (6.9 cm/year) in the second year (p=0.05), with a further gain of 0.5 SD in height. Group 3 had a -3.3 +/-0.7 SD height deficit with a gain of 0.5 SD in the first year and of another 0.4 in the second year. The GV was 2.7 SD – 9.1 cm/year (compared with the group 1 p= 0.15) respectively 1.2 SD - 6.8 cm/year (p=0.1). In the 4th group, the initial growth deficit was -3.3 +/-0.5 SD, with a growth of 0.6 SD in the first year of treatment. The GV was 1.4 SD, (8.5 cm/year) significantly lower than in the first group (p=0.01). There was an increase of blood glucose levels (p=0.03), but the values remained normal.

Conclusions: GH therapy in short children is effective, especially in children with GH deficiency. The maximum of catch-up growth is obtained in the first year of treatment. The therapy is safe, but clinical and biochemical follow-up is necessary.

Introduction: Classic congenital adrenal hyperplasia is one of the causes of virilisation of the female fetus and can have dramatic implications if it is not diagnosed in time.

Case presentation: We present the case of a 4 yrs 8 month old boy, who was admitted for bilateral cryptorhism and pubic hair development. The patient had been surgically investigated for cryptorhism at the age of 2.6 yrs, but no tests were found. He had been admitted to various pediatric hospitals for repeated episodes of severe dehydration with low levels of sodium (Na – 128.8 mEq/L, normal range 136-145) and hyperkaliemia (K – 6.1 mEq/L, normal range 3.5-5.1) and was treated for salt wasting nephritis. The clinical exam revealed a patient with normal height (±0.37 SD) and weight with a well developed penis, and no evident testes. The pubic hair was P3-4. The rest of the clinical exam was unremarkable and the patient was not dehydrated. The hormonal panel revealed: Testosterone – 2.23 ng/mL; LH – 0.87 mUI/mL; FSH – 3.11 mUI/mL; cortisol – 3.92 µg/dL (normal range 4.3-22.4); ACTH – 173 pg/mL (normal range 8-60); 17 OH Progesterone – 533 ng/mL (normal range 0.07-1.7). The abdominal CT exam showed adrenal hyperplasia and a uterus. The pelvic ultrasound revealed fluid in the uterus and 2-3 follicles in each ovary. The bone age was 11 years. The caitotype was 46 XX. The diagnosis was of virilizing congenital adrenal hyperplasia, probably due to 21-hydroxylase deficiency, with female pseudohemaphroditism and secondary central precocious puberty. Treatment with hidrocortisone was started. Triphthoreline 3.75 mg/month i.m. was administered for precocious puberty. Because vaginoplasty was not possible and respecting the parents’ wishes, the assigned male sex was preserved and the patient will undergo surgery to remove the internal reproductive organs.

Conclusions: Congenital adrenal hyperplasia is still a largely undiagnosed condition, especially in absence of neonatal screening. All cases of bilateral cryptorhism should undergo extensive investigations, including caitotype.

Background: Pituitary thyrotroph hyperplasia secondary to primary hypothyroidism is a rare cause of pituitary enlargement. Clinical presentation is variable.

Objective: To present a clinical presentation and evolution in 5 cases (4 girls) of pituitary hyperplasia appearing as a result of longstanding hypothyroidism.

Methods: Clinical appearance was variable (Table 1). Common finding in all children was growth delay during months or years before the diagnosis. All had moderate clinical hypothyroidism. Diagnosis was made by measuring T4, TSH, thyroid antibodies and ultrasonographic examination of the thyroid gland. Pituitary function was revealed by measuring GH, FSH, LH, Prolactin and ACTH. MRI of the pituitary was performed.

Results: TSH was very high, and T4 low in all patients. Ultrasound finding of the thyroid gland was typical for Hashimoto thyroiditis. GH deficiency, as well as FSH, LH deficiency were revealed in two patients. One girl had elevated levels of prolactin. Magnetic resonance imaging revealed symmetrical pituitary enlargement associated with contrast enhancement simulating macroadenoma. After introduction of therapy with levothyroxine, both symptoms and pituitary hyperplasia regressed within a period of 1.5 - 13 months. Children were followed for 2-9 years. Growth resumed in all patients, and puberty followed regularly.

Conclusion: Pituitary tumor associated with elevated thyroid stimulating hormone and low levels of free T4 is most frequently caused by Hashimoto thyroiditis and should always be treated with thryoxine replacement before other diagnostic tests are ordered. Careful follow up is warranted.
PAO-84

Clinical characteristics of subclinical rickets in infants less than two years of age

Ji Young Seo, Ji Hyun Yoon
Eulji General Hospital, College of Medicine, Eulji University, Pediatrics, Seoul, Republic of Korea

Background: In young children, cases with both of vitamin D deficiency and iron deficiency anemia (IDA) are common.

Objective and hypotheses: To evaluate the clinical characteristics of vitamin D deficiency and its association with IDA.

Methods: A total of 261 children aged ≤2 years underwent 25-hydroxyvitamin D3 tests between January 2007 and July 2009. The study cohort was classified into two groups: normal and vitamin D deficient, by their 25-hydroxyvitamin D3 levels.

Results: In total, 171 children were in the normal group (mean age, body weight and height 12.5±7.0 months, 9.3±0.9 kg and 76±1.1 cm), and 51 children in the vitamin D deficient group (9.9±5.4 months, 9.0±0.9 kg and 75.1±0.9 cm). Vitamin D deficiency was most commonly diagnosed in the spring (44%). The proportion of complete breast-feeding was higher in the deficient group (92%), and 25.5% of the children in the deficient group also experienced iron deficiency anemia compared that 12% of normal group. Wrist radiographs showed findings suggestive of rickets in 7 children in the normal group. Nine children in the deficient group experienced persistent bony changes. Six children received calcitriol medication in the normal group, in whom the mean vitamin 25-hydroxyvitamin D3 level increased from 39.6±14.6 ng/ml (pre-medication) to 41.8±17.2 ng/ml (post-medication), and in the deficient group, in whom the mean vitamin 25-hydroxyvitamin D3 increased from 13.3±5.2 ng/ml (pre-medication), to 34.5±23.8 ng/ml (post-medication).

Conclusions: This study demonstrated that approximately 30% of children aged ≤2 years experienced vitamin D deficiency associated with subclinical rickets. Many children also experienced concurrent iron deficiency anemia. Guidelines for vitamin D supplement in such children must therefore be established.

PAO-85

Decreased serum testosterone levels in long-term adult survivors with fatty liver after childhood stem cell transplant

Haruyuki Ishiguro1; Yuichiro Tomita1; Hiromi Hyodo2; Takashi Koike1; Sei-ichiro Kojima4; Takashi Minemura4; Shunichi Kato2
1Tokai University, Pediatrics, Kanagawa, Japan; 2Tokai University, Cell Transplantation and Regenerative Medicine, Kanagawa, Japan; 3Tokai University, Clinical Laboratory, Kanagawa, Japan; 4Tokai University, Internal Medicine, Kanagawa, Japan

Background: Fatty liver and gonadal dysfunction have been identified as potential late effects of therapy in adult survivors treated with SCT. Obesity and metabolic syndrome are also associated with low testosterone levels in general population.

Objectives: The objective was to determine the relationship between degree of fatty liver and testosterone levels in adult survivors.

Methods: We reviewed the clinical records of 34 patients who received allogeneic SCT at Tokai University Hospital. The median age of the 34 patients at SCT was 10.0 years, the median age at the last evaluation was 25.5 years, and the median follow-up duration after SCT was 15.9 years. The study population was categorized into 4 groups: CRT (cranial radiotherapy) + TBI (total body irradiation) group, TBI group, TAI (thoraco-abdominal irradiation) group, and Chemo groups.

Results: Among the 34 patients, 1 patient treated with only chemotherapy had a greater than 25 kg/m2 BMI. On the other hand, 11 patients had a BMI less than 18.5 kg/m2. No patient satisfied the criteria for metabolic syndrome.

Conclusions: Further studies will be performed to out the compliance of GH administration due to the response of growth after GH administration.

PAO-86

Abstract withdrawn.

PAO-87

Short—term effect of the diabetes education program in children and adolescents with type 1 diabetes mellitus

Min Jae Kang; Shin Mi Kim; Young Ah Lee; Jieun Lee; Juyoung Yoon; Sei Won Yang; Choon Ho Shin
Seoul National University Children’s Hospital, Pediatrics, Seoul, Republic of Korea

Background: Diabetes mellitus is a chronic disorder and strict glycemic control, which cannot be successfully obtained without behavior modification, is the most important factor in prevention and management of complications.

Objective and hypotheses: The purpose of this study was to investigate the short—term effects and associated factors of the diabetes education program and to assess the necessity of regular and structured education and support in diabetic children and adolescents.

Methods: Thirty patients (10.0—18.9 years) with type 1 diabetes mellitus (T1DM), attending the diabetes clinic in Seoul National University Children’s Hospital, were included in the diabetes education program with intensified treatment. A six—day—course program was provided by a diabetes care team with doctors, a specialist diabetes nurse, a clinical dietitian, and a social worker. Patient data of disease duration and complication studies at the time of enrollment were reviewed and changes in HbA1c levels before and after the education program were analyzed.

Results: In 28 of 30 patients, significant decrease of average HbA1c levels (average 0.9%, median 0.8%, P<0.001) was observed after education. The decrease in average HbA1c levels was prominent in patients who were educated for the first time. On follow—up, HbA1c level at 3 months was significantly decreased (P=0.009) but after 9 months, it tended to increase again. The decrease of average HbA1c levels after education was negatively correlated with disease duration (r=-0.60, P<0.001).

Conclusions: The short—term effect of the diabetes education program with intensified treatment in diabetic children and adolescents was optimistic but regular education and support in these patients should be sustained.
Phenotypic and metabolic characteristics in non-obese adolescents with PCOS

Hae Soon Kim1; Hye Jin Lee2; Ji Young Oh1; Young Sun Hong1; Yeon-Ah Sung1
1Ewha Womans University School of Medicine, Pediatrics, Seoul, Republic of Korea; 2Ewha Womans University Mokdong Hospital, Internal Medicine, Seoul, Republic of Korea

Purpose: Polycystic ovary syndrome is characterized by hyperandrogenemia, insulin resistance, and dyslipidemia. We evaluated the clinical characteristics and metabolic components of non-obese adolescent girls with PCOS.

Subjects and methods: Thirty-six non-obese (BMI<25 kg/m2) adolescent girls (16-18 years) with PCOS were compared to thirty-two control group girls in similar age and BMI with regular menstrual cycles and were evaluated for anthropometric data and blood pressure. Fasting glucose, triglyceride, HDL-cholesterol, LDL-cholesterol, GOT, GPT were measured.

Results: BMI and waist circumference of the PCOS group were not different to the control. Frequency of menstruation and FG score of the PCOS group were significantly lower than the control. Blood pressures of the PCOS group were different compared to the control. Fat mass and fat percent were not evaluated. The PCOS group BMI was significantly higher than the control group BMI. Bone age was significantly lower than the PCOS group.

Conclusions: In non-obese adolescents with PCOS, metabolic derangements were not remarkable.

Does gonadotrophin-releasing hormone analogue affect of the body mass index in the girls with idiopathic precocious puberty?

Aylin Gunen
Goztepe Educational and Training Hospital, Pediatric Endocrine Clinic, Istanbul, Turkey

Background: To assess whether Gonadotrophin-releasing hormone analogue (GnRHa) affects body mass index in children with idiopathic central precocious puberty (ICPP).

Patients and methods: At least 12 months followed up 41 girls (mean age 8.66±3.3 years) with CPP were included in the study: 34 girls with ICPP were followed up 18 months. Complaints had been begun before 8 years old. 28 girls underwent GnRH stimulation test. All children were treated with Leuprolide acetate (LA) 3.75 mg/q4wk and the dose was increased only if there is a complaint.

Results: An initial dose of LA 3.75 mg/4 wk was efficient in most girls with ICPP. Unfortunately if this dose would be increased, patients would have a tendency having increased BMI. Clinicians should be alert of obesity risk in children treated with LA.

Age of puberty in a sample of Iranian girls

Fatemeh Saffar1; Maryam Rostamian2; Toktam Karimzadeh2; Neda Esmailzadeh1; Stel Van Buuren2
1Qazvin university of medical sciences, Pediatric Endocrinology, Qazvin, Islamic Republic of Iran; 2Qazvin university of medical sciences, Pediatrics, Qazvin, Islamic Republic of Iran; 3Qazvin university of medical sciences, Children hospital clinical research center, Qazvin, Islamic Republic of Iran; 4TNO Quality of life, Statistics, Leiden, Netherlands

Introduction: Entering puberty is an important milestone in reproductive life. Many physiological and psychological processes are influenced by puberty and hormone secretion. Based on data from late 1980s to present, pubertal entry and menarche is occurring earlier than in the past. National data on these milestones can serve as a baseline for assessing secular trends in pubertal development for the population.

Objective: To obtain normal values of pubertal stages in 6-16 years old girls of Qazvin province, Iran.

Methods: This cross-sectional study was conducted during 2009-2010 in 2759 elementary and middle school girls in Qazvin. Healthy girls (6.0 to 16.0 years old) were selected by clustered random sampling. In all subjects height and weight were measured and pubertal stages were evaluated by trained general practitioners. Breast stages 1-5 were determined by both inspection and palpation, using the criteria and definitions described by marshel and tanner. The self-reported date of menarche was recorded as well. Pubic hair stages were not evaluated because of cultural difficulties and most subjects disagree.

Results: The mean age of Tanner stage2 breast development (B2) was 9.67 years. The 3rd and 90th percentile for B2 was 6.5 and 12.5 years old, respectively. The mean age of menarche between 548 (24.5%) girls was 12.55 years (9.5 -14.75). The mean BMI was significantly higher in pubertal females (at stage B2 and menarche) comparing to prepubertal girls (at stage B1). In comparison with percentile value proposed by tanner, the 50th percentile age of stage B2 is decreased by 1.7 years in our subjects.

Conclusions: The mean age of pubertal onset in girls living in Qazvin (9.67 year) is lower than internationally accepted. Mean age of menarche is 12.55 years old and the onset of puberty less than 6.5 years is considered precocious in the study area.
PAO-91

Comparison of antithyroid antibodies in type 1 diabetic children and control group in 2010

Fatemeh Saffar1; Ali Asgari2; Tahereh Sadeghi3; Neda Esmaiilzadehdeh4
1Qazvin university of medical sciences, pediatric endocrinology, Qazvin, Islamic Republic of Iran; 2Qazvin university of medical sciences, pediatrics, Qazvin, Islamic Republic of Iran; 3Qazvin university of medical sciences, Nursing and Midwifery Faculty, Qazvin, Islamic Republic of Iran; 4Qazvin university of medical sciences, Children hospital clinical research center, Qazvin, Islamic Republic of Iran.

Background: Type 1 diabetes is the most common metabolic disease worldwide. thyroid autoimmune diseases accompany with type 1 diabetes is the most common endocrinopathy. Therefore, thyroid function tests and antithyroid antibodies in patients suffering from Type 1 diabetes is essential to diagnosis of thyroid autoimmune disorders.

Objective: To compare the anti-thyroid antibodies in patients with Type 1 diabetes and healthy individuals.

Methods: In this descriptive-analytic study, 65 children with Type 1 diabetes and 65 healthy children were selected using simple sampling. Anti-TG, Anti-Tpo, TSH and T4 hormones were measured. The amount of antibodies in both groups compared by using Chi-square statistical analysis, t-independent, Kruskal Wallis.

Results: There was not significant difference between two group of samples (case and witness group) in case of sex and age but BMI percentile of two group was significantly different. Positive Anti-TG in patients was 10.8% and in controls was 1.5% and the difference was statistically significant (p=0.029). 16.9% of patients and 3.1% of controls had positive Anti-Tpo that was significantly different between tow groups (p=0.024).10.8% of patients had overt hypothyroidism and 4.6% of controls had subclinical hypothyroidism. The difference was not significant statistically.

Conclusions: According to the results of research, it seems that the prevalence of Hashimoto thyroiditis in patients with type 1 diabetes is more than healthy people. Hence, thyroid function tests (TFT) and antithyroid antibodies (Anti-Tpo) in patients with Type 1 diabetes is necessary in order to early diagnosis of autoimmune thyroid disorders, prevention of their complications and timely treatment.

PAO-92

Maturity onset diabetes of the young (MODY) 2: clinical and genetic spectrum in five children

Maria Joao Oliveira; Cristina Couto; Manuel Oliveira; Joana Freitas; Helena Cardoso; Teresa Borges
Centro Hospitalar do Porto, Paediatrics Department - Paediatric Endocrinology Unit, Oporto, Portugal.

Background: MODY is a genetically heterogeneous form of diabetes (DM) characterised by early onset, autosomal dominant inheritance and a primary defect in pancreatic β-cell function. MODY2, caused by mutations in the glucokinase (GCK) gene, is one of the most common types. The authors describe 5 cases of MODY2 diagnosed in paediatric age.

Case report:

<table>
<thead>
<tr>
<th>Case</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of detection of diabetes (years)</td>
<td>5</td>
<td>5</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Family history of type 2 diabetes mellitus and/or hyperglycaemia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Body mass index (Kg/m2) at 1st exam (percentile)</td>
<td>12.6 (3)</td>
<td>19.4 (85)</td>
<td>15.8 (40)</td>
<td>24.1 (90.5)</td>
<td>14.2 (11)</td>
</tr>
<tr>
<td>Fasting glucose &gt;126 mg/dl</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Initial HbA1c (%)</td>
<td>7.3</td>
<td>6.5</td>
<td>5.3</td>
<td>6.1</td>
<td>5.9</td>
</tr>
<tr>
<td>Serum insulin (µU/ml)</td>
<td>&lt;2</td>
<td>9.4</td>
<td>&lt;2</td>
<td>8</td>
<td>6.6</td>
</tr>
<tr>
<td>Serum C peptide (ng/ml)</td>
<td>1.2</td>
<td>1.1</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Antibodies: anti-ICA, anti-GAD</td>
<td>negative, negative, negative, negative, negative</td>
<td>positive, negative, negative, negative, negative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose at 0h and 2h in oral glucose tolerance test (mg/dl)</td>
<td>0</td>
<td>116, 157</td>
<td>130, 189</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Genetic testing (GCK)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.579 +1_579 +33del33 in exon 5</td>
<td>mutation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.616A&gt;C in intron 5</td>
<td>mutation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.1268T&gt;A in exon 10 (not previously described)</td>
<td>mutation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.616A&gt;C in exon 6 (not previously described)</td>
<td>mutation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at genetic diagnosis (years)</td>
<td>7</td>
<td>11</td>
<td>12</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Treatment</td>
<td>diet measures</td>
<td>diet measures</td>
<td>diet measures</td>
<td>diet measures</td>
<td>diet measures</td>
</tr>
<tr>
<td>Complications</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
</tbody>
</table>
PAO-93  Persistent pubertal gynecomastia: an unusual presentation of a steroid 17-alpha-hydroxylase deficiency
Franoise Paris1; Marianne Ribottot1; Yves More1; Charles Sultant1
1CHU and UMI, Hormonologie and Unité d’Endocrinologie Pédiatrique, Montpellier, France; 2Centre de Biologie et pathologie Est, Service d’Endocrinologie Moléculaire et Maladies Rares, Brin, France

Background: Pubertal gynecomastia is a frequent reason for consultation in pediatric endocrinology. Although it is usually idiopathic, hypogonadism, hyperprolactinemia, hyperthyroidism and rare testicular or adrenal tumors must be considered. Most often, idiopathic pubertal gynecomastia regresses at the end of puberty when the testosterone (T) level increases.

Objective and hypotheses: We report a case of persistent pubertal gynecomastia revealing a mutation of steroid 17-alpha-hydroxylase (CYP 17).

Methods: This 15-year-old boy was referred to our pediatric endocrinology clinic because of bilateral gynecomastia, stage III with pigmented and developed areolae. Pubertal development was P3,G3 with a normal penis (length=7 cm). Basal LH and FSH were 7.5 µIU/ml (N=7-10) and 17.8 µIU/ml (N=15-18). E2 level was 175 µmol/l (N<180). Basal PRL level was 230 µIU/ml (N<500). Plasma TSH and T4L levels confirmed euthyroid state. Plasma βCG and αFP were negative. Testicular sonography found normal testis structure. The low plasma T led us to evaluate other steroid precursors. Plasma progesterone (P) level was 10.9 nmol/l (N=0.7-2) with low and non-ACTH-stimulated plasma cortisol level (15.4–212.3 µmol/l).

Results: The discordance between the high P level and the low values of other 17OH steroid precursors suggested 17OH deficiency. Sequencing of the CYP17a gene identified an heterozygote composite mutation: p.Pro35Thr and p.Arg239X. Substitution by testosterone enanthate was introduced.

Conclusions: This report points out the usefulness of investigating adolescent with persistent pubertal gynecomastia to identify a specific cause and thus propose adequate management.

PAO-94  Congenital hypothyroidism in a neonate born to a mother with autoimmune thyroid disease
Malgorzata Kumorowicz-Czoch1; Dorota Tylek-Lemanska2
1Polish-American Institute of Pediatrics, Collegium Medicum, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Krakow, Poland; 2University Children’s Hospital in Krakow, Division of Screening and Inborn Errors of Metabolism, Krakow, Poland

Background: Congenital hypothyroidism (CH) induced by maternal TSH receptor-blocking antibodies is responsible for approximately 2% of all CH cases.

Objective: A case report of a newborn with CH born to mother with autoimmune disease.

Methods: TSH in blood on filter paper, serum TSH, FT4 and TSH receptor antibodies (TRAb) tests, imaging pictures.

Results: A female newborn was presented pregnancy 1, delivery 1, terminated by a cesarean section at 40 weeks of gestation, birth weight 3150g, length 54cm, Apgar score 8 and 10 at 1 and 5 minutes, respectively). Maternal medical history indicated hyperthyroidism treated with thiamozol for 5 years, followed by hypothyroidism supplemented with L-thyroxin (LT4) for 3 years prior to conception and during pregnancy.

Available data suggested LT4 substitution during pregnancy to be insufficient, resulting in periodic hypothyroxyxena. Suspected fetal arrhythmia led to echocardiography at 31 weeks of gestation, showing regular, but rather slow heart action (112-120/min). In mass screening for CH, TSH concentration in blood on filter paper was 130.5 µIU/L [N<15]. Serum levels of TSH >60 mIU/L [N<0.49] and FT4 9.6 pmol/l [N<10.26] determined in the 4th day of life confirmed the diagnosis of CH. A high neonatal TRAb value [67.8 IU/L, N<1] was correlated with maternal TRAb [68.5 IU/L]. Ultrasound showed the thyroid situated normally and normal in size, yet no marker uptake by the gland was demonstrated by Tc99m scintiscan.

On day 7 of life, the neonate received LT4 substitution at the dose of 12 µg/kg/d, the dosage being modified based on serum FT4 and TSH levels. A decreasing demand for LT4 was seen along with normalization of TRAb concentration; at 4 month of life, TRAb was 0.7 IU/L. At 13 month of life serum FT4 and TSH levels during LT4 substitution (1 µg/kg/d) were normal.

Conclusions: The presented case confirms the diagnostic importance of TRAb determinations in newborns with CH born to mothers with autoimmune disease, additionally pointing to maternal hypothyroxinemia in pregnancy as a significant CH risk factor in newborns.

PAO-95  Central precocious puberty in a female child of very young age
Kim Jong-Duck1; Choi Seo-Seung2
1Wonkwang University Hospital, Pediatrics, Iksan, Republic of Korea; 2Wonkwang University Hospital, Radiology, Iksan, Republic of Korea

Background: Central precocious puberty under age of 6 years old is rarely related to morphological abnormality of hypothalamus and pituitary gland, and the type of abnormality was variable.

Objective and hypotheses: We report a case that a two year and 10 month old female child was diagnosed central precocious puberty with pituitary intermediate cyst.

Methods: This child was visited the pediatric out-patient clinic due to breast budding and progressively increased size of breast for three months. Physical examination with laboratory and radiological study for precocious puberty of this patient was done.

Results: On visiting day, breast size was 3 x 3 cm and pubic hair was not noticed. Height and weight of this patient were 99.6 cm (95-97 percentile) and 16 kg (90-95 percentile). Head circumference of this patient was 49 cm (50-75 percentile). This patient was born by the full term normal spontaneous vaginal type delivery and birth weight was 3,200 gm, and height 49 cm. Bone age was 5 years old but chronological age was two year and 10 months old. The basal serum level of E2 and LH was 25.58 pg/ml and 7.8 µIU/ml respectively, but the maximum serum level of LH was 43.8 pg/ml after GnRH stimulation. Brain MRI shows pituitary cyst between anterior and posterior pituitary lob. Breast size of this patient regresses to 2 x 2 cm and sustained after GnRH agonist therapy.

Conclusions: We report a case of central precocious puberty that is very young age with intermediate cyst of the pituitary gland and respond well to GnRH agonist therapy. However, careful follow-up will be needed in this patient.

PAO-96  The association of thyroid autoimmunity with statural development in a group of type 1 diabetes mellitus children
Aura Diana Reghina1; Alice Albu1; Nicoleta Petre1; Madalina Constantirii1; Maria Mihu1; Suzanna Florea1; Simona Fica1
1University of Medicine and Pharmacy Carol Davila, Elias Hospital, Endocrinology and Diabetes, Bucharest, Romania; 2Elias Hospital, Endocrinology and Diabetes, Bucharest, Romania; 3Marie Curie Hospital, Pediatric, Bucharest, Romania; 4Elias Hospital, Laboratory, Bucharest, Romania

Background: Type 1 diabetes mellitus is frequently associated with other endocrine autoimmunity and the risk is increased by the duration of diabetes. These associations may have a negative impact on diabetes control and children development.

Aim: The aim of the study was to evaluate the impact of thyroid autoimmunity on statural growth of children with type 1 diabetes mellitus.

Material and method: We examined a group of children with type 1 diabetes mellitus. We collected demographic data; we performed general physical examination, height, weight, thyroid gland, and laboratory data: glycated hemoglobin, thyroid peroxidase antibodies (TPOAb). The score of standard deviation (SDS) was calculated as the difference of actual height and mean height for age and gender divided by standard deviation value. We defined short stature as a SDS under –2 DS. An informed consent was obtained from children’s parents or legal tutors.

Results: We studied 68 patients (36 boys) with mean age 11.22±4.02 years, mean duration of diabetes 3.43±2.55 years and mean glycated hemoglobin 7.54±1.58.

50th Annual Meeting of the ESPE Horm Res 2011;76(suppl 2) 289
8.94±1.9%; 16 patients (23%) had thyroid autoimmunity. None of our patients had short stature.

We found a significant association between thyroid autoimmunity and lower SD score: 0.26 SD vs 0.98 SD (p=0.043). Mean glycated hemoglobin was significantly higher in patients with thyroid autoimmunity 9.7% vs 8.6% (p=0.05), but BMI did not differ significantly between the two groups. Logistic regression analysis revealed that low SDS (SDS under 0) was independently associated with duration of diabetes (p=0.049), but not with birth weight, glycated hemoglobin, and TPOAb.

Conclusion: Our data suggest a significant association between thyroid autoimmunity and height in children with type 1 diabetes mellitus, but this seems to be explained by other factors such as diabetes duration.

**PAO-99**

A case of myasthenia gravis with Graves disease

ORDER ASAN: Aycaan Zehra; Semra Cetinkaya; Havva Nur Pelet

Kendirci; Sebahat Yilmaz Azagaloglu; Veselij Nijat Basci

Ankara, Pediatric Endocrinology, Ankara, Turkey

Background: Thyrotoxicosis due to autoimmune thyroid disease (AITD) occurs in % 5-10 of patients with Myasthenia Gravis (MG) whereas MG has a frequency of % 0.2 among the patients with AITD. MG and AITD can also be seen together in Autoimmune Polyglandular Syndrome (APS) type 2 and type 3

Objective and hypotheses: Hereby, we report a patient with MG and Graves diseases.

Methods: A 15 years old male patient was referred to our clinic for hyperthyroidism. He had diaphoria since 8 months and pititis since 3 months. His height was 169.5 cm, weight was 64 kg, blood pressure was 130/80 mmHg and he had a heart rate of 132/minute. He had unilateral pititis and diffuse enlarged thyroid gland. Laboratory findings were as follows: TSH: <0.004 mU/l, free T4: 4.4 ng/dl, free T3: 13.7 pg/ml, anti thyroglobulin antibody: 2175 U/ml, anti microsomal antibody: >1000 IU/ml, TSH receptor antibody: 36.9 U/l. He had a positive response when we performed prostigmine test.

Results: Our case was diagnosed with MG and Graves diseases. He started to receive methimazole, propranolol, predostigmine. We found that plasma cortisol was 10 µg/dl, ACTH was 23 pg/ml, c ANCA, p ANCA, anti dsDNA, ANA, anti Ro, anti La and anti tissue transglutaminase antibodies, anti GAD, anti insulin antibody, islet cell antibody were negative. Vitamin B12 was 175 pg/ml and parietal cell antibody was positive. So, we started to give B12 vitamin replacement. We regulated methimazole dosage, beta- blocker therapy was terminated and there was a decline in TSH receptor antibody levels. His diaphoria was recovered on the second month of predostigmine treatment.

Conclusions: Autoimmune thyroid diseases should be investigated in the presence of Myasthenia Gravis. Further exploration about Autoimmune Polyglandular Syndrome type 2 and type 3 is needed in the association of Myasthenia Gravis and Graves diseases.

**PAO-100**

Abstract withdrawn.

**PAO-101**

Recombinant GH treatment in a female patient with Seckel-like syndrome and a novel homozygous mutation 7055 – 7056insC in the PCNT gene

Natyalia Volvodz;1 Elena Hennessy; Louise Bicknell; Andrew Jackson

1Endocrinology Research Centre, Institute of Paediatric Endocrinology, Moscow, Russian Federation; 2Western General Hospital, MRC Human Genetics Unit, Edinburgh, United Kingdom

Background: Seckel syndrome is a rare autosomal recessive disorder, characterized by pre- and postnatal growth deficiency, microcephaly, mental retardation, and characteristic facial appearance beaklike protrusion of the mid-face (bird-headed). This disorder is associated with defective ATR-dependent DNA damage signaling. Mutations in ATR gene and also gene encoding pericentrin (PCNT) cause Seckel syndrome.

Objective and hypotheses: We describe rGH treated patient with confirmed Seckel-like syndrome.

Methods: We report a female patient, 1.5 years old, who has classic features of the syndrome Seckel: height at birth -3,3SD, postnatal growth retardation -10,5SD, OFC -9,9SD, bird-beak phenotype, mental retardation. She also has...
micronathia, face asymmetry, low-fitting ears, disproportionately large eyes, clinodactyly of fifth finger. The patient’s tooth system is at the initial stage of eruption. She does not have haematological and bone abnormalities.

Results: The girl had treatment of recombinant growth hormone “Saizen” 0.05 mg/kg/day. After six months of treatment height was -9.52SD, height velocity 5.5 cm/6 months (+0.53SD), the level of IGF-1 increased to 80.2 ng/ml (before growth hormone treatment IGF-1 was 46.9 ng/ml). Molecular genetic researches confirmed Seckel-like syndrome in our patient: a novel homozygous mutation in the PCNT gene 7055 – 7056insC. Her unaffected parents and two brothers are heterozygous for this mutation.

Conclusions: We described a positive effect of GH treatment in patient with Seckel-like syndrome with a novel homozygous mutation (7055 – 7056insC) in the PCNT gene.

**Results:**

**Method:**

Young women.

**Objective:**

Metabolic and breast cancer and metabolic syndrome.

**Conclusion:**

Her unaffected parents and two brothers are heterozygous for this mutation.

**Conclusions:**

We described a positive effect of GH treatment in patient with Seckel-like syndrome with a novel homozygous mutation (7055 – 7056insC) in the PCNT gene.

**Background:**

Juvenile granulose cell tumors a rare tumor which originates from the sex stromal cord, occurs in the first two decades of life and represents less than 5% of ovarian tumors in girls. It contains granulose and theca cells and is associated with endocrine manifestations of excess estrogen production. Treatment is surgical. The tumors markers are estrogens and inhibin.

**Objective and hypotheses:**

Describe two patients with granulose cell tumors presenting with precocious puberty.

**Methods:**

Describe two cases: case1: Five year old girl with thelarche, pubic hair, axillar odor and menarche. Physical examination breast Tanner 3, hyperpigmentation of the nipple and pubic hair Tanner 2. LH 0.1ng/dl, FSH 0.3 ng/dl pelvic ultrasound Heterogeneous isodense mass of right ovary. Bone age 10 years 6 months. Inhibit post quirurgical 45ng/dl. Two cases were diagnosed precocious puberty. Treatment was surgical and pathological. Two cases were diagnosed precocious puberty. Treatment was surgical and pathological report was JUVENIL GRANULOSA CELL TUMORS. CEA and alpha fetoprotein negative.

**Conclusions:**

Patients with granulosa cell tumors presented with precocious puberty, increased estrogen production and decreased gonadotropins. Pelvic Ultrasound reveals an ovarian mass. Treatment was surgical and supervision of inhibin of less than 10ng/ml.

**Background:**

Juvenile granulose cell tumors a rare tumor which originates from the sex stromal cord, occurs in the first two decades of life and represents less than 5% of ovarian tumors in girls. It contains granulose and theca cells and is associated with endocrine manifestations of excess estrogen production. Treatment is surgical. The tumors markers are estrogens and inhibin.

**Objective and hypotheses:**

Describe two patients with granulose cell tumors presenting with precocious puberty.

**Methods:**

Describe two cases: case1: Five year old girl with thelarche, pubic hair, axillar odor and menarche. Physical examination breast Tanner 3, hyperpigmentation of the nipple and pubic hair Tanner 2. LH 0.1ng/dl, FSH 0.3 ng/dl pelvic ultrasound Heterogeneous isodense mass of right ovary. Bone age 10 years 6 months. Inhibit post quirurgical 45ng/dl. Two cases were diagnosed precocious puberty. Treatment was surgical and pathological report was JUVENIL GRANULOSA CELL TUMORS. CEA and alpha fetoprotein negative.

**Conclusions:**

Patients with granulosa cell tumors presented with precocious puberty, increased estrogen production and decreased gonadotropins. Pelvic Ultrasound reveals an ovarian mass. Treatment was surgical and supervision of inhibin of less than 10ng/ml.
PAO-105

Growth hormone excess in two children with neurofibromatosis type 1 and optic pathway glioma
Patrizia Bruzzi; Assunta Albanese
Royal Marsden Foundation Trust, Paediatric Endocrine Unit, Sutton, United Kingdom

Background: In children with neurofibromatosis type 1 (NF1) growth hormone excess (GHE) is extremely rare, but reported in the presence of optic pathway glioma (OPG). GHE can be the result of hypothalamic regulatory defect due to OPG infiltration of somatotatinergic pathways reducing somatostatin tone and leading to GH-RH-mediated overproduction of GH.

Objective and hypotheses: We present 2 cases of children with NF1, OPG and GHE.

Methods: It is a case-report.

Results: First case. A pre-pubertal 5 years old girl with NF1 and a diffuse suprasellar low grade glioma involving the optic pathway was referred for tall stature. After completion of chemotherapy, GHE was documented by failure of GH levels to suppress during a standard OGTT and elevated age-adjusted plasma IGF1 levels. She was started on long acting somatostatin analogue (SSa) therapy which normalized her growth velocity and plasma IGF1 levels. Six months after starting SSa she developed central precocious puberty (CPP) and from age of 7.8 years she also received LHHRa therapy. However following an episode of acute pancreatitis at the age of 10.2 years SSa was stopped. IGF1 levels and growth velocity remained normal while off SSa and subsequently when at the age of 13.5 years LHHRa was also discontinued.

Second case. A tall 7.3 years old girl with NF1 and OPG treated with chemotherapy was referred for precocious puberty. CPP was confirmed and treated with LHHRa. Despite documented biochemical and clinical suppression of puberty, growth velocity remained accelerated with raised IGF1 age-adjusted plasma levels. GHE was suspected and then confirmed by a failure of GH levels to suppress in response to an OGTT. Treatment with SSa was started with a normalization of both auxological and biochemical data.

Conclusions: Tall stature and growth acceleration in children with NF1 and OPG require investigation for both precocious puberty and GHE.

PAO-106

Screening results for vascular complications and associated autoimmune diseases in children and adolescents with type 1 diabetes
Fatma Damar-Derya Top; Ozlem Kara-Dunis Essen
Ankara Child Diseases Hematology and Oncology Education and Research Hospital, Pediatric Endocrinology Department, Ankara, Turkey

Background: Diabetes-related microvascular complications, as retinopathy, nephropathy and neuropathy are life-threatening complications in children and adolescents with type 1 diabetes mellitus (T1DM). Longer duration of diabetes, older age and puberty are the risk factors for the development of complications. Further risk factors include smoking, hypertension, higher body mass index and dyslipidemia. Therefore prevention and screening for complications is an important part in the care of children and adolescents with T1DM.

Objective and hypotheses: Our aim was to investigate diabetic complications and associated autoimmune diseases in children and adolescents with T1DM of more than 5 years duration.

Methods: The study included 46 children and adolescents with T1DM (18 male, 28 female), mean aged 14.1±2.8 years, with a T1DM duration of 8.4±2.9 years. Forty-two (91.3%) cases were adolescent and 4 (8.7%) cases were in prepubertal age.

Results: Insulin treatment consisted of four daily injections in all of the patients and mean HbA1c level was 8.3% (range 5.9%-12.4%). The prevalence of microalbuminuria was 32.6%, dyslipidemia was 21.7%, hypertension was 17.4%, and peripheral neuropathy was 2.2%. None of the patient had diabetic retinopathy. Prevalence of autoimmune thyroiditis and celiac disease were found to be 21.7% and 6.5% respectively. Despite intensive insulin treatment, 47.8% (n=22) of patients with T1DM developed at least one detectable diabetes complication after approximately 8 years of diabetes. Microalbuminuria was the most common complication and the strongest risk marker was high blood pressure.

Conclusions: Annual complication screening should be done after diabetes duration of 5 years in patients with T1DM. Additionally screening at an onset and repeated measurements for autoimmune thyroiditis and celiac disease are recommended.

PAO-107

Cushing's disease in a 14-year old female: difficulties of diagnosis
Violeta Csakvary1; Zoltan Locsei2; Gyorgy Oroszlan3; Zita Halasz4; Miklos Toth5; Sandor Czirjak6; Karoly Raczi2
1Markusovszky Teaching Hospital, Department of Pediatrics, Szombathely, Hungary; 2Markusovszky Teaching Hospital, 1st Department of Internal Medicine, Szombathely, Hungary; 3University of West Hungary - Savaria Campus, Institute for Health Promotion, Szombathely, Hungary; 4Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary; 5Semmelweis University, 2nd Department of Internal Medicine, Budapest, Hungary; 6National Institute of Neurosurgery, Department of Neurosurgery, Budapest, Hungary

Background: Cushing’s disease (CD) is rare in childhood and remains a difficult condition to diagnose and treat. Although the diagnosis of CD is of crucial importance in effective diagnosis and treatment. Sometimes it is difficult to confirm the location of microadenoma in CD.

Objective and hypotheses: We report the case of 14-year old girl, who was referred to our hospital because of growth retardation with muscle weakness and rapid onset weight gain. On admission, she had typical Cushingoid appearance with Tanner pubic hair stage 3.

Endocrinological examinations showed elevated levels of serum cortisol, and 24-h urinary free cortisol (UFC), and plasma ACTH. Lack of diurnal variation of ACTH and cortisol was observed. Serum cortisol levels were not suppressed by low and high dose dexamethasone as well. We established ACTH dependent CD. Performing the corticophilin-releasing hormone (CRH) test, increased cortisol response confirmed the diagnosis of CD. Gonadotropin levels were subnormal suggesting a suppressive effect of chronic hypercortisolemia. Although, on 3.0 Tesla brain MRI, no microadenoma was detected in the pituitary gland. Considering the patient’s age, hormonal findings compatible with pituitary ACTH production and the possible complications the bilateral inferior petrosal sinus sampling for ACTH was not performed.

Results: Despite of the lack of positive radiomorphological MRI signs, the patient underwent successful and curative transphenoidal pituitary surgery and a 2 mm microadenoma was removed. The histopathological features–ACTH secreting microadenoma-was consistent with the diagnosis.

Conclusions: Hypercortisolism was resolved after pituitary surgery. Possessing the typical clinical presentation and endocrinological investigation of CD in special cases–lack of detected microadenoma- the transphenoidal surgery is henceforward a safe and effective procedure in children.

PAO-108

Noonan syndrome: clinical phenotype and response to GH treatment
Yuliya Makarava; Julia Boiko
State Center of Medical Rehabilitation, Pediatric Department, Endocrinology Group, Minsk, Belarus

Background: Noonan syndrome (NS) is a disorder characterized by congenital heart defects, facial dysmorphism, skeletal malformation and short stature. Objective and hypotheses: The aim of the study was to describe a cohort of patients with NS in Belarus, evaluate the effect of rhGH treatment for 24 months on metabolic, clinical and cardiac status in patients with NS.

Methods: Since 2008 at the State Endocrinology Center 8 NS patients (5m, 3f) were observed. Median age was 13.7yr (11.0-17.8). All but one were in puberty Tanner stage 2-3 at the first observation. One boy had early puberty, a gonadal atrophy was found in one boy also. Two patients had a mild growth retardation (mean height SDS -2.9 (from -4.8 to -2.0SDS)) according to population standards. Means birth weight and length were normal. Typical face dysmorphism were found in all patients. 3/8 were diagnosed with pulmonary valve...
stensosis, 3- with atrial septum defect, one at a time - with hypertrophic cardiomyopathy, tetralogy of Fallot and ventricular septal defect. Only 1/8 had mental retardation. 6/8 patients with severe growth retardation were undergone rGH treatment. Basal serum IGF-1 levels according to age and puberty stage were -1.9SDS. rGH dose ranged from 47 to 67 µg/kg/d. Anthropometry, bone age, serum IGF-1 level, lipids, fasting glycaemia and insulin, cardiac evaluations were performed at baseline, at 12 and 24 months of treatment.

Results: At 12 and 24 months of treatment mean height SDS elevation was found (A1 height SDS = 0.43 and A2 height SDS = 0.64, respectively). Basal serum IGF-1 levels normalized after 1st yr of rGH therapy: -0.48SDS. No significant difference was observed in lipids profiles, fast glycaemia, fast insulin levels and clinical cardiac status during two years of rGH treatment.

Conclusions: Cohort of patients with NS in Belarus showed the typical clinical phenotype as well as in other researches. Effect of rGH treatment starting at the age of puberty in NS is minimal. Early genetic analysis is required to be helpful in selecting the appropriate patients for rGH therapy.

PAO-109
Delayed diagnosis of a giant virilizing adrenocortical carcinoma in a girl presenting with mutism
Huseyin Demirbilek1; Mehmet Nuri Ozbek2; Serhan Kupelli8; Murat Kemal Cigdem2; Selver Ozcukic7
1Diyarbakir Children Diseases Hospital, Pediatric Endocrinology, Diyarbakir, Turkey; 2Dicle University, Pediatric Surgery, Diyarbakir, Turkey; 3Dicle University, Pathology, Diyarbakir, Turkey

Background: Adrenocortical carcinoma (ACC) is an unusual, and highly malignant childhood tumor. In children, the incidence is reported 0.3 cases per million per year. We describe a giant virilizing ACC in a girl who presented with a history of virilization and mutism.

Case report: A 5.5 year-old girl admitted to our clinic with mutism caused by deepening of voice. Her previous history revealed that pubic and axillary hair appeared at the age of 1 year and she was admitted to another hospital. However, the parents could not have brought the child to the regular follow up because of economic deprivation. During subsequent years, clinical progression of virilization have resulted in deepening of voice and ultimately a voluntary mutism have occurred which was chief complaint for admission to our hospital.

Overall mean HbA1c level was 8.1±1.8% (4.7-13.8). Glycemic control in children with T1DM requires optimal conditions guided by diabetes team both at home and at the school since children spend a remarkable time at school.

Methods: 114 children with T1DM from randomly selected schools from 1st to 12nd grade (6-18 yrs) were interviewed and a questionnaire was filled by the patients and the parents.

Results: The same mutation was found in the father; a family tree provides more evidence on the heredity transmission. The inter-disciplinary treatment concept is shown.

Conclusions: The exact clinical description, confirmation of SPRED1 gene mutation and the assessment of heredity allow for an individual treatment and reduction of psychological strain.

PAO-110
Growth disorders in Legius syndrome (LS) - a differential diagnosis to neurofibromatosis I (NF1)
Klaus-Peter Ullrich1; Gudrun Wiedemann2; Sebastian Ullrich3; Eric von Bueren4; Allhard Hoffmann5; Sabine Weidense6
1Helios Clinics Gotha, Clinic for Pediatrics and Youth Medicine, Gotha, Germany; 2Private practice, Pediatrics, Erfurt, Germany; 3Regional government, Continuing Education Emscher Lippe, Dorsten, Germany; 4Thermo Fisher Scientific, Inc., Strategic Marketing, Kalamazoo, United States; 5Research Center for Medical Technology and Biotechnology, Research, Erfurt, Germany; 6Center for Human Genetics, Genetics, Erfurt, Germany

Background: Albeit growth disorders occur in 1 of 33 children, only in 1 of 6,000 children a growth hormone deficiency (GHD) results to be the cause, being early discovered and treated successfully. Seldom genetic disorders require complex diagnosis, like the LS, termed after Dr. Eric Legius since 2009 (Messiaen et al 2009), which belongs to the group of neuro-facial-cutaneous syndrome related to NF1. Children with short stature and macrocephaly, axillary freckling cafe-au-lait spots, signs of Noonan syndrome and learning disability funnel diagnosis towards NF1. If no punct-mutation of NF1 gene is present, LS is to be considered as a less severe and predictable prognosis. A mutation in the SPRED1 gene confirms LS. 155 patients have been reported so far.

Objective and hypotheses: Investigation of heredity transmission of LS.

Methods: We report a 6-year-old patient with typical NF1 symptoms. With no NF1 mutation, the analysis of SPRED1 gene showed the mutation c.293dupA in Exon 4, which was decided to also investigate in other family members.

Results: The same mutation was found in the father; a family tree provides more evidence on the heredity transmission. The inter-disciplinary treatment concept is shown.

Conclusions: The exact clinical description, confirmation of SPRED1 gene mutation and the assessment of heredity allow for an individual treatment and reduction of psychological strain.

PAO-111
Diabetes related problems and diabetic controls among the school children with type 1 diabetes mellitus living in Istanbul
Eda Sunnetci; Serap Turan; Zeynep Atay; Tulay Gurur; Abdullah Bereket
Marmara University, Pediatric Endocrinology, Istanbul, Turkey

Background: Adequate glycemic control in children with T1DM requires optimal conditions guided by diabetes team both at home and at the school since children spend a remarkable time at school.

Objective and hypotheses: We aimed to search problems related to diabetes management encountered at school.

Methods: 114 children with T1DM from randomly selected schools from 1st to 12nd grade (6-18 yrs) were interviewed and a questionnaire was filled by the patients and the parents.

Results: Overall mean HbA1c level was 8.1±1.8% (4.7-13.8). Glycemic control was good (HbA1c ≤7.5 %) in 42% of the patients. 68% of the diabetic children were followed by a pediatric endocrinologist, 12% by a paediatrician in government hospital and 15% by a pediatrician in private practice. HbA1c levels were lower in patients followed by a pediatric endocrinologist than those followed by a government based or private-practicing paediatricians (7.9%, 8.7% and 9.1%, respectively, p<0.05). 72% of the patients were visiting their doctors at least every 3 months while in 28%, doctor visits were less frequent and in 15%, there was no regular follow-up. 27% of the patients were checking their blood sugar ≤1-2/day. 55% of children were avoiding
BS measurement at school. The classmates and teachers of the patient knew that they were diabetic in %95 and %94 respectively. 30% of the children were avoiding injections at school, 33% were injecting at classroom, 15% at infancy, 11% at cantina and 11% at restrooms. There was no school nurse in 80% of the schools. 18% of the children reported severe hypoglycemia in the last year. Glukagon was present at 19% of the schools and 72% of the homes of diabetic children.

Conclusions: This survey demonstrated a need for a more vigorous education and organisation for diabetes-care (especially for blood sugar measurement, insulin injections and glucagon) at school environment in Istanbul. It also demonstrates importance of a specialist (pediatric endocrinologist) in care of children with T1DM.

PAO-112

Wolcott Rallison syndrome (WRS): a case report of a rare genetic disorder presenting with permanent neonatal diabetes mellitus

Waqas Imran Khan1; Muhammad Waqar Rabbani2; Sian Ellard3; Sara Flanagan2

Children’s Hospital & Institute of Child Health, Department of Endocrinology, Multan, Pakistan; 2Children’s Hospital & Institute of Child Health, Department of Paediatric Medicine, Multan, Pakistan; 3Royal Devon & Exeter NHS Hospital, Molecular Genetics, Exeter, United Kingdom

Introduction: WRS is the most common genetic cause of Permanent Neonatal Diabetes Mellitus in consanguineous families. Much information can be gained by the identification of a susceptible gene in a particular disorder. WRS is a rare autosomal recessive disorder resulting from mutations in EIF2AK3 (or PKR), the gene encoding the eukaryotic translation initiation factor 2 α kinase 3 (eIF2α kinase).

Description: We report a case of 35 days old female, who presented with seizures, hepatic dysfunction and diabetes mellitus and diagnosed as WRS on the basis of genetic studies with identification of mutations in the gene EIF2AK3. The baby was born an uneventful 36 weeks pregnancy from healthy consanguineous parents with birth weight of 1700 grams. Initial glucose level was 1020mg/dl, insulin needs dropped gradually from 4u/kg to 0.5u/kg until adequate glycemic control was achieved.

Result: Sequencing analysis has shown that she is homozygous for the nonsense mutation, L425X, in exon 7 of the EIF2AK3 gene. This mutation is a T → A substitution at nucleotide 1274 (c.1274T>A) resulting in a premature termination codon (p.Leu425X). This result confirms a diagnosis of Wolcott Rallison syndrome. Her mother is heterozygous for the EIF2AK3 nonsense mutation L425X and her father, heterozygous for a nonsense mutation in exon 7 of the EIF2AK3 gene.

Discussion: WRS results from the lack of trans-membrane enzyme activity which leads to the cell death by apoptosis in a number of different tissues. The development of early onset diabetes mellitus and skeletal dysplasia in almost all patients of WRS explains the high level of expression of EIF2AK3 in both pancreatic β cells and bone tissues. However the gene is expressed at a lower level in several other tissues, which all patients of WRS explains the high level of expression of EIF2AK3 in both tissues. The clinical features of variable intensity found in different tissues demonstrate importance of a specialist (pediatric endocrinologist) in care of children with T1DM.

PAO-149

Keeping neonatal diabetes mellitus under control in children with cerebral palsy

M. van der Graag1; F. van den Berg2; A. van der Meer3; P. van der Linden4

1Department of Pediatrics, Academic Medical Center, Amsterdam, The Netherlands; 2Department of Endocrinology, Academic Medical Center, Amsterdam, The Netherlands; 3Department of Physiotherapy, Rehacity, Elst, The Netherlands; 4Department of Orthopedics, Academic Medical Center, Amsterdam, The Netherlands

Introduction: The prevalence of cerebral palsy (CP) is approximately 150/100,000 births in The Netherlands. Diabetes mellitus (DM) is present in 0.5-1% of children with CP. In this study we investigated how neonatal diabetes was managed in children with CP.

Materials and methods: This was a retrospective study involving all children with CP and diabetes mellitus (n=5) born between January 2000 and December 2009 in the Academic Medical Center, Amsterdam, The Netherlands. Data were retrieved from medical records.

Results: All children were male and the median age at diagnosis of diabetes mellitus was 1.5 months (range 1-6 months). No obesity was present. All children had a cochlear implant and were on a school program. The majority of children were on a diet, combined with oral glucagon or intravenous insulin. One child was on continuous intravenous insulin. All children were followed up for a median of 6.5 years (range 1.5-12.5 years).

Discussion: This study demonstrates that neonatal diabetes can be managed successfully in children with CP. Early diagnosis and appropriate treatment are essential to prevent long-term complications.

PAO-114

Following up plasma LH and estradiol in overweight girls with idiopathic precocious puberty during GnRH agonist therapy

Se-Min Lee

Hanyang University, College of Medicine, Pediatrics, Seoul, Republic of Korea

Background: They have reported that obesity was associated with development of idiopathic precocious puberty (IPP). Objective and hypotheses: We compared suppression of plasma LH and estradiol between overweight girls and nonoverweight group to evaluate whether overweight is associated with suppression of plasma LH and estradiol during GnRH agonist therapy in patients with idiopathic precocious puberty. Methods: We measured plasma LH and estradiol of overweight (n=16) and nonoverweight group (n=27) before and after 3 months of GnRH agonist therapy. Results: Follow-up plasma LH and estradiol were not significantly different between overweight group (0.57 ± 0.31 mIU/mL, 7.77 ± 3.55 pg/mL, respectively) and nonoverweight group (0.4 ± 0.29 mIU/mL, 7.80 ± 4.91 pg/mL, respectively). Significant suppression of plasma LH (<0.6 mIU/mL) was observed in 62.5% of overweight group (n=10) and in 70.4% in nonoverweight (n=19). Significant suppression of plasma estradiol (<10 pg/mL) was observed in 81.3% of overweight group (n=13) and in 81.3% in nonoverweight (n=22). Conclusions: In 3 months of GnRH agonist therapy, suppression of plasma LH and estradiol was not significantly different between overweight and control group.

PAO-115

The analysis of the CYP21A2 gene in children with 21-hydroxylase deficiency from Republic Bashkortostan (Russia)

Vita Akhmetova1; A. Rakhkimkulova2; Oleg Malievsky2; Elza Khusnutdinova2

1Institute of Biochemistry and Genetics, Department of Molecular Genetics, Ufa, Russian Federation; 2Bashkir State Medical University, Department of Pediatrics, Ufa, Russian Federation

Background: Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders of adrenal steroidogenesis in which 21-hydroxylase deficiency (21-OHD) accounts for over 95% of cases.

Methods: We studied 87 patients with 21-OHD from Republic Bashkortostan with salt wasting (SW) (n=42) and simple virilizing (SV) (n=45) forms. Mutations of the CYP21A2 gene were revealed in 71.82% of SW. Objective and hypotheses. To evaluate age of patients with 21-hydroxylase deficiency, at which the disease was diagnosed, during performance of the neonatal screening.

Population and/or methods: In 2006-2010, in Republic of Bashkortostan, using the neonatal screening the 21-hydroxylase deficiency was revealed in 15 newborns. To evaluate efficiency of the neonatal screening, we determined terms of performance of each screening stage, age (median, minimal and maximal age) at making out the diagnosis of SW and SV 21-OHD in boys and girls.

Results: Age at making out the diagnosis of SW 21-OHD in girls after introduction of screening did not essentially change (medians 11 and 8 days, respectively). SV 21-OHD in girls in all cases began to be diagnosed at the neonatal period (median 15 days, min-max 0-21 days). In boys, all cases of the SW 21-OHD after the beginning of screening were revealed at the neonatal period as early as before development of the salt-wasting crisis (median 20 days, min-max 14-28 days). After introduction of screening, median of the age, at which the diagnosis was finally established, were 43 days. SV 21-OHD in boys was diagnosed later as compared with SW 21-OHD in boys and with both forms in girls. This is accounted for by that due to a large amount of the increased 17-hydroxyprogesterone values in boys the repeated study of this marker was performed every 2 weeks.

Precise conclusion: Neonatal screening has allowed decreasing essentially the time of diagnostics of the 21-hydroxylase deficiency, especially in boys.
the studied CAH-chromosomes with the following frequencies: delA2orL-GC (27.62%), R356W (16.02%), l2splice (11.6%), I172N (7.18%), P318X (4.97%), V281L (2.76%), P30L (1.1%) and P453S (0.55%).

Results: The mutations frequency distribution in the CYP21A2 gene in 2 groups of patients with classical disease forms showed statistically significant differences. SW 21-OHD patients demonstrated delA2orL-GC of the gene CYP21A2 twice more often than patients with SV (37.65% and 19.32%, respectively), y2=6.28, p=0.014; mutation R356W - 2.6 times higher (23.53% and 9.09% respectively, y2=5.62, p=0.018), mutation l2splice = 2.9 (16.47% and 5.68%, respectively, y2=4.1, p=0.043), and mutation P318X = 8.3 (4.41% and 1.14% respectively, y2=4.4, p=0.04). The mutation I172N, on the contrary, was more typical for SV patients than for SW patients (13.6% and 1.18%, respectively, y2=7.95, p=0.005). Mutations P30L and V281L were detected only in SV patients.

Thus, we have been able to detect the spectrum of diagnostic significant CYP21A2 gene mutations typical for SW and for SV forms in CAH patients. We found 6-21-OHD patients who carried 3 mutations, two of which formed a cluster, 318X=R356W (2.87%, 5/174), I172N=P318X (0.57%, 1/174).

Precise conclusion: The studying of molecular-genetic nature of 21-OHD represents the doubtless scientific and practical importance in respect of use of the received data for differential diagnostics of its various forms, medical and genetic consultation and prenatal diagnostics.

PAO-116
A rare case of adiposegenital puberal obesity
Susanne Frick-Otto1, Reinhardt Mühlenberg1, Katrin Held2
1Helios Clinic Krefeld, Department of Endocrinology, Krefeld, Germany; 2Helios Clinic Krefeld, Children's Department, Department of Endocrinology, Krefeld, Germany

Background: We present a girl with the diagnosis of a growth hormone producing tumour of the pituitary gland.

Objective: We would like to present the case of a 1411/12-year-old girl who was referred to our outpatient clinic for endocrine evaluation of obesity. The auxology findings showed a body weight of 97.6 kg, a BMI of 32.8 (> 99.8 Perc.) and a body height of 172.6 cm (> 90. Perc.) with familiar aim size of 156 cm. X-ray of the left hand showed a retardation of the bone age of 1.6 J, the prospective final size was calculated at 177 cm. 2-3 years ago, at the beginning of the first puberty signs remarkable changes of the physical development and the appearance were noted for the first time.

The patient increased extremely in weight and showed a persistent growth push by shoe size at last 45. Clinically she suffered from occasional episodes of headaches, strong sweating and a primary amenorrhoe. Because of the clear discrepancy between informal aim size and prospective final size, the external appearance of the patient and her distinct obesity we performed detailed endocrinology analysis incl. chromosome analysis, cerebral MRI and ophthalmologic investigation and could diagnose a growth hormone producing tumour of the pituitary gland. The patient was transferred to a specified neurosurgery for transsphenoidal tumor extirpation.

Methods: Clinical history and clinical findings, measuring of height, familiar auxology findings showed a body weight of 97.6 kg, a BMI of 32.8 (= 99.8 Perc.) and a body height of 172.6 cm (= 90. Perc.) with familiar aim size of 156 cm. X-ray of the left hand showed a retardation of the bone age of 1.6 J, the prospective final size was calculated at 177 cm. 2-3 years ago, at the beginning of the first puberty signs remarkable changes of the physical development and the appearance were noted for the first time.

The patient increased extremely in weight and showed a persistent growth push by shoe size at last 45. Clinically she suffered from occasional episodes of headaches, strong sweating and a primary amenorrhoe. Because of the clear discrepancy between informal aim size and prospective final size, the external appearance of the patient and her distinct obesity we performed detailed endocrinology analysis incl. chromosome analysis, cerebral MRI and ophthalmologic investigation and could diagnose a growth hormone producing tumour of the pituitary gland. The patient was transferred to a specified neurosurgery for transsphenoidal tumor extirpation.

Result: After diagnosis of a growth hormone producing tumour of the pituitary gland, the patient was transferred to a specified neurosurgery for transsphenoidal tumor extirpation.

Conclusion: If you see a clear discrepancy between informal aim size and prospective final size in a patient you have to search after a tumor in the pituitary gland.

PAO-117
Delirium in diabetic ketoacidosis
Ayse Nurcan Cebeci1, Ayla Guven2
1Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey
2Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Background: Neurologic changes during the course of diabetic ketoacidosis (DKA) should be considered as early signs of cerebral edema and should be treated immediately. Yet, delirium is not a usual neurological complication of DKA and has not been reported in pediatric DKA so far. We report our experience with a teenage girl who developed hyperactive delirium during the treatment of DKA.

Case report: A 15-year-old female patient with known type 1 diabetes mellitus of two years duration was referred because of fatigue and symptomatic hyperglycemia. She had abdominal pain for the last 24 hours, could not eat her meals appropriately and had hypoglycemia in the morning of admission. Due to appetite loss and hypoglycemia, she omitted the insulin dose at lunch time. On physical examination she was alert, had dehydration, deep sighing respiration and a smell of ketones. Her height was 168 cm (+1.02 SDS), weight 68 kg (+1.66 SDS), respiratory rate was 38/min, pulse 80/min. She had normal body temperature and blood pressure. Blood glucose was 414 mg/dl (23 mmol/l), capillary pH: 6.99 and bicarbonate: 5.0 mmol/l. Basic excess was -25.2 mmol/l and anion gap was 29.8 mmol/l. Blood urea, liver enzymes and electrolytes were within normal limits. At the sixth hour of treatment the acidosis with administration of fluid and insulin, the patient became delirious. The delirium persisted despite the normalization of acidosis and was difficult to manage. Brain imaging studies revealed neither brain edema nor other intracranial pathologies. No evidence of intoxication could be found. The patient gradually regained consciousness and "merely" suffered from massive DKA associated with infection.

Conclusions: We did not find any similar case in childhood period in the literature thus we thought that clinicians should be aware that delirium can be seen in DKA due to severe acidosis.

PAO-118
Differences in clinical features and responses to treatment in different age groups of children with diabetic ketoacidosis and ketosis
Ayse Nurcan Cebeci1, Ayla Guven1, Heves Kirmizibekmez1, Metin Yildiz1, Fatma Dursun2
1Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey
2Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Objective and hypotheses: To compare clinical features and responses to a certain treatment protocol in different age groups.

Material and methods: Hospital records of patients with diabetic ketoacidosis (DKA) and ketosis (DK) who admitted to our hospital between January 2007 and December 2009 were reviewed. Symptoms, clinical and laboratory findings of all patients were recorded. Patients were divided into subgroups regarding to age [Group 1 (0-5.0 years), Group 2 (5.1-10.0 years), Group 3 (> 10.1 years)]. All patients with DKA were treated with a standardized intravenous fluid and insulin therapy while patients with DK were treated with subcutaneous insulin. The therapy protocol was analyzed in terms of amount and duration of fluid therapy, dose of insulin infusion and complications of therapy.

Result: 132 episodes in 107 patients with DKA (101 episodes) and DK (31 episodes) were studied. 64 patients (%60) were female, 43 (%40) were male, 81 (%60) were in new onset, 51 (%40) were in established diabetes. There were 22 episodes in group 1 (16.7%), 30 episodes in group 2 (22.7%) 80 episodes in group 3 (60.6%). Patients in group 1 and 2 reported more polydipsia and polyuria than patients in group 3 involving patients mostly with established diabetes. Blood glucose and corrected Na levels, as well as pH and osmolality did not differ between groups. HbA1c was found significantly higher with age. Children in group1 had significantly lower HCO3 levels compared to group 2 (p=0.047) and group 3 (p=0.014). Duration and amount of fluid therapy did not differ between groups. Patients in group 3 received significantly higher doses of insulin and patients in group 1 received significantly more bicarbonate therapy. Only one patient experienced cerebral edema which recovered without any sequel owing to appropriate therapy.

Conclusion: Children less than five years of age are at higher risk of acidosis and require more attention and closer monitoring during treatment.
PAO-119

Long term longitudinal evaluation of overweight and insulin-resistance in patients treated for acute lymphoblastic leukaemia during childhood

Federico Baronio; Martina Zanotti; Alessandra Rollo; Arcangelo Prete; Riccardo Masetti; Alessandro Cicogna

University of Bologna, Pediatrics, Bologna, Italy

Background: Cranial radio-prophylaxis (CR) and total body irradiation (TBI) for hematopoietic stem cell transplantation are risk factors for obesity and insulin resistance (IR) in long term childhood cancer survivors.

Objective and hypotheses: To evaluate overweight and IR in a group of childhood acute lymphoblastic leukaemia (ALL) survivors who received or not radiotherapy (RT).

Methods: We evaluated 74 patients (pts) treated for ALL at our Centre, at mean age 5.2±3.1 years (yrs). They were subdivided in 3 groups according to RT: group 1 (CR 1800 cGy) 17/74 pts, group 2 (TBI 800-1800 cGy) 16/74 pts, group 3 (CR 1600 cGy, TBI 500-800 cGy) 21/74 pts. At the age of 18 yrs pts were divided in overweight and obese (BMI >90% SD of age/d) and normal weight. HOMA (insulin resistance index) was calculated in all pts.

Results: A significant higher mean BMI SDS (p<0.05) and IR prevalence (p<0.05) was found in group 1 compared to groups 2 and 3. In group 2 a significant lower HOMA (p<0.05) was found.

Conclusions: CR and TBI had a different effect on overweight and IR prevalence, CR being more detrimental than TBI.

PAO-120

Comparison of efficacy of growth hormone (GH) treatment in short children with neurosecretory dysfunction (NSD) and partial GH deficiency - 3 years of observation

Marek Hilczer1; Joanna Smyczynska1; Renata Stawerska1; Andrzej Lewinski2

1Medical University of Lodz, Department of Pediatric Endocrinology, Lodz, Poland; 2Medical University of Lodz, Department of Endocrinology and Metabolic Diseases, Lodz, Poland

Background: Improvement of height velocity (HV), related to an increase of insulin-like growth factor-I (IGF-I) secretion, is the most important index of GH treatment effectiveness.

Objective and hypotheses: The aim of the study was an assessment of the efficacy of 3 years GH treatment by estimation of HV, IGF-I secretion and IGF-I to IGF binding protein-3 (IGFBP-3) molar ratio.

Methods: The analysis comprised 54 children (40 boys) with short stature and: partial GHD (pGHD – GH peak in 2 stimulating tests 5-10 ng/ml), and neurosecretory dysfunction (NSD – GH peak in stimulating tests >10 ng/ml but after falling asleep <10 ng/ml, decreased IGF-I secretion). All the patients were treated with GH in a dose of 0.18±0.02 mg/kg/week for – at least – 3 years. Before GH administration and after following years of therapy HV, IGF-I secretion and the IGF-I/IGFBP-3 molar ratio were compared.

Results: There were no significant differences in any of the analysed parameters between the groups either before the therapy or at any time of treatment, except for the significantly lower (p<0.01) IGF-I/IGFBP-3 molar ratio in NSD group before treatment. For detailed data see the Table.

Conclusion: The effectiveness of treatment presented similar in NSD and pGHD groups. It seems that normal GH results of stimulating tests should not be a reason for disqualifying short children with disorders of spontaneous GH secretion from GH therapy.

PAO-121

A case of osteopetrosis tarda in childhood presenting with polyarthralgia and rickets

Gonul Cattı; Korcan Demir; Ayça Altnik; Ayhan Abaci; Ece Bober

Dokuz Eylul University, Department of Pediatric Endocrinology, Izmir, Turkey

Background: Osteopetrosis refers to a clinically and genetically heterogeneous group of rare, heritable disorders of the skeleton characterized by increased bone density resulting from abnormalities in osteoclast differentiation or function. Based on clinical features, mode of inheritance and pathogenetic mechanisms osteopetrosis is classified into several distinct entities ranging in severity from asymptomatic to fatal in infancy. Osteopetrosis tarda (autosomal dominant osteopetrosis) typically has onset in adolescence and adulthood and the main complications are confined to the skeleton, including fractures, scoliosis, hip osteoarthritis and osteomyelitis.

Objective and hypotheses: To present the clinical features of a child presenting with osteopetrosis tarda.

Methods: An 8-year old girl was admitted suffering from back, neck and ankle pain for six months. She was born to nonconsanguineous parents with a birth weight of 3600 grams. At the age of 4 she was referred for pain in thumb, wrist and knees and was diagnosed as having reactive arthritis. She had broken her finger in an accident 1 year ago. Family history was unremarkable except her fathers’ broken fingers and metacars after a minor trauma.

Physical examination revealed no pathological sign with a height of 138 cm (SDS 1.46) and weight 34 kg (SDS 1.24).

Results: Laboratory studies showed mild anemia and normal biochemistry with mildly elevated values of PTH (78.4 pg/ml, normal range 12-72) and osteocalcin (30.2 ng/ml, normal range 3.2-13.7) and a low 25-hydroxy vitamin D level of 58 nmol/L (normal range 80-250 nmol/L). Radiographic examination revealed findings of generalized osteosclerosis, sandwich vertebra and thus diagnosis of osteopetrosis tarda and rickets was made. After stoss therapy her complaints have diminished and PTH level was normalized (51 pg/ml).

Conclusions: Osteopetrosis tarda is generally diagnosed incidentally in adolescence and adulthood but it may also present in childhood with mild anemia, fractures, polyarthralgia and rickets as in our case.

Table

<table>
<thead>
<tr>
<th>HV [cm/year]</th>
<th>IGF-I SDS</th>
<th>IGF-I/IGFBP-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st year of GH</td>
<td>9.6±2.0</td>
<td>0.73±0.02</td>
</tr>
<tr>
<td>2nd year of GH</td>
<td>8.9±1.7</td>
<td>0.45±0.15</td>
</tr>
<tr>
<td>3rd year of GH</td>
<td>7.4±2.3</td>
<td>0.49±0.83</td>
</tr>
</tbody>
</table>

References

1 Medical University of Lodz, Department of Pediatric Endocrinology, Lodz, Poland; 2 Medical University of Lodz, Department of Endocrinology and Metabolic Diseases, Lodz, Poland

Horm Res 2011;76(suppl 2) Printed Abstracts Only
Multiple endocrine complications of allogeneic hematopoietic stem cell transplantation

Anna Wyderchowicz1; Agata Zygmunt-Górka2; Joanna Wojtyra3; Marta Ciechanowska4; Aleksandra Krassowska-Kwiecien4; Jerzy Starzyk5
1Polish-American Children's Hospital, Medical College, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Department of Transplantation, Krakow, Poland; 2University Children's Hospital, Pediatric and Adolescent Endocrinology, Cracow, Poland; 3Polish-American Children's Hospital, Medical College, Jagiellonian University, Department of Pediatrics and Adolescent Endocrinology, Cracow, Poland; 4Polish-American Children's Hospital, Medical College, Jagiellonian University, Department of Pediatric and Adolescent Endocrinology, Cracow, Poland

Background: Since the 1980s, hematopoietic stem cell transplantation (HSCT) has been performed for malignant and non-malignant disorders leading to increasing numbers of long-term survivors. Some of them have endocrine complications that arise many years after the end of the initial disorder treatment.

Objective and hypotheses: We present the 16,5 year-old girl with endocrine complications after treatment of acute lymphoblastic leukemia diagnosed at the age of 10.

Method: First chemotherapy was complicated with an acute pancreatitis after L-asparaginase. Eight months after diagnosis an allogeneic HSCT from HLA-matched sibling donor was performed. In the conditioning regimen fractionated total body irradiation and high-dose etoposide were used. After HSCT several early and late complications occurred: bacterial and mycotic infections, engraftment syndrome with renal and respiratory failure, graft versus host diseases (GVHD) and pancreatitis.

Results: We observed multiple endocrine complications successively appearing after HSCT: i) transient carbohydrate metabolism disorders in first days, followed by regular diabetes requiring insulin therapy, ii) euthyroid sick syndrome in first months, then an overt primary hypothyroidism treated with L-thyroxin, iii) transient hyponatremia due to SIADH syndrome, iv) growth hormone deficiency supplemented with recombinant human growth hormone since second year after HSCT until the age of 16 according to the patient’s decision, v) delayed spontaneous puberty followed by secondary amenorrhea requiring an estrogen-progesterone replacement therapy, vi) low bone mineral density detected in repeated densitometry examination, in spite of calcium and vitamin D supplementation, vii) some elements of metabolic syndrome in spite of diabetes with insulin resistance, as high blood pressure, and dyslipidemia.

Conclusions: The significant endocrine complications of HSCT in the presented patient were associated with radiation exposure, but were also related to some chemotherapeutic agents, GVHD, and prolonged corticosteroid exposure.

Central hypothyroidism following chemotherapy for acute lymphoblastic leukemia

Federico Baronio; Laura Battisti; Giorgio Radetti
Regional Hospital of Bolzano, Pediatrics, Bolzano, Italy

Background: Thyroid dysfunction is frequently reported in patients treated with radiotherapy for childhood cancer. However, it has been suggested that chemotherapy per se might also impair the hypothalamus-pituitary-thyroid axis.

Objective and hypotheses: We examined 8 patients, out of a cohort of 31 subjects treated for acute lymphoblastic leukemia (ALL) with chemotherapy alone, who showed, during the follow-up, thyroid findings consistent with central hypothyroidism (CHT).

Methods: The patients were diagnosed with ALL at a mean age (range) of 3.8 (0.3-6) years and were, at the time of the study, for 6 years (range 6-13) off therapy. Aulogical data were recorded and TSH, FT4, thyroid peroxidase and thyroglobulin antibodies, cortisol and IGF-I were evaluated and a thyroid ultrasound was performed. Four subjects, who gave their consent, underwent a TRH test and a MRI scan of the hypothalamic-pituitary region.

Results: All subjects showed basal TSH above the normal range, while FT4 was abnormally low in two patients only. FT3 was always in the normal range. At TRH infusion, an increase in TSH serum level was observed; however, 2 patients showed an exaggerated TSH increase while 3 patients showed a slow TSH decline. Two patients showed an impaired FT3 net increase.

Conclusions: Our study shows that central hypothyroidism could arise at any time after childhood leukemia following only chemotherapy treatment. Although overt hypothyroidism was detected in only two patients, a careful follow-up of the thyroid function is recommended also for not irradiated ALL survivors.

Hyponatremia, hypothyroidism and metabolic acidosis

Ozlem Korkmaz1; Damla Goksen1; Gulgun Yenmen1; Alif Berdeli2; Sukran Darcan1
1Ege University, Faculty of Medicine, Pediatric Endocrinology, Izmir, Turkey; 2Ege University, Department of Pediatrics, Izmir, Turkey

Background: Severe hyponatremia with hyperkalemia and dehydration is an uncommon but life-threatening occurrence in infancy.

Objective and hypothesis: To highlight the importance of diagnosis and treatment of hyponatremia in infancy.

Method and results: A two month old female patient with a history of first degree parental consanguinity admitted to hospital with failure to thrive. At initial examination her weight was 2990 gr. height was 53 cm and she was hypotonic. Laboratory evaluation revealed serum sodium concentration 108 mEq/l, potassium 5.3 mEq/l, chloride 71 mEq/l. She received saline solution, hydrocortisone and fludrocortisone with an initial diagnosis of adrenal failure. Additional evaluation was not remarkable with adrenal failure since ACTH was 18.8 pg/ml (10-70 pg/ml), 17-OH Progesteron, 7.7 ng/ml (1.7-17 ng/ml), cortisol, 14 mcg/dl (3-23 mcg/dl), DHEA-S: 35 mcg/dl(<45 mcg/dl) and aldosteron was 408 pg/ml(20-1300 pg/ml). Urinary sodium excretion was 27 mEq/l and serum osmolarity was normal. Thyroid replacement therapy was initiated because her TSH and FT4 levels were 100 mU/l and 0.47 mcg/dl respectively. With the initiation of L thyroxin therapy and with the exclusion of adrenal failure fludrocortisone was tapered. An immediate decrease in serum Na levels was seen and fludrocortisone was restarted. Metabolic diseases that can becaue hyponatremia was excluded with normal lactic acid, pyruvic acid, tandem mass and quantitative urinary amino acid levels. She was noted to have increasing values of urea, creatinine and uric acid and intermittent metabolic acidosis on the second week of her hospitalization. She died with metabolic acidosis and septic shock on the 6th week of admission.

Conclusion: The patient was negative forNR3C2, SCN1B,SCNN1G and a heterozygous genetic variant in SCN1A gene (pThr663Ala) was found. Glycosilation deficiency disorder, syntesis and membrane transport defects (Pendrin mutation) was thought in the differential diagnosis of these two siblings.

Intractable hypercalcemia following transplantation for osteopetrosis

Sung Yoon Cho; Sohn Young Bae; Jin Dong-Kyu
Samsung Medical Center, Pediatric, Seoul, Republic of Korea

Background: Autosomal recessive osteopetrosis is characterized by insufficient osteoclast activity resulting in defective bone resorption and marked increase in skeletal mass and density. Osteopetrosis results in generalized sclerotic bones and bone marrow failure. Allogeneic bone marrow transplantation(BMT) is the only treatment for cure, secondary to engraftment of donor-derived functioning osteoclasts resulting in remodeling of bone and establishment of normal hematopoiesis. One of the complications following a successful BMT is hypercalcemia that is a unique complication in this group of patients.

Methods and results: We report a three-yr-old girl with osteopetrosis who developed hypercalcemia following the successful bone marrow transplantation. These findings indicated an active donor-derived osteoclastic function and thus bone resorption following the successful donor engraftment in the patient. Her calcium level was 14.8 mg/dL at postBMT 10 days, therefore calcitonin (4 IU/kg sc every 12hr) as well as hyperhydration and furosimide were started. However, the calcium level increased to 16.8 mg/dL at postBMT 13 days, and then intravenous pamidronate (15mg/BSA) and steroid (methylprednisolone 1mg/kg every 12hrs) was started. At that evening, she...
was very irritable with more increased calcium level of 18.2 mg/dL. Her status was considered malignant hypercalcemia, therefore we started continuous renal replacement therapy. After two days, the calcium level decreased to 13 mg/dL without any adverse events, and CRRT had been maintained for six days. At present (post-BMT 45 days), her calcium level below 11 mg/dL with weekly pamidronate, daily calcitonin and daily methylprednisolone with tapering dose.

Conclusions: In conclusion, hypercalcemia is common in patients with osteoporosis after BMT. If the conventional therapeutic strategies including isonic acid, furosemide and calcitonin would not be successful, continuous renal replacement therapy should be considered seriously to prevent severe adverse events of hypercalcemia.

PAO-126

Vitamin D status in pediatric patients with malignancy

Dalia Moden-Moses1; Ori Pinhas-Hamiel1; Vered Temam2; Dafna Mintz-Shenkar2; Toren Amos3
1The Edmond and Lily Safra Children’s Hospital, Pediatric Endocrinology, Ramat-Gan, Israel; 2The Edmond and Lily Safra Children’s Hospital, Pediatric Hemato-Oncology, Ramat-Gan, Israel; 3The Edmond and Lily Safra Children’s Hospital, Pediatric Hematology-Oncology and BMT, Ramat-Gan, Israel

Background: Multiple studies demonstrated an inverse association between vitamin D and its metabolites and cancer morbidity and mortality. Despite this impressive body of evidence, only a handful of studies estimated vitamin D status in pediatric patients with malignancy.

Objective and hypotheses: Our aim was to assess vitamin D status in a large cohort of pediatric cancer patients and survivors, and to define risk factors to vitamin D deficiency. We hypothesized that 25OHD levels will be low in this population, particularly among actively treated patients.

Methods: 25OHD levels were obtained in 154 consecutive patients (aged 12.1±5.9y, M=76) during their routine visits to the hematono- oncology department (mean time from diagnosis 4.4±3.9y). Patients or their parents were asked to answer a questionnaire regarding calcium intake and sun exposure habits.

Results: Average daily calcium intake was 742.1±415.5mg/day. Mean 25OHD levels were 21.8±8.2ng/ml. Eighteen patients (11.8%) were vitamin D deficient (<11ng/ml), and another 87 (80.3%) were vitamin D insufficient (11-32ng/ml). Only 12 patients (7.9%) were vitamin D sufficient.

Conclusions: The prevalence of vitamin D deficiency and insufficiency in pediatric hematopoietic patients is high, while daily calcium intake is significantly lower than the RDA. While these values may be similar to those of the general pediatric population in Israel, they are of particular concern in this patient population, which is at high risk for osteoporosis. Furthermore, given the current knowledge regarding the importance of vitamin D in the context of malignancy, maintaining an adequate vitamin D status may be important for recovery and prevention of recurrence of pediatric malignancy.

PAO-127

Quantitative ultrasound evaluation of bone status in obese children with or without metabolic syndrome

Valeria Calcateria; Tiziana Muratori; Paola Brambilla; Alexandre Diouf; Rossana Toglia; Claudia Caramagna; Daniela Larizza
1University of Pavia and IRCCS Policlinico San Matteo Foundation, Department of Pediatrics, Pavia, Italy

Background: The relation between metabolic syndrome (MS) and bone metabolism is not clear, because MS has both conflicting factors of osteoporosis, one with a protective property, obesity, and another one which can activate bone resorption, inflammation. We evaluated bone status with quantitative ultrasound (QUS) technique in pediatric obese subjects with or without MS.

Methods: Phalangeal QUS measures for amplitude-dependent speed of sound (ADoSos) and bone transmission time (BTT) were obtained in 56 obese patients (30M/26F; mean age 12.9±2.16 vs females -0.92±0.9, p=0.26) and mean BTT Z-score -0.18±1.3 (M -0.41±1.25 vs F 0.07±1.35, p=0.18), with significant difference in subjects with or without MS (AD-S Z-score -1.16±0.82 vs -0.5±1.5, p=0.89, BTT Z-score -0.06±0.11 vs -0.21±0.35, p=0.75). ADoSos and BTT Z-scores were reduced in 10 (2 with MS, p=1) and 4 subjects respectively (none with MS, p=0.17); bone event was not found. None subject presented signs of inflammation.

Conclusions: In our patients normal bone parameters were found, without significant difference in pts with or without MS. Probably, in obese children the inflammation is low and protective role of obesity is predominant on the bone status.

PAO-128

Osteoporosis-pseudoglioma syndrome: clinical outcome after treatment with growth hormone and bisphosphonates

Glória Bueno1; Feliciano Ramos1; Jesus Fleta1; Inés Bueno1; Jesus María Garargorn2; Nizar Smaoui3; Jose Luis Olivas4
1Lozano Blesa University Clinical Hospital, Department of Pediatrics, Zaragoza, Spain; 2GeneDx, DNA Diagnostic Experts, Gaithersburg, United States

Background: Osteoporosis-Pseudoglioma Syndrome (OPPG, MIM 259770) is a very rare genetic autosomal recessive condition characterized by early blindness and bone fragility with fractures. The affected gene is called LRPS, located at the chromosomal region 11q13.4. Recently, the combined growth hormone (GH) and bisphosphonates treatment in OPPG patients was proposed.

Objective: To present the case and the clinical evolution of a 10-year-old romanian girl with OPPG, confirmed by the identification of a mutation in exon 11 of the LRPS gene (c.2409_2503+79del174), who was treated for one year with GH and intravenous bisphosphonates.

Case report: She was the third child of healthy non-consanguineous parents. Sibs were apparently normal but she has two maternal cousins, living in Rumania, who are blind. She was first seen in our Hospital at the age of 10 years. She weighted 23.5 kg (<3%), measured 110 cm (<3%) and had a head circumference of 48,5 cm (<10%). She was disproportionate with shortening of the upper segment secondary to a severe kyphoscoliosis. She could not walk. Extremities were not deformed neither had visible fracture calluses. She had hypotonia and hyperextensibility joints. She had bilateral microphthalmia, cataracts and entropion. Bilateral horizontal nystagmus was also present. She was blind.

Laboratory analyses included: Calcemia: 10.3 mg/dL, phosphatemia: 5 mg/dL, alkaline phosphatase: 221 U/L, PTH 43,4 pg/mL, 25(OH)D3: 28 ng/mL, osteocalcin: 17 mg/mL, all in normal ranges.

Skeletal survey: Generalized osteopenia, thin long bones, flattened dorsal vertebrae, pectus carinatum and deformed chest. Epiphyses were normal. No anomalies were found in the skull. Bone densitometry (L1-L4): 0.378 g/cm2 (-4 SD for age). She was treated with Pamidronate, calcium, vitamin D and GH.

Conclusion: After 1 year of treatment, the intravenous pamidronate therapy was safe, bone mineralization increased (-2.5 SD for age) and fracture rate and pain decreased. Further follow-up is needed in order to confirm the long term efficacy of this treatment.
PAO-129

Evaluation of cardiovascular risk factors in children with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Nicola Improda; Lucia De Martino; Flavia Barbieri; Daniela Cioffi; Raffaella Di Mase; Mariacarolina Salerno
Federico II University, Department of Pediatrics, Naples, Italy

Background: Classical Congenital Adrenal Hyperplasia (CAH) may present some traits of the metabolic syndrome. Objective: Aim of this study was to investigate cardiovascular and metabolic risk profiles in children and adolescents with classical CAH. Subjects and methods: We compared 20 classical CAH patients (10 males and 10 females, age range 9-19 years) with 20 age- and sex-matched controls. Anthropometry, lipids, blood pressure, fasting glucose concentrations, serum insulin levels and insulin sensitivity were studied. Adiposity was expressed as BMI SDS. Waist Circumference (WC) and Waist-to-Hip Ratio (WHR) were used to evaluate visceral adiposity. Results: BMI SDS was significantly higher in patients than controls (0.9±0.9 vs 0.1±1.53, p=0.000). Five patients (25%) and two controls (10%) had a BMI SDS of >2.0. WC, but not WHR, resulted significantly higher in patients than in controls (82.9±13.7 vs 72.7±13.6; p=0.01). No differences were found for lipid parameters and mean systolic and diastolic blood pressures between the two groups. Fasting insulin levels (12.0±7.6 vs 5.1±5.08; p=0.003) and HOMA index (2±1.34 vs 0.98±1.03; p=0.01) were significantly higher in CAH patients, compared to controls. A significant correlation was observed between WC and BMI SDS (r=0.78, P<0.0001), fasting insulin levels (r=0.4525, p=0.04) and HOMA (r=0.45, p=0.04). Obese patients showed higher WC, BMI SDS and abdominal circumference. WC, but not WHR, resulted significantly higher in patients with NDM (p=0.003) and HOMA index (2±1.34 vs 0.98±1.03; p=0.01) were significantly higher in CAH patients, compared to controls. A significant correlation was observed between WC and BMI SDS (r=0.78, P<0.0001), fasting insulin levels (r=0.4525, p=0.04) and HOMA (r=0.45, p=0.04). Conclusion: Children with classical CAH are at risk for increased BMI, obesity, hyperinsulinism and reduced insulin sensitivity. WC is an accurate predictor of these metabolic abnormalities and thus it should be monitored during follow-up in patients with classical CAH.

PAO-130

Successful switching from insulin to oral sulfonylureas in neonatal diabetes mellitus patients
Ngoc Can1; Chi Dung Vu1; Phuong Thao Bu1; Ngoc Khanh Nguyen1; Maria Craig2; Sian Ellard3; Hoan Nguyen1
1National Hospital of Pediatrics, Endocrinology, Metabolism and Genetics, Hanoi, Vietnam; 2St George Hospital and The Children's Hospital, Endocrinology, Westmead, Australia; 3Human Molecular Genetics, Peninsula Medical School, Department of Molecular Genetics, Exeter, United Kingdom

Background: Neonatal diabetes mellitus (NMD) may be defined as hyperglycemia diagnosed within the first 6 months of life and can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K+ channel. Transfer from insulin to oral sulfonylureas in patients with NMD due to Kir6.2 or SUR1 mutations is well described. Objective and hypotheses: Determine gene mutation of KCNJ11 and ABCC8 in NMD patients; assess the results of oral sulfonylureas therapy relative to insulin injection. Methods: Case study: 5 patients suffer NDM at 45, 35, 47, 36, 44 days of age, respectively with ABC8 or KCNJ11 mutations are treated in National Hospital of Pediatrics, Hanoi, Vietnam. Results: 2 patients have heterozygous for a missense mutation on KCNJ11: R201H (p.Arg201His) & R201C (p.Arg201Cys); 3 patients with ABC8 mutations: missense R1183W (p.Arg1147Trp), nonsense E747X and compound heterozygotes for E747X & E128K. All 5 patients switched from insulin to sulfonylurea at 5 years, 2.5years, 7 years, 5 years and 8 months of age, respectively. Before of switching, HbA1C levels were 9.9; 6; 6; 8.3; 5.8 percent with insulin dose of 1.1; 0.5; 0.2; 0.5; 0.67 UI/kg/d, respectively. After 15; 10; 5; 5 and 5 days, they successfully discontinued insulin, respectively. HbA1C levels improved in 3 first patients to 6.3; 6.2; 6.1 percent after 12 weeks of treatment) other patients has received sulfonylureas for 5 days. Improved glycemic control was sustained at one year. Conclusions: KCNJ11 & ABC8 mutations for NDM has been determined in Vietnam and treatment with sulfonylureas.

PAO-131

A child with concomitant precocious puberty secondary to factor V leiden mutation and type II diabetes mellitus
Ayla Guven; Fatma Duran; Hewes Kirmizibekmez; Nurcan Cebeaci
Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Background: In children, the prevalence of type 2 diabetes (T2D) is increasing worldwide. At diagnosis, most patients have a positive family history of T2D. Heterozygosis for Factor V Leiden mutation (FVLM) leads to a 3-fold increase in relative risk of venous thrombosis. The most common causes of precocious puberty are organic cranial lesion such as tumors, trauma, cerebral anomalies, anoxic encephalopathy, in males. Case: An eight year-old-boy was presented with polyuria. He was diagnosed as cerebral venous thrombosis secondary to FVLM two years ago. The patient’s father also was diagnosed as T2D and FVLM. Due to cerebral stroke the patient was on artificial ventilation with BIPAP, has spastic paraplegia and no verbal response. His weight was 40 kg (97th p), height couldn’t measured because of spasticity. Testes volume was Tanner stage 2, pubic hair Tanner stage 3. Basal LH (2.8 IU/L), FSH (2.38 IU/L) and testosteron (0.55 ng/ml) levels of the patient were found pubertal. The other hormonal evaluation was normal. He was diagnosed as central precocious puberty with basal hormonal evaluation. Cranial and pituitary Magnetic Resonans was revealed encephalomalous changes secondary to cerebral thrombosis. We considered that his central precocious puberty was secondary to cerebral thrombosis and anoxic encephalopathy. His blood glucose was measured 350 mg/dl with ketone in urinary analysis and no acidosis, he was diagnosed as diabetes mellitus and treated with insulin. All antibodies for type 1 diabetes were negative. HbA1c was high for his age (%10.4). Because of high C-peptide (14.7 ng/ml) the patient was diagnosed as type 2 diabetes. He was discharged with metformin and basal insulin glargine treatment. Conclusions: In this report we presented an eight-year-old boy with concomitant precocious puberty, T2D and positive family history for these diseases.

PAO-132

Element and thyroid status in newborns from mothers with Graves’ disease
Shakhlo Muratova1; Larisa Nugmanova1; Elena Danilova2
1Republic specialized scientific - practice medical center of Endocrinology, Thyroid Department, Tashkent, Uzbekistan; 2Institute of Nuclear Physics, Department of activatory analysis, Tashkent, Uzbekistan

Aim: To study effect of Graves’ disease (GD) of a mother in region with severe iodine deficiency, on element and thyroid status of a newborn. Materials and methods: We examined 36 newborns in two groups. 1st group (n=18) included newborns born from mothers with GD receiving adequate thyrostatic therapy and the 2nd one (n=18) including those born from the untreated mothers with GD. Content of microelements in hair was measured by means of instrumental neutron activation method at the Institute of Nuclear Physics, Uzbekistan Academy of Sciences. Results: Confidently high content of iodine was found in the 1st group newborns hair as compared with those in the 2nd (22.77 ± 13.33 versus 10.48 ± 4.95; p=0.04), calcium and iron proportions being confidently lower in the 1st group (Ca: 1038.89 ± 27055 versus 3468.89 ± 243.52, p<0.001; Fe: 90.48 ± 28.41 versus 140.73 ± 118.41, p<0.02). In the 1st group newborns thyroid status parameters were close to normal (TSH: 2.52 ± 0.29 mU/l, T3 1.69 ± 0.11 nmol/l, T4: 111.1 ± 10.99 nmol/l), no case of neonatal transitory thyrotoxicosis (NTT) being registered. Only in one newborn isolated T4 increase was found with normal TSH and T3 was found. On the contrary, in the 2nd group NNT was found in 6 (33.3%) examinees, transitory neonatal hypothyroidism being registered in one (5.6%). In this group thyroid status parameters were as follows, TSH: 0.77 ± 0.24 mIU/l; T3: 2.59 ± 0.1 nmol/l; T4: 148.8 ± 7.95 nmol/l, p<0.05. Conclusions: 1. Inadequate thyrotoxicosis compensation in patients with gestational GD results in neonatal transitory thyrotoxicosis and transitory neonatal hypothyroidism in 33.3% and 5.6% of newborns. 2. In newborns from mothers with the untreated gestational GD confidently high proportions of calcium and iron were found to be the evidence for the enhanced elimination of the elements from the organism.
Isolated 17,20-lyase deficiency with testicular regression

Ayla Guven1; Heves Kirmizibekmez2; Fatma Dursun3; Berrin Gucluer2; Hamit Okur2
1Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey; 2Goztepe Educational and Research Hospital, Pathology, Istanbul, Turkey; 3Goztepe Educational and Research Hospital, Pediatric Surgery, Istanbul, Turkey

Background: The CYP17A1 gene encodes P450c17 and is expressed in adrenal and gonads. Mutations of this gene is the cause of combined 17-hydroxylase/17,20-lyase deficiency or in very rare cases isolated 17,20-lyase deficiency. Disturbance of sex steroid production leads to disorder of sex development in 46 XY individual and failure of pubertal development in 46 XX individual.

Case report: A 2 years old male patient referred as bilateral undescended testis. He has been investigated for disorders of sex development. Physical examination revealed bilateral non-palpable gonads and hypoplastic scrotum, penile size was 3.2 x 1.5 cm (lower limit for age). In baseline hormonal analysis; total testosterone and androstenedione levels were low, while FSH and LH were elevated. ACTH (250 µg) and hCG stimulation tests were performed in order to evaluate adrenal and gonadal steroidogenesis. There was no meaningful increase in testosterone, androstenedione. DHEAS was low (0.54 mg/dl, N: 5-57 µg/dl). Cortisol production was normal. Normal deoxycorticosterone level and absence of water retention, hypertension or hypokalemia.

Aims: The National Hospital of Pediatrics (NHP) in Hanoi is an 900 bed tertiary referral centre serving approximately 40 million people from northern provinces of Vietnam. This audit was undertaken to analyze anecdotal reports of increasing patient numbers.

Methods: Retrospective review of all CAH patients registered at NHP from 1999-2010. Ethical clearance was granted by the NHP Directorate.

Results: At the start of 1999 there were 90 children with CAH managed at NHP. By December 2010 this increased to 551 (47% male and 53% female; 72% salt wasting CAH), representing a more than five fold increase over 11 years. Number of new cases doubled from 30 to 60 in 2009. Most children (72%) were diagnosed at less than 12 months of age (39% at less than 1 month of age); 70% of all children were younger than 10 years. Formal mortality figures were low (6 known deaths), although loss to follow-up unknown. There are data to suggest persistent mortality from undiagnosed CAH (evidenced by low ethnic minority group representation; few children from remote provinces; higher average income of CAH families; gender ratio shift; reports of sibling deaths).

Patient to paediatric endocrinologist (551:6) ratios at NHP are very high compared with higher income countries.

Conclusions: The caseload of CAH at NHP has increased since 1999 and additional capacity is needed for patient care given high patient to staff ratios. Introduction of NBS would enable more accurate estimation of CAH incidence, reduce infant mortality and minimize trauma to affected infants and their families.

Ethnic background influences the distribution of body fat in obese children and adolescents

Gabriel Angel Martinez-Moren1; Sara Sirven1; Guillermo Martinez1; Federico Hawkins1; Jesús Argente1
1Hospital Infantil Universitario Niño Jesús, Universidad Autónoma, ISCIII, II La Princesa, Endocrinology, Department of Pediatrics, CIBERobn, Madrid, Spain; 2Hospital Infantil Universitario Niño Jesús, Radiology, Madrid, Spain; 3Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Endocrinology, Madrid, Spain

Background: The ethnic background, sex and pubertal progression determine body fat in growing children. These factors could also influence the deposition of excess adipose tissue in obese children and adolescents, with potential metabolic impact.

Objective and hypotheses: Our aim was to compare the amount and distribution of body fat between obese Latino and Caucasian children and adolescents.

Methods: One-hundred obese children [11.5 ± 2.9 years; 4.1 ± 1.4 BMI-SDS; 53 females/47 males; 57 Caucasian (C), 43 Latino (L)] were studied. Glucose, insulin, uric acid, cholesterol and triglyceride levels were measured. Body composition (DXA) and abdominal MRI and ultrasonography were performed in all patients.

Results: Both ethnic groups showed similar ratios of visceral and subcutaneous (SQ) abdominal fat in the MRI. DXA scans showed that Latinos had higher trunk to whole body (T/WB;
The frequency of chronic complications (%).

### Table 1. The frequency of acute complications (%) and HbA1c level (%).

<table>
<thead>
<tr>
<th>Years</th>
<th>DKA 2-3</th>
<th>Hypo</th>
<th>HbA1c</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>6.04</td>
<td>0.45</td>
<td>8.9±1.52</td>
</tr>
<tr>
<td>2008</td>
<td>9.23</td>
<td>0.43</td>
<td>8.8±1.45</td>
</tr>
<tr>
<td>2009</td>
<td>11.39</td>
<td>0.57</td>
<td>8.9±1.44</td>
</tr>
</tbody>
</table>

### Table 2. The frequency of acute complications (%) in children with different age.

<table>
<thead>
<tr>
<th>Age</th>
<th>DKA 2-3</th>
<th>Hypo</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-5 y.o.</td>
<td>9.83</td>
<td>17.32</td>
</tr>
<tr>
<td>6-10 y.o.</td>
<td>5.32</td>
<td>9.24</td>
</tr>
<tr>
<td>11-14 y.o.</td>
<td>5.82</td>
<td>8.98</td>
</tr>
<tr>
<td>15-17 y.o.</td>
<td>5.94</td>
<td>7.90</td>
</tr>
<tr>
<td>Total</td>
<td>6.04</td>
<td>9.23</td>
</tr>
</tbody>
</table>

### Table 3. The frequency of chronic complications (%).

<table>
<thead>
<tr>
<th>Years</th>
<th>DK</th>
<th>DR</th>
<th>DN</th>
<th>DA</th>
<th>DNP</th>
<th>DL</th>
<th>DH</th>
<th>DS</th>
<th>CWC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>0.94</td>
<td>7.56</td>
<td>10.69</td>
<td>15.42</td>
<td>18.67</td>
<td>3.01</td>
<td>7.59</td>
<td>11.49</td>
<td>51.29</td>
</tr>
<tr>
<td>2008</td>
<td>1.92</td>
<td>8.52</td>
<td>11.43</td>
<td>19.14</td>
<td>19.31</td>
<td>7.29</td>
<td>8.55</td>
<td>16.12</td>
<td>47.68</td>
</tr>
<tr>
<td>2009</td>
<td>2.01</td>
<td>8.92</td>
<td>12.95</td>
<td>19.04</td>
<td>20.46</td>
<td>8.26</td>
<td>8.30</td>
<td>14.75</td>
<td>51.55</td>
</tr>
</tbody>
</table>
developed T1DM at ages 0 - 5 years increased in the second decade (24.5 vs 17.4 %). The seasonal distribution at the time of diagnosis (higher incidence during winter and autumn months) disappeared in the second decade. 

Conclusion: The incidence of T1DM in Cyprus is rising. The identification of environmental factors, which increase the risk of T1DM development in genetically susceptible individuals, will theoretically explain this phenomenon. New preventive strategies will therefore be developed if such factors that are implicated in the etiopathogenesis of T1DM will be recognized.

PAO-140
A rare cause of primary ovarian failure in a 16 years old patient: 48,XXXX karyotype

Marie-Béatrice Saade1; David Briard2; Laurent Passquier3; Livie Chatelais4; Marc de Kerdanet5; Sylvie Nivot6; Patrick Pladys7

CHU Rennes, Paediatric department, Rennes, France

Background: 48,XXXX is a rare karyotype . Since first described in 1961, fewer than 60 patients have been described in literature as suffering from this condition. The main feature described is mental retardation. Some women have tall stature, as in other extra X chromosome karyotype (47,XXX, 47,XXXX). Only three patients have been reported so far with primary ovarian failure. Irregular or normal menses are more often described.

Case report: Our patient was first seen in the paediatric endocrine ward at 16 years old for primary amenorrhea. She had a mild mental retardation and attended a special school. She had hyperprolactinaemia and obesity, her parents also had obesity. Her pubertal status was A2P2S1 with important adiposity giving a “false” stage 3 breast development. She had a tall stature (183 cm) above her target height (168.5cm) and had little finger insertion anomaly. Her bone age was 15 years as determined by the Greulich and Pyle method.

Blood analysis showed high levels of gonadotrophins: luteinizing hormone: 25.6 mU/ml and follicle-stimulating hormone: 33.3 mU/ml and low level of estradiol 10 pg/ml, consistent with primary ovarian failure. Neither pelvic ultrasound nor MRI showed any ovaries. She had prepubertal uterus. She had chromosome analysis regarding to the amenorrhea associated with the mental retardation and it showed a 48,XXXX karyotype. Estrogen therapy was started to develop sexual secondary characters, close epiphyseal growth plates and prevent osteoporosis.

Conclusion: These features add data on height and ovarian function in 48,XXXX women. Mental retardation is often described in women with 48,XXXX but tall stature and primary ovarian failure are described in a few cases. This patient had obesity which is not, to our knowledge, described in literature. Not only small patients (Turner syndrome) but also tall women with primary amenorrhea should benefit from chromosome analysis.

PAO-141
Pituitary enlargement due to partial IGF-I insensitivity

Soraya Milan1; Mariana Sarli de Paulea; Ligia Bataglin de Carvalho1; Rodrigo Custodio1; Marcelo do Amaral Ruiz2; Ayrton Moreira3; Sonir R. Antonini1; Carlos Eduardo Martinelli Jr1

1School of Medicine of Ribeirão Preto, Paediatrics, Ribeirão Preto, Brazil; 2School of Medicine of Ribeirão Preto, Medicine, Ribeirão Preto, Brazil

Background: Until recently patients bearing partial GH or IGF-I insensitivity have been diagnosed as idiopathic short stature.

Objective and hypotheses: Few data are available regarding pituitary image in these patients

Methods: We describe a 5.5 year-old girl that was seen at the emergency room with nausea, vomiting, headache and unilateral eye lid ptosis. Cranial MRI was normal and ophthalmoplegic migraine was diagnosed.

Results: Five years later a second MRI showed a 0.7x0.4cm pituitary lesion with suprasellar extension. Furthermore, a severe progastahism was observed. On the other hand, teeth gapping were normal, her hands and feet were deltal and there were no other signs of possible GH/IGF-I excess or hypopituitarism. Pupillary stage was B3P3. Serum IGF-I was 1490ng/dl (+6.1SDS). GH Daytime GH profile was suggestive of increased GH secretion as only 4 determinations were below the detection limit of the assay (0.1ng/ml). GH suppression (<0.1mg/l) was confirmed by OGTT. Due to the severe progastahism, pituitary image and maintained elevated IGF-I levels, the diagnosis of acrogigantism was considered and a surgical procedure was proposed. However, facing the slow size increase of the pituitary lesion an option for a regular follow-up was taken with laboratory and image control. Nowadays she is 16 years-old, bone age is 18yr and puberty is complete with regular menses.

Conclusion: After 10 years of follow up we believe that the lack of IGF negative feedback due to a partial IGF-I insensitivity could explain the high concentrations of GH and IGF-I with normal height and the pituitary image.

Height velocity analysis was mislead by puberty during the investigation.

PAO-142
Comparison of injection dose force between three growth hormone injection pens: NordiFlex®, FlexPro® and GoQuick®

Anne-Marie Kangapelgaard1; Marianne Pye Hansen2; Niels Aage Hansen3


Background: A reduced injection force potentially makes it easier for patients to administer their injected medication.

Objective and hypotheses: This report compares dose force and dose accuracy of three growth hormone injection devices: Norditropin® NordiFlex® (NF), Norditropin® FlexPro® (FP) (both Novo Nordisk A/S, Denmark) and Genotropin® GoQuick® (GQ) (Pfizer Inc, NY, USA).

Methods: Mean of maximum dose force was determined for a 1.5 mg dose at speeds of 4, 6 and 8 mm/s for NF and GQ pens and the dose activation force was measured for FP in 25 pens of each type. Dose accuracy was assessed at 0.1, 0.75 and 1.5 mg doses (60 measurements at each level) in 30 pens of each type. All pens were fitted with a Novofine 32 G x 6 mm needle. Testing was done at 20°C, 45% relative humidity. Dose force was measured with a tensile testing machine in compression mode (within specifications) Lloyd, LRx plus (ID: 24K-04-115) and transducer (measuring cell) of max 100 N (ID: 24K-08-02). Dose accuracy was assessed using an analytical balance (ID: M17813) and METDose data system (ID: LP38188).

Results: Estimated relative dose force (N/N) for FP was significantly lower than for GQ (3.6, 4.4, 5.2; p<0.0001) and NF (2.5, 2.9, 3.5; p<0.0001) at all speeds (4, 6, 8 mm/s). Dose force for NF was reduced compared with GQ (1.4, 1.5, 1.5; p<0.0001). Dose accuracy at 0.10, 0.75 and 1.50 mg doses was 97, 99 and 99% for FP, 100, 95 and 97% for GQ, and 101, 99 and 99% for NF. Dose precision (CV, %) was 2.5, 0.8 and 0.8 for FP, 11.1, 2.6 and 1.6 for GQ and 3.8, 0.7 and 0.7 for NF.

Conclusions: Dose force was significantly lower for FP and NF than for GQ. Dose accuracy was not dissimilar between devices but dosing precision was improved with FP and NF vs. GQ.

PAO-143
Virilization of a toddler girl by paternal use of testosterone cream

Sophie Stoppa-Vaucher1; Timothy Hirter1; Franziska Phan-Hugi2; Claire-Lise Fawer1; Michael Hauschild3

1University of Lausanne, Pediatric Endocrinology and Diabetology Unit, Lausanne, Switzerland; 2University of Lausanne, Pediatrics, Lausanne, Switzerland

Background: A 15-month-old healthy female was referred because of rapid growth of dark pubic hair and a high testosterone (T) level (9 nmol/L, normal value (N) < 0.45).

Objective and hypotheses: Demonstrate the cause of the patient’s virilization

Methods: Clinical and laboratory work up as well as imaging studies were performed to exclude the main causes of an androgen excess.

Results: Past medical history and review of systems were unremarkable. Family history revealed a 4 year-old brother and unrelated parents, all in good health. Weight (11 kg, 0.78 SDS), height (78.1 cm, 0.4 SDS) were normal.
mal, no growth acceleration was observed. Tanner stage II pubic hair and an enlarged clitoris (12 mm) were found. She had no palpable breast tissue or posterior labial fusion, axillary hair, or acne. Pelvic ultrasound showed prepubertal uterus but no ovarian or ovarian mass were visualized. Adrenal hyperandrogenism was ruled out based on normal values of 17-OHP (0.7 nmol/L; N<3), Androstenedione (<0.5nmol/L; N = 0.38 ± 0.20) and DHEAS (<0.5 nmol/L; N = 0.06 ± 0.04). Prolactine, thyroid function test and tumoral markers (β-hCG (< 2 U/L; N<5), αFP (5.5 KU/L; N<10)) were normal. Her father, a former elite athlete, reported that he was using a T-cream (T 10% in PCCA Lipoderm-Base®) for muscle problems the last 2.3 months. Four weeks after the father had ceased the treatment, T level decreased to 1.7 nmol/L. The child’s clinical virilization signs regressed. We observed no sign of hyperandrogenism in her brother.

Conclusions: We describe a virilized toddler girl with isolated high T level due to trasdermal intoxication. The differential diagnosis of virilization in childhood includes both endogenous and exogenous causes. Increased utilization of easily available cutaneous androgen applications should prompt clinicians to inquire about exogenous androgen exposure in the medical history of virilized children.

1. PAO-144

Silent corticotrope adenoma – report of two cases
Liliana María Mejía 1; Ernesto Szenz 2; William Jubi 2
1Clinica Valle del Lili, Centro de Endocrinología, Universidad Libre
2Clinica Valle del Lili, Valle Del Cauca, Cali, Colombia

Background: Some Pituitary adenomas exhibit immunoactivity to hypothalamic hormones but because of the absence of clinical syndromes. They are know as silent adenomas. In 1979 Hassouny and collaborators describe the silent pituitary adenomas. In reference to corticotrope adenomas 43% are silent because they produce a biologically inactive hormone. They can be large and have a tendency to invade and recur.

Objective and hypotheses: We describe two cases of silent corticotrope adenoma in children.

Methods and results: CASE 1: Nine years old boy presented with frontoparietal headaches, loss of vision, no hypertension, no obesity or evidence of Cushing syndrome Laboratory: 8 am cortisol 4.2 µg/dl, TSH 2uml/ml prolactin 25.9 ng/ml/m MRI revealed Intrasselar mass of 3,7x2,4x2,4 mm. Treatment surgery, Pathology revealed a ACTH producing adenoma Pituitary K167 3%. Tumor recurred 6 months later. ACTH 15 pg/ml, cortisol 12µg/dl, similar results pathology but K167 15%. Case 2 A fourteen years old girl had a cranepharyngioma removed a year before. She presented with headaches visual loss and obesity, acantosis nigricans, no hypertension and no clinical manifestation of Cushing’s syndrome. A solid suprasellar mass of 15 x 19 mm MRI. Surgical pathology revealed an ACTH producing Adenoma Pituitary K167 1%. Post surgery ACTH 13.4 pg/ml cortisol 7µg/dl prolactina 20.4ng/ml

Conclusions: Silent corticotrope adenoma are not associated with a clinical picture of hormone excess but they can cause pituitary damage and they have a tendency to recur - Clinical diagnostic is difficult.

2. PAO-146

Late development of celiac disease in type 1 diabetes mellitus
Guglielmo Maiteni; Stefano Zucchini; Mirrella Scipione; Angela Rizzello; Silvana Salardi; Alessandro Cicognani
S.Orosia-Malpighi Hospital, Pediatrics, Bologna, Italy

Background: Patients with type 1 diabetes mellitus (T1DM) are at a high risk for developing autoimmune diseases such as coeliac disease (CD). Although CD mainly occurs at T1DM onset, it can also develop in the following years, but in our experience never after 6 years from T1DM onset (Salardi et al, J Pediatr Gastroenterol Nutr 2008). There is no consensus as to the duration of follow-up for autoimmune diseases in T1DM. We report a case of a male who developed CD 15 years after the diagnosis of T1DM.

Case report: A 19 yr-old male diagnosed with T1DM at 4 years of age. HLA phenotype was DR 3, 4 and DQ 2, 3. His siblings were also tested for autoimmune diseases but in our experience never after 6 years from T1DM onset. (Salardi et al, J Pediatr Gastroenterol Nutr 2008). The development of CD so far from diabetes onset (>15 years) has been never described before to our knowledge and the literature reports a follow up period never longer than 10 years. We conclude that screening for autoimmune disease should be annually performed in T1DM patients possibly lifelong, even in the absence of clinical symptoms, especially in those with a strong family history of autoimmune disease.

3. PAO-147

A case of congenital hypothyroidism with Hirschsprung’s disease: an unusual association
K D Moduri; Madan Mohan Rao; Sunil Kumar Kota
1Medwin Hospitals, Endocrinology, Hyderabad, India; 2HOPE Children’s hospitals, Paediatrics, Hyderabad, India

Background: Hirschsprung’s disease (HD) as well as congenital hypothyroidism can present with functional intestinal obstruction and abdominal distension in neonate. Both the diseases are considered as differential diagnosis, rather than as coexistence. We report one such interesting case with unusual coexistence between these 2 conditions.

Objective and hypotheses: Thyroid hormone is necessary for neuronal migration and lamination during brain development. Although hypothyroidism impairs colonic motility resulting in pseudo-obstruction the effects of hypothyroidism on neuronal migration through bowel have not been adequately studied.

Methods: A 21 days baby girl, product of consanguineous marriage presented with congenital heart abnormalities were diagnosed in 59/81 (72.8%) of pts; 13/81 (16.0%) had bicuspid aortic valve, 6/81 (7.5%) - coarctation of the aorta. The number of severe heart problems tended to be higher in 45,X (p<0.01). Thyroid disorders were found in 63/81 (77.8%) of pts; 21/81 (25.9%) had ATE. Totally, 46/81 (56.8%) pts had hypothyroidism. Thyroid failure was more frequent in other than 45,X girls (61.1% vs.53.3%, p<0.05). Seventeen pts (21%) had kidney abnormalities. GH therapy (0.33 mg/kg/wk) was initiated at the age of 11.1±4.9 yrs. Only 34.6% of pts were younger than 10 yrs at start of treatment. Baseline HSDS in the whole group was -3.4±1.2; time of GH treatment - 2.9±2.1 yrs, regardless of karyotype. The AHSDS were 0.7±0.5, 0.5±0.3 and 0.3±0.5 for year 1, 2 and 3 of GH therapy, respectively. Growth response was not correlated to karyotype. In 25 pts who completed GH treatment final height at 17.2 yrs was 148.4±4.8 cm. In 3.9±1.4 yrs of GH therapy they benefited 6.2±3.6 cm; height increase was + 1.5 cm/year.

Conclusions: TS in Belarus are manifested with high genetic variability and somatic abnormalities rates. Due to rather late diagnosis, GH therapy of TS in Belarus is often belated. Nevertheless, TS girls have good growth response.
with vomiting and abdominal distension. Weight was 2.5 kg and length 48 cm. On examination, there was facial puffiness, open posterior fontanelles, dry skin, cold peripheries and prominent abdominal veins with visible peristalsis. There was no maternal history of hypothyroidism. Patient was subjected to various investigations.

Results: Routine hemogram, liver & kidney function tests were within normal limits. Plain abdominal radiographs revealed gas filled bowel loops with barium enema showing dilated proximal colon, empty rectum, delayed emptying time with funnel like transition zone between proximal dilated & distal constricted bowel (Image 1). TSH was > 150 µU/ml. Thyroid scintigraphy revealed athyrosis, confirming congenital hypothyroidism due to athyrosis. Biopsy following colostomy revealed aganglionic segment, confirming the diagnosis of Hirschsprung’s disease. Baby was discharged with oral levothyroxine treatment.

Conclusions: With the present case, we propose that thyroid hormones may have a role in the development of HD. Further studies are needed to establish this.

PAO-148
Metabolic syndrome in obese Ukrainian schoolchildren: prevalence and risk factors
Ihor Hrytsyuk
Western Ukrainian Specialized Children’s Medical Centre, Paediatrics, Lviv, Ukraine

Background: Obesity in children and adolescents is currently on a rise in Ukraine, posing challenges to personal health and state health care system.

Objectives: To assess prevalence of metabolic syndrome (MS) among obese children and adolescents residing in Lviv, Ukraine, and risk factors leading to its development.

Methods: Obese children and adolescents were selected during annual (2009) medical check-up in 10 city schools. These were referred for further investigations. The major components of MS (abdominal obesity, hypertension, dyslipidemia, and glucose intolerance) were evaluated in a cross-sectional study. Potential risk factors for developing MS (weight at birth, parental obesity, degree of obesity, age, sex) were assessed in a multivariate logistic regression analysis.

Results: The nutritional status of 8523 school students aged 11 to 18 years showed that the prevalence of obesity (BMI ≥95%) is 9.1% (n = 776, boys = 381, girls = 395). The prevalence of MS among obese children reaches 14.3% (n = 111, boys = 62, girls = 49). The prevalence of MS tends to increase with increasing of BMI class (3.1% in class I, 6.2% in class II and 18.2% in class III). In a multivariate analysis more advanced age (OR = 4.08, CI = 3.13 - 6.24), BMI (OR = 2.71, CI = 1.34 - 4.75) and parental obesity (OR = 2.11, CI = 1.07 - 4.14) were found to be the most significant risk factors for having MS in obese children and adolescents.

Conclusions: Although lower than in neighbouring countries, the prevalence of MS in Ukrainian schoolchildren is growing, which warrants preventive measures. The older the obese child, the higher are chances for MS. The most important preventable risk factors are degree of obesity (BMI) and parental obesity.

PAO-149
Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia and its association with mineral homeostasis and duration of inpatient stay
Musab Elmantaser1, David Young2, Brenda Gibson2, S. Faisal Ahmed2
1Bone and Endocrine Research Group, Department of Child Health, Glasgow, United Kingdom; 2University of Strathclyde, Department of Statistics and Modelling Science, Glasgow, United Kingdom; 3University of Glasgow, Department of Haematology, Royal Hospital for Sick Children, Glasgow, United Kingdom; 4Bone and Endocrine Research Group, Department of Child Health, Royal Hospital for Sick Children, Glasgow, United Kingdom

Background: Reduced activity, older age and abnormal bone mineral status are considered as important determinants of poor bone health in children with acute lymphoblastic leukaemia (ALL).

Aim: To investigate the influence of activity, age and mineral status over the first 12 months of chemotherapy on subsequent SM.

Patients and methods: The medical records of 56 children presenting with ALL between 2003 and 2007 and treated on UKALL 2003 were reviewed for the number of in-patient days over the first 12 months of chemotherapy as a surrogate marker of inactivity and lack of well-being. Data for serum Ca, Alb, Mg and Phe were also collected over this period. SM was defined as any episode of musculoskeletal pain (MSP) or fractures.

Results: The median duration of in-patient days in the first 12 months of treatment in children with no SM was 58 days (40,100) whereas the median number of in-patient days during the first 12 months in those children with any SM, MSP only or fractures was 83 days (54, 131), 81 days (52, 119) and 91 days (59, 158), respectively (p=0.003). Children with SM and fractures particularly had lower levels of serum Ca, Mg and Phe compared to those without SM over the first 12 months of chemotherapy. There was a higher risk of SM in those who were diagnosed after the age of 8 years (p=0.001, OR=16.95, CI:3.80). Multiple regression analysis showed that the incidence of SM only had a significant independent association with age at diagnosis (p=0.001) and the number of inpatient days (p=0.03) over the first 12 months (r=23). All children who were diagnosed after the age of 8 years with an inpatient stay of greater than 75 days in the first 12 months of the chemotherapy (n,14) children had some form of SM (OR=64).

Conclusion: The incidence of SM in children receiving chemotherapy for ALL is associated with a higher likelihood of being older and having longer periods of in-patient stay. The close link between age and changes in bone mineral status may be one explanation for the increased bone morbidity in ALL children.

PAO-150
Trends of body mass index in children with craniopharyngioma from the west of Scotland
Muhammad Jaffer Khan1; Khadija Humayun2; Malcolm Donaldson2; S. Faisal Ahmed2; M Guftar Shaikh3
1University of Glasgow, Human Nutrition, Glasgow, United Kingdom; 2Aga Khan University, Department of Pediatrics and Child Health, Karachi, Pakistan; 3Royal Hospital for Sick Children, Paediatric Endocrinology, Glasgow, United Kingdom

Background: Hypothalamic obesity is one of the major causes of reduced quality of life in survivors of childhood craniopharyngioma, predisposing the patient to a wide variety of complications, including cardiovascular disease.

Objectives and hypothesis: The aim of this study was to examine the trends of change in body mass index (BMI) in childhood onset craniopharyngioma patients over 5 years. The hypothesis being all children with a craniopharyngioma gain weight irrespective of their BMI at presentation.

Methods: This was a retrospective study of 23 children with a diagnosis of craniopharyngioma presenting to the West of Scotland regional endocrine unit over a 5 year period. Data on weight, height, gender and age was collected. BMI SDS for each patient was subsequently calculated and analysed over time. Patients were categorised into 2 groups according to their BMI at presentation, obese BMI ≥2SDS, non-obese BMI < 1.95SDS. Obesity was defined as patients having a BMI SDS.

Results: At presentation, (M: F 11:12) 47.5% (n=11) patients were obese, with 52.5% (n=12) non-obese patients. BMI increased further in 7 of the
obese patients. There was a rise in mean BMI SDS in the first year after diagnosis, followed by a fall in BMI over the 5 year period in both groups; however the obese group at presentation remained obese. In the non-obese group only 10 had an increase in BMI SDS from presentation, with 8 patients becoming obese during the 5 years.

**Conclusions:** Cerebriophagiomi patients who are obese at presentation continue to gain weight and remain obese. This probably reflects a greater degree of hypotalamic damage in these individuals.

**PAO-151**

**Pseudotumor cerebri and diabetes insipidus:**

**Association or coincidence?**

Gabriella Pozzebon; Giuseppe Canningar; Chiara Maria Damia; Gisella Garbett; Maria Piera Ferrarello; Alessandra Musio; Berardo di Natale; Giovanna Weber; Giuseppe Chiumello

Vita Salute San Raffaele University, Pediatric Endocrine Unit, Milano, Italy

**Background:** Pseudotumor cerebri (PTC) is characterized by intracranial hypertension in the absence of clinical, laboratory or radiological evidence of space occupying lesion. It can occur in the pediatric population with an increasing incidence among adolescents, especially in obese females. Idiopathic PTC can be associated with anterior pituitary deficiency but there is no evidence in literature of association with central diabetes insipidus (CDI).

**Objective and hypotheses:** We report a case of PTC and concomitant CDI.

**Methods:** 13-year-old obese female (BMI 2.64 SDS) presented progressive headache, important visual impairment followed by complete blindness, sixth cranial nerve palsy, bilateral papilloedema, right hemisyndrome with alteration of the state of consciousness. MRI ruled out the presence of a cerebral tumor. Testosterone was still present, even if less severe. Neuroradiological follow-up revealed a reduction of intracranial hypertension.

**Results:** During follow up (1 year), the intracranial hypertension gradually resolved. No more headaches were reported, but visual impairment and diabetes insipidus were still present, even if less severe. Neuroradiological follow-up remained negative for brain tumors.

**Conclusions:** We assume that the increased intracranial pressure might have altered the activity of hypothalamic osmoreceptors and baroreceptors, inducing a lower synthesis of ADH.

**PAO-152**

**Maturity onset diabetes of the young (MODY) - presentation of two cases**

Ileana Puiu1; Simona Cosoveanu1; Veronica Elena Maria1; Alexandru Otilia Puiu1; Ioana Opri1ou1

1University of Medicine and Pharmacy, Emergency County Hospital, Craiova, Romania; 2Emergency County Hospital, Craiova, Romania

**Background:** Maturity onset diabetes (MODY) is characterized by a young-onset diabetes that is inherited in an autosomal dominant pattern.

**Method:** The authors present characteristic features of MODY diabetes in two sisters.

**Results:** The family history has shown that the father and paternal relatives had moderately elevated blood glucose levels, down through successive generations.

**Case 1:** Second child, gestational age at birth 38 weeks, birth weight 2300g, breastfed for five months. Case summary: two weeks of polyuria, polydipsia, decreased appetite, in the context of an upper respiratory tract infection. Clinical examination: 8 year-old girl, weight 24 kg, length 120 cm, BMI 17.1 kg/m2. Glucose levels ranged between 95-195 mg%, presence of glycosuria, with no ketones, HbA1c level 7.5%, negative anti GAD antibodies and ICA antibodies. Treatment: diet and a dose of 0.5 IU/kg/day of insulin for 2 months, followed by the diet only, while keeping glucose values between 85-112 mg% and HbA1c level decreased to 6.5%.

**Case 2:** The 12 year-old sister was hospitalized after two months without clinical signs of diabetes, but with the ambulatory blood glucose levels between 112-138 mg%, HbA1c level 6%, OGTT with fasting blood glucose 124 mg% and 2-h postprandial blood glucose 174 mg%, negative anti GAD antibodies and ICA antibodies. Personal history: first child, with normal evolution of the pregnancy, gestational age at birth 36 weeks, birth weight 2600g, Apgar score 9, breastfed for four months, psychomotor and weight development according to child development stages. Clinical examination: weight 35 kg, length 143 cm, BMI 17.5 kg/m2. It was established a diet that maintained a good glycemic control, after 3 months HbA1c was 6.5%.

**Conclusions:** The main goal of treatment in these cases of MODY diabetes was to maintain blood glucose levels as close to normal reducing the risk of complications. An early diagnosis of the disease is very important for family screening and also for therapy and prognosis.

**PAO-153**

**Long-term (five-year) height outcome in children treated with Norditropin®**

Judith Ross1; Peter Lee2; Robert Guth2; John Garbetta2

1Thomas Jefferson University, DuPont Hospital for Children, Dept. of Pediatrics, Philadelphia, PA, United States; 2The Milton S Hershey Medical Center, Penn State College of Medicine, Dept. of Pediatrics, Hershey, PA, United States; Novo Nordisk Inc., Dept. of Clinical Development, Medical and Regulatory Affairs, Princeton, NJ, United States

**Background:** The American Norditropin Studies: Web-enabled Research (ANSWER) Program®, a US-based registry, has collected long term efficacy and safety information on patients treated with Norditropin® (somatropin rDNA origin, Novo Nordisk A/S) at the discretion of participating physicians.

**Objective and hypotheses:** To assess the long-term (5 years) height standard deviation score (HSDS) and AHSDS by age, gender, and pubertal status in children treated with GH.

**Methods:** Treatment-naive pediatric patients with isolated/idioopathic GH deficiency (GHD; n=4454), multiple pituitary hormone deficiency (MPHD; n=387), small for gestational age (SGA; n=461), idiopathic short stature (ISS; n=758), and Turner syndrome (TS; n=435) were analyzed.

**Results:** Mean baseline ages (yrs) were generally younger in patients with MPHD (7.4), SGA (8.5), and TS (8.6) than with GHD (10.8) and ISS (11.2). Lowest peak GH levels were observed in patients with MPHD (3.1 ng/mL) and GHD (5.3 ng/mL). In the overall population, HSDS increased from -2.2 to baseline to -1.1 at Y3 and -0.9 at Y5, with GHD, MPHD, and SGA showing better growth response. Boys had significantly greater AHSDS than girls after 3 years or longer treatment duration (p<0.001). When stratified by baseline age, younger patients showed greater AHSDS than older patients for both genders (Table). In addition, children with GHD who remained pre-pubertal after 5 years of treatment had the greatest AHSDS (2.0±1.14) as compared to patients who were already pubertal at treatment start (1.42±0.69) or who transitioned into puberty during the study (1.58±0.68).

**Conclusions:** These results show that boys generally have greater height gain than girls after long-term treatment. A better growth response is observed in younger and pre-pubertal children, emphasizing the importance of starting GH treatment at a young age and pre-pubertal status.

**Table. Mean (SD) AHSDS over 5 years by Age and Gender.**

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 yrs</td>
<td>0.53</td>
<td>0.49</td>
</tr>
<tr>
<td>11 yrs</td>
<td>0.73</td>
<td>0.57</td>
</tr>
<tr>
<td>12 yrs</td>
<td>0.39</td>
<td>0.35</td>
</tr>
</tbody>
</table>

50th Annual Meeting of the ESPE

Horm Res 2011;76(suppl 2) 305
Role of prophylactic medical examination for early diagnosis of endocrine disorders

Alexey Resnenko1; Leila Namazova-Baranova2
1Scientific Center of Children’s Health, Diagnostic, Moscow, Russian Federation; 2Scientific Center of Children’s Health, Head, Moscow, Russian Federation

Background: Considerable increasement of endocrine disorders in pediatric population within last years was observed. Routine children and adolescent check up does not include examination by endocrinologist.

Objective and hypotheses: To estimate rate of endocrine disorders in pediatric population we explored 911 Moscow schoolchildren.

Methods: All children were splitted into groups by sex (sex ratio was 54% boys to 46% girls), age (junior school - from 6 to 11 years, middle school from 11 to 14 years, senior school- from 14 to 17 years). Physical examination, anthropometric measuring, and thyroid ultrasound were performed. On the base of measurements BMI, height velocity and standard deviation score of measurments were estimated.

Results: 12% of children had signs of endocrine disorders. Leading position belongs to overweight and obesity (61% of revealed endocrinological disorders). 25% of children with endocrinological disorders had thyroid gland enlargement, 9% had growth abnormalities (7% cases of short stature and 2% cases of high stature), abnormalities of sexual development were revealed in 5%. 9% of children with detected endocrine disorders had two of more diagnosis. Our data shows that overweight and obesity more common for middle and senior school groups and had no significant differences between sexes (sex ratio for overweight and obesity was 51% boys to 49% girls). Thyroid abnormalities predominate at the age of 11-17 years and more common for female population (sex ratio was 13% boys to 87% girls). Most children with growth abnormalities revealed at age 7-14 years, and sex ratio was 82% boys to 18% girls. 5% of boys and 95% of girls with endocrine disorders had sexual development abnormalities with predomination at the age of 11-17 years.

Conclusions: Results of our study show importance of endocrine function assessment in school-age children on a regular basis. This tactics helps to reveal possible endocrine disorders at early stages and form groups of children with high risk of endocrine disorders for prophylactic medical examination.

Rett syndrome associated with thyroid hypothyroidism – a synergic association for neurological disturbances: case report

Ottila Margineanu1; Ioan Simedrea2; Tamara Marcovici2; Daniela Chiriu2
11st Pediatric Clinic University of Medecine and Pharmacy Timisoara, Endocrinology, Timisoara, Romania; 21st Pediatric Clinic University of Medecine and Pharmacy Timisoara, Gastroenterology, Timisoara, Romania

Background: Rett syndrome is a neurodevelopmental disorder that characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability.

Case presentation: CA 4 years 3 month old girl admitted in our department in September 2010 for developmental regression, loss of purposeful hand movements, hand stereotypes, and seizures. The patients neonatal and perinatal history were normal (BW 3100g, BH 50cm). She could play with toys with support, she can not sit up or walk. At one and one half years she had stopped using her hands completely and at age two and one half her hand growth was markedly delayed and she had seizures. According the progressing neurological problems the child was diagnosed with Rett syndrome (the genetic analysis reveal a nucleotide change in the coding region of 4 exons of MECP2 in a heterozigote state) and she received treatment with carbamazepin 10mg/kg/day. At the admission in our department the child have weight 19kg, height 98.5 cm (age weight 104.96SdS -1.70 according to Prader criterias), dry rough pale skin, coarse, dry hair, hair loss, constipation, small feet and hands and severe neurologic problems; blood samples show normal BC, liver function, low Fi3, elevated TSH (73.5mU/ml), Low IGF1(23.5ng/ml) according to the age; small thyroid volume 1 ml (more then -2SD). We add to the treatment L thyroxine. The evaluation after 2 month show mild improved movements but her communications with family was improved.

Conclusions: 1. Rett syndrome is a rare genetic disease. 2. Brain damage can be induced by synergistic mechanism of synaptic damage and neuronal metabolism 3. Are necessary more sofisticate genetic analysis to solve the link between hypothyroidism and Rett syndrome.

Central hypothyroidism secondary to maternal hyperthyroidism

Pier Sevilla-Ramos; Maria Alia; Esther Cid; Nerea Lopez-Andres; José Maria Jiménez-Bustos
Hospital Universitario Guadalajara, Paediatric Endocrinology, Guadalajara, Spain

Background: Neonatal central hypothyroidism is very rare in paediatric patients. We present the case of a breast-fed baby developing central hypothyroidism when aged 2 months old, secondary to maternal Graves’ disease detected after birth.

Results: PA: Pregnancy monitored. Caesarea at 34 weeks due to premature rupture of membranes, APGAR 9/10. WAB: 2.570 g (P 75-90); LAB: 45 cm (P 75). FH: Father healthy, height 170 cm. Mother healthy, height 165 cm. Evolution during neonatal period: Admission at birth due to early asymptomatic hypoglycaemia birth. Metabolopathy screening for low TSH, with TSH of 0.03 mU/L and T4L of 1.84 ng/dl detected. Presents TA 90/43-78/40, FC 157-130 bpm during the first 5 days of life. Irritability and diarrhoea observed. Mother: TSH undetectable, T4L 2.82 ng/dl, antithyroglobulin Ab 45, antiperoxidase Ab 75, TSI Ab 13 (N=10). Follow-up at surgery: 15-day follow-up: Weight: 2.570 kg (P3), Length: 46 cm (P3), macroglossia. TSH 0.02 mU/L, T4L 1.31 ng/dl, T3 1.05 ng/dl, antimicrosomal Ab 71 (N 0-5.6) 2.5 month follow-up: Weight: 4.250 (P3), Length: 53.

Conclusions: In maternal Graves’ disease the transplacental transfer of Ac TSI affects the development of the hypothalamic-pituitary-adrenal axis (HPA). Rarely, exposure to high levels of intrauterine thyroid hormones in Graves’ disease can halt the hypothalamic-pituitary-adrenal axis, leading to a hypothyroidism in the fetus that continues for a variable period of time among newborns.

Congenital chloride diarrhea with congenital hypothyroidism in two siblings: case report

Erdal Ada1; Atilla Ersen2; Hasan Onal3; Sezen Ugast2; Tuğba Kontbay3; Ahmet Aydoğan1
1Ministry of Health Bakırköy Maternity and Children Education Hospital, Pediatric Endocrinology, Istanbul, Turkey; 2Kasimpasa Military Hospital, Pediatrics, Istanbul, Turkey; 3Ministry of Health Bakırköy Maternity and Children Education Hospital, Pediatrics, Istanbul, Turkey; 4Istanbul University, Cerrahpaşa Medical Faculty, Division of Metabolic Diseases, Istanbul, Turkey

Background: Congenital chloride diarrhea (CCD) is a rare autosomal recessively inherited disorder causing watery stool and dehydration characterized by impairment of Cl-/HCO3 exchange.

Objective: Infrequency of CCD makes diagnostics difficult and CCD compaining with congenital hypothyroidism has never been reported so far.

Population: A 7-year-old male who was followed with the diagnoses of congenital hypothyroidism, Barter syndrome and idiopathic chronic diarrhea in different medical centers and treated with L-thyroxine and indomethacin, admitted our unit with electrolyte abnormalities and mental retardation.

His medical history was notable for prolonged jaundice and congenital hypothyroidism in neonatal period. L-thyroxine was started but euthyroidism status was hardly supplied with alterations of thyroid hormones. Additionally, dehydration and metabolic alkalosis were recognized in his second months of age with the history of intrauterine polyhydramniosis; he was diagnosed as Barter syndrome and indomethacin treatment was started. But all the medications until now could not heal the problems of watery diarrhea, abdominal distention and electrolyte abnormalities. Additionally, we recognized that this family had a 3-month-old sibling and he was followed-up with the initial diagnoses of congenital hypothyroidism and Barter syndrome.

Results: We figured out CCD in our investigation of these two siblings that...
Tall stature, gonadal dysgenesis and obesity: unusual phenotype in a female with X chromosomal aberration

Eva Al Taji1; Daniela Zemkova2; Drahuse Novotna3
1Charles University, 3rd Faculty of Medicine, Department of Paediatrics, Prague, Czech Republic; 2Charles University, 2nd Faculty of Medicine, Department of Paediatrics, Prague, Czech Republic; 3Charles University, 2nd Faculty of Medicine, Department of Biology and Medical Genetics, Prague, Czech Republic

Background: Whilst X chromosome structural aberrations in female patients are most frequently characterized by a short stature and Turner’s phenotype, only several patients with strikingly different phenotype have been reported so far.

Objective and hypotheses: To describe clinical and genetic findings in a girl with a rare structural X chromosome rearrangement.

Methods: Physical examination, biochemical analysis, cytogenetic studies, imaging methods, neurological and psychological investigation were performed.

Results: The patient was referred at the age of 13 years because of obesity (BMI 26.3 kg/m², +3.53 SD). She had a tall disproportional stature (183cm, +3.3 SD), only initial pubic hair (Tanner P2), breast enlargement was caused by fatty tissue. No psychomotor delay or mental retardation were mentioned, however she had to attend a special school. Basal gonadotropins levels were high (FSH 49.5 U/L, LH 7.5 U/L), estradiol was prepubertal (0.05 mmol/l), that was consistent with hypergonadotrophic hypogonadism indicating gonadal dysgenesis. IGF1 levels and thyroid function were normal. Chromosome analysis revealed chromosomal aberration - an isochromosome i(Xp).

The result was confirmed by FISH analysis 46, X, i(X) (p10), ish (STS++, DXZ2+, SRY). Bone age corresponded to calendar age. Ultrasound visualized a hypoplastic uterus, ovaries were not visible. MRI of central nervous system demonstrated slight cortical atrophy.

Conclusions: We describe a girl with tall stature, obesity, mild mental retardation, gonadal dysgenesis and a rare structural rearrangement of X chromosome: Tall stature can be explained by a triple gene dosage of SHOX (short stature homeobox containing gene) together with estrogen deficiency. Oral estrogen replacement therapy was initiated to accelerate puberty and promote epiphyseal fusion, unfortunately the therapeutic effect was diminished due to non-compliance.
PAO-162
Re-evaluation of metabolic parameters of obese children after 5-7 years
Gulay Demirdag1; Sibel Tulgar Kinik2; Ayse Canan Yazıcı3
1Baskent University, Pediatrics, Ankara, Turkey; 2Baskent University, Pediatric Endocrinology, Ankara, Turkey; 3Baskent University, Biostatistics, Ankara, Turkey

Background: Obesity beginning in the childhood continues to adulthood and becomes more complicated.

Objective and hypotheses: In this study we aimed to re-evaluate obese children with respect to obesity status and metabolic parameters after 5-7 years from the first admission.

Methods: 100 cases who admitted to our clinic for exogen obesity were called again. 40 of them were male. Their relative BMI was calculated, serum levels of lipids, glucose, insulin, free T4,TSH were studied. There was significant. The cases were divided into 4 group according to metabolic disorders in the first visit.

Group 1: only dislipidemia (HDL<40 mg/dL, triglyceride>150 mg/dL, LDL>130 mg/dL)
Group 2: only insulin resistance (HOMA>3)
Group 3: dislipidemia and insulin resistance
Group 4: norm

Results: At the last evaluation, rel BMI decreased significantly in group 1 and 2 compared to first visit (p=0.006 and 0.034 respectively). The percentage of cases whom metabolic parameters improved to normal limits were 56% in groups 1,2,4 and 18% in the group 3.

Conclusions: Loosing weight is easier in children whom have only dislipidemia or only insulin resistance than children who have both of them. Having that metabolic disorders together makes the metabolic improvement harder. So, prevention of early stages of obesity and metabolic disorders plays important role in adulthood life quality.

PAO-163
Factors to predict the result of GnRH stimulation test in girls with suspicious precocious puberty
Hyo-Kyoung Nam; Young Jun Rhee; Chang Sung Son; Sang Hee Park; Kee-Hyung Lee
College of medicine, Korea university, Department of Pediatrics, Seoul, Republic of Korea

Background: In girls with early breast development and bone age advancement, sometimes the clinical findings and the results of gonadotropin-releasing hormone (GnRH) stimulation test are inconsistent.

Objective and hypotheses: The aim of this study was to investigate the factors to predict the positive results of GnRH stimulation test in girls with suspicious central precocious puberty (CPP).

Methods: We reviewed records of 574 girls who visited at Pediatric Endocrinology Clinic of Korea university hospital from March 2005 to May 2010 and underwent GnRH stimulation test under the age of 9 years old. Each of the initial and follow-up tests was divided into two groups based on whether peak luteinizing hormone (LH) level was less than 5 IU/L (negative) or not (positive).

Results: The growth velocity ratio was significant predictive factor [initial test, OR 10.7, (95% CI 4.3, 26.7), P = 0.01; follow-up test, OR 6.6, (95% CI 1.5, 28.9), P = 0.01] of positive results.

Conclusions: Considering when the GnRH stimulation test is thought to be helpful for girls with suspicious precocious puberty, rapid growth velocity could be the most useful predictive factor for the positive results.

PAO-164
Autoantibody positivity and clinical characteristics of childhood diabetes
Jiyun Park; Jong Seok Oh; In Chang Seong; Jeesuk Yu
Dankook University Hospital, Department of Pediatrics, Cheonan, Republic of Korea

Background: Most childhood diabetes was usually thought as type 1 diabetes (T1DM), but there is a tendency of increasing type 2 diabetes (T2DM) and sometimes, it might not be easy to determine the type of diabetes. It’s important to know the type of diabetes and it’s very useful to choose the best treatment modality.

Objective and hypotheses: In this study, we searched the clinical and laboratory characteristics of the patients with childhood diabetes to compare those according to the type of diabetes.

Methods: We retrospectively reviewed the medical records of the patients who was diagnosed as diabetes and followed at the department of Pediatrics, Dankook University Hospital to find the clinical and laboratory characteristics.

Results: Total 43 patients were enrolled in this study. The patients were grouped as T1DM (n=29), T2DM (n=10) and unclassified (n=4), according to the clinical characteristics and laboratory findings. There was a little female predominance (M:F 1.1:1.5). Autoantibody positivity was high in T1DM, implying it as the very valuable marker in T1DM. T1DM had an earlier onset age, as expected. In 55%, diabetic ketoacidosis (DKA) was the presenting symptom in T1DM, but no DKA in T2DM as an initial symptom. Initial and FU HbA1c did not show statistically significant differences between the groups. Initial serum c-peptide or insulin levels were lower in T1DM. Obesity was not the major portion in childhood T2DM but BMI was higher in T2DM. In T2DM, oral hypoglycaemic agents with or without insulin were chosen as a treatment. During follow up, adolescence, especially in girls, was thought as a very vulnerable period to manage the diabetes requiring more intensive emotional support including family cooperation.

Conclusions: In this study, we can confirm that the autoantibody test is very valuable to diagnose specific type of diabetes and to determine the diverse treatment modality. And female adolescence was thought as a vulnerable period to manage the diabetes requiring more intensive emotional support including family cooperation.

PAO-165
A hemophilia b carrier girl with central precocious puberty associated with supernumerary marker chromosome, hypercholesterolemia and investigated by FISH and array comparative genomic hybridization
Mei-Chyn Chang1; Hui-Pin Hsiao2; Cheng-Yu Liao3; Li-Min Chen4
1Kaohsiung Medical University Hospital, Division of Genetics, Endocrinology and Metabolism, Department of Pediatrics, Kaohsiung, Taiwan; 2Kaohsiung Municipal Hsiao-Kang Hospital, Department of Pediatrics, Kaohsiung, Taiwan; 3Kaohsiung Medical University Hospital, Division of Genetics, Endocrinology and Metabolism, Department of Pediatrics, Kaohsiung, Taiwan

Background: Supernumerary marker chromosome (SMC) in general are extremely rare findings and approximately 1/100,000 newborn cases. Hemophilia B is caused by mutation of the coagulation factor IX (FIX) gene.

Objective and hypotheses: To estimate genomic copy number changes in a Hemophilia B carrier 8 years old girl had central precocious puberty, associated with a supernumerary marker chromosome and hypercholesterolemia in array comparative genomic hybridization.

Methods: We report on a 8 years old Taiwanese girl with central precocious puberty. Her elder brother was a victim of Hemophilia B and confirmed she was a carrier of Hemophilia B at the age of 4 years old. Central precocious puberty was diagnosed at the age of 8 years old due to develop of menarche and high levels of FSH and LH. Bone age was significant advanced to 12 years old. Her height was 130 cm (50th percentile), her weight was 28 kg (50th percentile). Her gross appearance was not specific but with moderate intellectual deficiency. Chromosome analysis showed non mosaic and de novo 47,XX,+ marker chromosome. The laboratory test revealed high total cholesterol 306mg/dl, high LDL-C 220 mg/dl, and HDL-C 60 mg/dl.
Results: FISH study confirmed the supernumerary marker chromosome is originated from the 14 or 22 chromosome and includes two copies of the acute p-arms. 47.XY- as mar imaging (14/22). Array comparative genomic hybridization were performed with array-CGH. PCR and sequence analysis for Hemophilia B and LDL receptor showed c.424 > T, Gln> stop gene mutation in factor IX gene and missense mutation of 4th exon of LDL receptor with genotype LDLR-C188 (C>V). 

Conclusions: Although no pathologic gene dosage variation was detected from array comparative genomic hybridization. Our patient still had a multiple anomalies with supernumerary marker chromosome, Hemophilia B, hypercholesterolemia and central precocious puberty. She had received GnRH agonist treatment till now.

**PAO-166**

**Patient with congenital hypothyroidism, adrenal insufficiency, and SRY deletion: a case report**

Shamita Tripathi; Carla Minutti; Carolyn Jones

Loyola University Medical Center, Pediatrics, Maywood, United States

**Background:** SRY deletion is a rare genetic condition which can cause androgen resistance syndrome and ambiguous genitalia. Congenital hypothyroidism and adrenal insufficiency together with an SRY mutation are rare. 

**Objective and hypotheses:** To determine whether congenital hypothyroidism and adrenal insufficiency have been reported in a patient with an SRY deletion. There may be a condition where congenital hypothyroidism, adrenal insufficiency, and SRY deletion occur together.

**Methods:** Literature search.

**Results:** This patient was born via in vitro fertilization at 37 weeks gestation to an Indian mother. Physical exam revealed jaundice, a broad nasal bridge, ambiguous genitalia with well-rugated empty scrotum/labia, microepispadias, no hypospadias, and bilateral descended testicles. Karyotype was 46, XY and FISH analysis showed deletion for part of the SRY region that is usually caused by a copying error during spermatogenesis. LH and FSH levels were elevated, while DHEA-S, DHT, and testosterone levels were low at 0.4mg/ml, 4ng/dl, and 115ng/dl respectively. As beta-TCG stimulation test yielded a no increase in testosterone, the patient was diagnosed with hypergonadotropic hypogonadism. Intramuscular injections of testosterone enanthate 25mg/month for 3 months were started with monitoring of phallic growth to follow. As his TSH level was high (19.5uu/ml) and free T4 level was low (1.3ng/dl), the patient was diagnosed with hypothyroidism. After starting levothyroxine, TSH and FT4 levels normalized. At two months of age, the patient developed hyperpigmentation. He subsequently failed an ACTH stimulation test and was therefore diagnosed with adrenal insufficiency.

**Conclusions:** To our knowledge this patient is a novel presentation of congenital hypothyroidism and adrenal insufficiency occurring with an SRY deletion in an in vitro baby.

**PAO-167**

**Response to rhIGF-1 therapy in patients with primary IGF-1 deficiency**

Oksana Lazareva; Sheila Perez; Iuliana Predescu; Shahid Malik; Svetlana Ten; Amrit Bhangoo

State University of New York, Downstate, Pediatric Endocrinology, Brooklyn, NY, United States

**Background:** Patients with growth hormone insensitivity or Laron syndrome are a heterogeneous group of children with a variety of clinical phenotypes and variable severity of short stature. A relatively high prevalence of IGF-1 deficiency has been reported in ISS patients without classical Laron syndrome features.

**Objective and hypotheses:** To study the response to rhIGF-1 therapy in short children with Primary IGFD.

**Methods:** 21 children with short stature, who passed GHRH (1 mg/kg IV) stimulation test (GH peak-15mg/ml) were included in the study. They were treated with Increlex® @ 0.24 mg/kg/day. Height velocity (HV) and Height (Ht) SDS were measured after 6 months of therapy.

**Results:** Patient’s characteristics: age 9.84±2.5 SD years, Ht -2.49 ± 0.36 SD (range -2.9 to -1.85 SDS) and IGF-1 levels -2.22 ±0.97 SD (range -3.6 to -1.85 SDS). The mean birth weight was 2.86 ±0.41 kg. The average peak of GH after GHRH was 48.9±24.1 SD ng/ml. HY after 6 months ofIncrelex® therapy was 10.3 ± 3.9 cm/yr. There were only 3 patients in this group whose HY was less than 3 cm/yr on Increlex® therapy. The mean change in Ht SDS was +0.35±0.33 SD after 6 months ofIncrelex® therapy.

**Conclusions:** This pilot data revealed that the rhIGF-1 therapy has good efficacy in less severe Primary IGFD. The average HY after 6 months of therapy is similar to the data on severe Primary IGFD (Ht<-3SDS, IGF-1<-3SDS) patients treated with rhIGF-1.

**PAO-168**

**Hot nodule harboring a papillary microcarcinoma in a girl from an iodine sufficient area**

Ana Tenaghi1; Horacio M. Solarz2; Javier Fariñas3; Horacio Bignon4; Paula Morano5; Patricia Papendieck6

1Sanatorio Güemes, Endocrinología Pediátrica, Buenos Aires, Argentina; 2Sanatorio Güemes, Departamento de Patología, Buenos Aires, Argentina; 3Sanatorio Güemes, Endocrinología, Buenos Aires, Argentina; 4Hospital de Niños Ricardo Gutierrez, Departamento de Cirugía, Buenos Aires, Argentina; 5Sanatorio Güemes, Clínica Pediátrica, Buenos Aires, Argentina; 6Hospital de Niños Ricardo Gutierrez, Division de Endocrinología, Buenos Aires, Argentina

**Background:** Hot nodules on radionuclide imaging of thyroid are generally benign but there are reported some cases of hot nodules associated with thyroid cancer with only a few cases in pediatric age. However a relative high incidence in children’s was reported in iodine deficiency area after introduction of iodine supplementation. 

**Objective and hypotheses:** To report a case of thyroid cancer associated with a hot nodule in a pediatric patient from an iodine sufficient area.

**Methods:** 3 years old girl consulted for a one week evolution tumor in her neck, her aunt had thyroid cancer. On physical examination an approximately 2 cm firm mobile nodule on thyroid topography was palpated. Thyroid ultrasound showed a cystic nodule of 19 x 14 x 13 mm with heterogeneous echoic polyloid mass of irregular limits in the right lobe. The rest of the gland was normal.99mTc thyroid scan showed a focal increase of the thyroid with an area of high Tc uptake in the nodule topography corresponding to a hyperfunctioning nodule with normal uptake in the rest of the gland. Thyroid function tests showed T4: 9.24 ug/dl (6-14) free T4: 1.44 ng/dl (0.8-2.2) T3: 178 ng/dl (80-220) TSH 4.42 mUI/ml(0.27-4.2) Calcitonin and thyroid antibodies were negative. Fine needle aspiration biopsy (FNAB) showed: macroraphages with hemosiderin and erythrocytes without follicular cells. Because the presence of the risk factor, irregular limits in polypoid mass and no conclusive FNAB a right hemithyroidectomy was performed. 

**Results:** Histologic section revealed a nodular hyperplasia with lymphocytic thyroiditis. A papillary microcarcinoma of 0.25 mm was detected.

**Conclusions:** Hot nodules in iodine sufficient areas could be associated with malignant disease in pediatric populations too. We recommend the systematic practice of FNAB in pediatric patients with hot nodules especially if suspicious ultrasonography characters or familial history of thyroid cancer are present. The concomitance of an inflammatory process with cancer was previously reported but others studies too.
testes and normal male external genitalia with infertility.

**Objective and hypotheses:** We herein report a male newborn who presented with ambiguous genitalia and had 45,X karyotype.

**Methods:** A 38-week gestation newborn with 3000 gr birthweight was admitted for evaluation of ambiguous genitalia during the neonatal period. He had predominantly male phenotype with microopenis, chordee, penoscrotal hypospadias and nonpalpable right gonad. His left gonad was palpable in scrotal region. Ultrasonographic examination showed Mullerian structures and right sided immature gonad at pelvic area; gonad with immature testis structure at left sided in the scrotum. Laboratory evaluation on 18th day of life revealed as LH: 3.07 mIU/ml, FSH: 4.69 mIU/ml, basal testosterone: 111 ng/dl. Neither mosaicism nor a structurally aberrant Y chromosome was observed by routine cytogenetic analysis. Although FISH revealed SRY negative, it was found to be positive with PCR. Thereafter biopsies of both gonads revealed left testes with immature testicular tissue (5x3x2cm) and right streak gonad (3x2x2cm) (compact ovarian stroma with no follicles). SRY evaluation of both gonads material were positive.

**Results:** The patient has been raised as male by removing Mullerian structures and streak gonad decisioning of our gender assignment team. The investigtion of translocation of Y chromosome in our patient is still ongoing. We will follow clinical course of this patient for developing Turner phenotype and hypergonadotropic hypogonadism.

**Conclusions:** The presented patient was evaluated as mixed gonadal dysgenesis due to autosomal SRY translocation with 45,X karyotype. SRY should be detected by PCR, in the patient with FISH negative for Y material, before gonadal genotyping.

---

**PAO-170**

**The difficulties of investigating and treating an endocrine patient in resource limited countries**  
*Edna Sime Masala,* Kandi Catherine Mute  
Muhimbili National Hospital, Paediatric and Child Health, Dar es Salaam, Tanzania

**Introduction:** Adrenal masses (AMs) are often discovered incidentally and are then termed adrenal incidentalomas (AIs). They are often discovered after an imaging procedure is performed that is unrelated to the adrenal gland. Less commonly, AIs are discovered as part of the clinical workup for suspected adrenal disease (e.g., Cushing syndrome). However it took us more than three months and we are not yet at the final diagnosis.

**Case presentation:** A 3 years old child presented with overweight. Was born prematurely, Birth weight 2.4kg and a mild birth asphyxia, current weight 18kg. On examination the weight was above 97th centile. He had a moon shaped face, strai, trunk obesity, hirsutism, pubarche and was hypertensive (117/67mmHg). Morning cortisol levels were increased. Abdominal USS showed an adrenal adenoma. Computed tomography showed a mass in the right adrenal tumor. Was put on ketoconazole tablets later on was operated and the capsulated tumor was removed, currently awaiting the biopsy results.

**Conclusion:** No diagnosis has been confirmed to date, most of the investigation were not done due to lack of facilities or high costs. This implies that it is very difficult to have a final diagnosis and manage endocrine patients fully.

---

**PAO-171**

**Vicious circle of poor compliance in a patient with congenital adrenal hyperplasia due to 21-hydroxylase deficiency - a case report**  
*Carmen Barbu; Alina Carmen Roman; Maria Magdalena Gisca; Suzana Florea; Simona Fica*  
Elias Hospital, Bucharest, Endocrinology, Bucharest, Romania

**Background:** Congenital adrenal hyperplasia (CAH) is a group of disorders resulting from the deficiency of one of the five enzymes required for the synthesis of cortisol. One form of gonadal abnormality in affected males with CAH is the development of testicular adrenal rests, during periods of sustained elevation of plasma ACTH levels. The prevalence of these testicular tumors between 0 and 47% has been reported, dependent on method of detection (palpation vs. ultrasound).

**Objective and hypotheses:** To evaluate a 17-year-old boy history, known with classic 21-hydroxylase deficiency, salt wasting type, diagnosed at birth, referred to our department with a discordant history in the context of the diagnosis of congenital adrenal hyperplasia with intravenous glucocorticoid in high doses, followed by treatment cessation soon after the acute episode due to self reported testicular pain. Physical examination showed normal stature (151cm), painful palpable mass in left testis, BP: 80-50 mmHg. The sodium level was 127mmol/L, potassium level was 5.6mmol/L. Morning plasma cortisol was decreased with increased ACTH plasma level, testosterone, LH, FSH, AFP and beta hCG levels were in normal range. The ultrasound examination showed normal adrenal glands and three homogeneously hypoechoic masses 1.1/0.9 cm maximum in right testis and three similar masses 3.1/1.8 cm each maximum in left testis.

**Conclusions:** Presence of testicular tumors in a patient with poor control of CAH is not unusual but in our case the testicular pain associated by mistake with glucocorticoid treatment in high doses administrated in acute crisis became a major factor in raising a vicious circle of poor compliance.

---

**PAO-172**

**Achondroplasia in a girl with G 1138 A mutation, response to growth hormone therapy, two and half years follow up**  
*Sarena Tawfei; Mona Atlar; Heba Hasam; Solal Mohamed*  
1Maardi, Pediatrics, Cairo, Egypt; 2Cairo University, Pediatrics, Cairo, Egypt; ‘Ain Shams, Pediatrics, Cairo, Egypt; ‘Ain Shams, Genetics, Cairo, Egypt

**Background:** Achondroplasia is the most common form of skeletal dysplasia in man, has autosomal dominant inheritance and causes extreme short stature. More than 90% of patients with achondroplasia have a G to A transversion or G to C transversion at position 1138 of the fibroblast growth factor receptor-3 (FGFR3) gene.

**Objective:** To evaluate the response to growth hormone of Egyptian patient with achondroplasia.

**Methods:** A prospective follow up study of a girl with achondroplasia.

**Case presentation:** The girl was born on 14.9.2006, is a first infant born to non consanguineous parents. She was delivered by caesarean section with birth weight 2.000 kgm , height 40 cm, OFC 41cm at full term, second baby is 3 years and is unaffected. Our patient presented with short stature and large head at birth. Examination on 16.2.2011. The child is active, cheerful with average intelligence. Paternal height 180 cm, maternal height 163 cm, patient height 92.8 cm (+2SD), upper segment 60 cm, lower segment 32.48 cm, span 85 cm, weight 18.9 kgm, OFC 55 Cm. Bone age is 5.6 years. Low set ears. Skull is large with prominent forehead, flat nasal bridge, small chest compared to the abdomen, medial arm and forearm creases are prominent.

**Molecular testing:** Fibroblast growth factor receptor-3 (FGFR3) mutation: G1138A and G1138C mutations.

**Method:** PCR and DNA sequencing for known mutation G 1138 A and G 1138 C mutation in codon 380 of FGFR3 gene for achondroplasia.

**Result:** One mutation G 1138 A is detected consistent with achondroplasia.

**Discussion:** On September 2008 he was given growth hormone (GH) 0.09 u/kg/day, patient height was 78 cm (+2SD), GH dose increased to 0.12 u/kg/day. On February height is 92.8 cm. +2.5 SD, height velocity 6.048 cm/year.

**Conclusion:** Patients with achondroplasia with G 1138 A mutation may benefit from GH at a dose range from 0.09a/kg/day to 0.12a/kg/day to maintain an appropriate height velocity.

---

**PAO-173**

**A case of transient pseudohypoaldosteronism complicated by cerebral artery infarction**  
*Akiko Saji; Keisuke Yoshii; Masako Sakauchi; Makiko Osawa*  
Tokyo women’s medical university hospital, Pediatrics, Tokyo, Japan

**Background:** Pseudohypoaldosteronism is a rare condition characterized by renal resistance to the action of aldosterone. Transient pseudohypoaldosteronism (TPHA) has been identified in neonates and young infants with obstructive uropathy and urinary tract infection. Objective: To describe a 8-month-old boy with TPHA complicated by cerebral infarction.

**Case:** The patient was born at a gestational age of 39 weeks after uncomplicated pregnancy. Birth weight was 2570g. He was admitted for evaluation of ambiguous genitalia during the neonatal period. He had predominantly male phenotype with micropenis, chordee, penoscrotal hypospadias and nonpalpable right gonad. His left gonad was palpable in scrotal region. Ultrasonographic examination showed Mullerian structures and right sided immature gonad at pelvic area; gonad with immature testis structure at left sided in the scrotum.
weight was 3,348g (75-90 percentile). Family history was unremarkable. He showed poor weight gain from the age of 4-month-old. He referred to our hospital for fever and irritability at 8-month. At admission, his weight was 6500g (<3 percentile). He was severely-dehydrated. He had neither genital pigmentation nor abnormalities of the external genitalia. Blood examination showed hyponatremia(117mEq/L), hyperkalemia(5.7mEq/L) and metabolic acidosis. Cloudy urine obtained by catheterization yielded Escherichia coli. Renal ultrasonography revealed left hydrenephrosis and hydroureret. Endocrine test results showed high levels of aldosterone (22900ng/mL) and plasma renin activity (88ng/mL/hr). We gave him a diagnosis of TPHA caused by urinary tract malformation and urinary tract infection. Serum sodium and potassium levels normalized after 24 hours of intravenous fluids and antibiotic therapy. On the fifth hospital day, he became irritable again and was made a diagnosis of right posterior cerebral infarction by head CT scan. We treated him with aspirin and free radical scavenger immediately. He underwent left uroteroplasty at 1-year. Now, he have normal development at the age of 1-year-4-month.

Precise conclusions: Hyperaldosteronism causes endothelial dysfunction and impairs vascular reactivity. Predominant causes of this patient’s infection were infection and severe-dehydration. Remaining cause might be involved in vascular damage from hyperaldosteronism because the action of aldosterone was not defective except in renal tubular tissue in patients with TPHA.

PAO-174

The efficacy of gonadotropin-releasing analogues in children with central precocious puberty

Anna Dolmasova; Maria Kareva; Elizaveta Ohorov; Valentina Petrovka

Endocrinological Research Center, Institute of Pediatric Endocrinology, Moscow, Russian Federation

Background: GNRH analogues have been used for treatment of precocious puberty for almost 30 years. However, it is still discussed whether this treatment significantly improve adult height (AH) and how it can impact body mass.

Objective and hypotheses: To evaluate the efficacy of GnRH analogues regarding final height and weight of children with central precocious puberty (CPP).

Methods: Total number of 50 patients was evaluated in this retrospective single-centre study. Group 1 included 33 patients (26 females, 7 males). All of them had been treated with triptorelin 100mg/kg/28 days during 3.5 yrs (0.9-7.8 yrs). The median age at the start of treatment was 5.2 (2.0 – 8.0 yrs). This group was subdivided for Group 1A - 19 patients with still opened epiphysis and Group 1B - 14 patients who have already reached adult height. Group2 included 17 CPP patients (14 females, 3 males) that have never received any treatment. Predicted adult height (PAH) was calculated according to the Bayley and Pinneau tables. Target Height (TH) was evaluated as midparental height adjusted for sex (+/- 6.5).

Results: GNRHa treatment significantly improved PAH in Group 1a. AH showed poor weight gain from the age of 4-month-old. He referred to our hospital for fever and irritability at 8-month. At admission, his weight was 6500g (<3 percentile). He was severe-dehydrated. He had neither genital pigmentation nor abnormalities of the external genitalia. Blood examination showed hyponatremia(117mEq/L), hyperkalemia(5.7mEq/L) and metabolic acidosis. Cloudy urine obtained by catheterization yielded Escherichia coli. Renal ultrasonography revealed left hydrenephrosis and hydroureret. Endocrine test results showed high levels of aldosterone (22900ng/mL) and plasma renin activity (88ng/mL/hr). We gave him a diagnosis of TPHA caused by urinary tract malformation and urinary tract infection. Serum sodium and potassium levels normalized after 24 hours of intravenous fluids and antibiotic therapy. On the fifth hospital day, he became irritable again and was made a diagnosis of right posterior cerebral infarction by head CT scan. We treated him with aspirin and free radical scavenger immediately. He underwent left uroteroplasty at 1-year. Now, he have normal development at the age of 1-year-4-month.

Precise conclusions: Hyperaldosteronism causes endothelial dysfunction and impairs vascular reactivity. Predominant causes of this patient’s infection were infection and severe-dehydration. Remaining cause might be involved in vascular damage from hyperaldosteronism because the action of aldosterone was not defective except in renal tubular tissue in patients with TPHA.

PAO-174

The efficacy of gonadotropin-releasing analogues in children with central precocious puberty

Anna Dolmasova; Maria Kareva; Elizaveta Ohorov; Valentina Petrovka

Endocrinological Research Center, Institute of Pediatric Endocrinology, Moscow, Russian Federation

Background: GNRH analogues have been used for treatment of precocious puberty for almost 30 years. However, it is still discussed whether this treatment significantly improve adult height (AH) and how it can impact body mass.

Objective and hypotheses: To evaluate the efficacy of GnRH analogues regarding final height and weight of children with central precocious puberty (CPP).

Methods: Total number of 50 patients was evaluated in this retrospective single-centre study. Group 1 included 33 patients (26 females, 7 males). All of them had been treated with triptorelin 100mg/kg/28 days during 3.5 yrs (0.9-7.8 yrs). The median age at the start of treatment was 5.2 (2.0 – 8.0 yrs). This group was subdivided for Group 1A - 19 patients with still opened epiphysis and Group 1B - 14 patients who have already reached adult height. Group2 included 17 CPP patients (14 females, 3 males) that have never received any treatment. Predicted adult height (PAH) was calculated according to the Bayley and Pinneau tables. Target Height (TH) was evaluated as midparental height adjusted for sex (+/- 6.5).

Results: GNRHa treatment significantly improved PAH in Group 1a. AH showed poor weight gain from the age of 4-month-old. He referred to our hospital for fever and irritability at 8-month. At admission, his weight was 6500g (<3 percentile). He was severe-dehydrated. He had neither genital pigmentation nor abnormalities of the external genitalia. Blood examination showed hyponatremia(117mEq/L), hyperkalemia(5.7mEq/L) and metabolic acidosis. Cloudy urine obtained by catheterization yielded Escherichia coli. Renal ultrasonography revealed left hydrenephrosis and hydroureret. Endocrine test results showed high levels of aldosterone (22900ng/mL) and plasma renin activity (88ng/mL/hr). We gave him a diagnosis of TPHA caused by urinary tract malformation and urinary tract infection. Serum sodium and potassium levels normalized after 24 hours of intravenous fluids and antibiotic therapy. On the fifth hospital day, he became irritable again and was made a diagnosis of right posterior cerebral infarction by head CT scan. We treated him with aspirin and free radical scavenger immediately. He underwent left uroteroplasty at 1-year. Now, he have normal development at the age of 1-year-4-month.

Precise conclusions: Hyperaldosteronism causes endothelial dysfunction and impairs vascular reactivity. Predominant causes of this patient’s infection were infection and severe-dehydration. Remaining cause might be involved in vascular damage from hyperaldosteronism because the action of aldosterone was not defective except in renal tubular tissue in patients with TPHA.
We suggest to diffuse treatment guidelines to healthcare providers to limit iatrogenic risks, to educate patients on management of situations at risk for DKA and to intensify the follow up of patients at risk of relapse.

### PAO-177
#### Follow-up of girls with complete androgen insensitivity syndrome (CAIS) and gonads in situ during and after puberty – two case reports
**Ulla Doelmer**, Lutz Wuenisch, Ralf Werner, Olaf Hirt

**Background:** In recent publications the prevalence of germ cell tumors in CAIS has been estimated < 1% until puberty. Leaving the gonads in situ will allow endogenous hormone production and spontaneous puberty. However there is no data on the tumor prevalence in CAIS after puberty.

**Patients and methods:** In two sisters with a 46,XY karyotype we identified a MT4V mutation in exon 5 of the androgen receptor gene. According to the family’s request the gonads remained in situ. The girls were first seen in our clinics at the age of 13.6 and 11.3 years. Follow-up visits every six months included clinical assessment of growth and puberty, gonadal ultrasound, hormone profiles (LH, FSH, SHBG, testosterone and estradiol) and tumor markers (HCG and AFP).

**Results:** Both girls showed a CAIS phenotype with normal female external genitalia and absence of Mullerian duct remnants. At the age of 15.8 years the older sister had normal breast development without growth of pubic hair. Hormone profiles showed elevated LH levels and FSH, testosterone, estradiol and SHBG levels within the adult male reference ranges. Gonadal ultrasounds and tumor markers revealed no pathology. The younger girl hadn’t shown any signs of puberty at the age of 12.7 years, but stimulated gonadotropins and testosterone levels were detected with prepubetal estradiol and SHBG levels. Ultrasonic scans displayed unsuspicious testes in the inguinal canals.

**Conclusions:** The two sisters are undergoing spontaneous puberty, at which they profit from their specific endogenous hormone production. A follow-up protocol has been designed for early diagnosis of malignancy. However further studies are necessary to evaluate the safety of such protocols and establish criteria for intervention.

### PAO-179
#### Secondary transient pseudohypoaldosteronism – a report of two cases
**Agnieszka Rudzka-Kocier; Elzbieta Moszczynska; Mieczyslaw Szalecki**

**Background:** Secondary pseudohypoaldosteronism (PHA) is a syndrome with a state of renal tubular unresponsiveness to aldosteron and is manifested by hyponatremia, hyperkalemia and metabolic acidsis. Major contributing factors are urinary tract infections, urinary tract malformations.

**Objective:** A report of two cases of transient PHA in infants, including one unusual case where PHA occurred in the course of diarrhea due to Crohn disease.

1. A 2-months-age boy admitted to hospital with diarrhea and weight loss. Clinical and laboratory findings revealed dehydratation, hyponatremia at 118 mmol/l, hyperkalemia at 7.05 mmol/l, metabolic acidosis (bicarbonate 15,7 mmol/l). Urinary tract infection was excluded. Renal sonography was normal. Congenital adrenal hyperplasia (CAH) was excluded. Pathologically high aldosterone in plasma, plasma renin activity (PRA) and elevated levels of corticosteron metabolites, THAldo (128,3; range: 4,3-12,3), 18-OXO-THF and 18-OHP in urinary steroid profile confirmed PHA. Oral supplementation of high dose sodium was applied. Secretive diarrhea was diagnosed. Colonoscopy was typical for Crohn disease. Treatment with high dose glucocorticosteroids and 5-ASA was applied. Sodium supplementation was withdrawn.

2. A 1-month-age boy admitted to hospital with dehydration and failure to thrive. Laboratory findings revealed hyponatremia at 114 mmol/l, hyperkalemia at 9,48 mmol/l, metabolic acidosis (bicarbonate 15.0 mmol/l), elevated levels of urea and creatinine, positive urine culture. Urosepsis was diagnosed. Laboratory tests confirmed PHA. Oral supplementation of sodium was applied. Obstructive uropathy was diagnosed and urological therapy applied. Salt supplementation was discontinued after about 5 months. Both electrolytes and PRA, aldosterone levels remain within range.

**Conclusions:** PHA should be suspected in cases of severe hyponatremia, hyperkalemia and weight loss in infants. Secondary PHA is usually associated with urological problems, however in our presented patient PHA occurred in the course of secretive diarrhea.

### PAO-180
#### Invasive pituitary adenoma secreting growth hormone, TSH, prolactin and α-subunit in a 12-year-old girl
**Elzbieta Moszczynska; Agnieszka Lecka-Ambroziak; Mieczyslaw Szalecki**

**Background:** Prolactinoma is the most common secreting pituitary adenoma, growth hormone (GH) secreting adenomas are less common and thyrotropinoma only constituting 1% of all pituitary adenomas.

**Objective:** 12-year-old girl first presented with headaches and worsening of vision of a left eye that lasted for 4 months. Clinical symptoms included: overgrowth, signs of acromegaly, hyperthyroidism and galactorrhea. Optima
tological examination revealed signs of raised intracranial pressure. Hormonal tests showed: high GH levels with lack of inhibition in an oral glucose tolerance test, high IGF-1, both free thyroid hormones and TSH levels were high with no reaction after TRH administration and very high concentration of prolactin (PRL) and α-subunit. Head MRI revealed a sellar invasive tumour, size 80x55x50 mm, penetrat
ing to interior jugular arteries and optic nerves. A stereotactic biopsy was performed, with tumour hemorrhage complication. Histopathological and immunohistochemical examinations confirmed the diagnosis of invasive pi-
sequently developed hyperkalemia. She was born at 33rd gestational week, 6 month female patient was hospitalized for vomiting and lose in

Introduction:
Lipoid congenital adrenal hyperplasia is an autosomal reces-

Objective:
We present a patient with coincidence of germinoma and lympho-

PAO-181
Coincidence of germioma and lymphocytic
hypophysitis in a 12 year-old-boy with diabetes
insipidus and growth hormone deficiency

Ewa Bicka-Moszczyńska; Agnieszka Lecka-Ambrozia;
Mieczysław Szalecki
The Children’s Memorial Health Institute, Department of Endocrinology and Diabetology, Warsaw, Poland

Background: Intracranial germinoma is a rare malignant tumor, only consti-
tuting 3–5% of paediatric intracranial tumor. It usually occurs in children and young adults and it’s highly sensitive to radiotherapy and/or chemotherapy. Lymphocytic hypophysitis is an uncommon autoimmune disease in which the pituitary function is usually impaired due to it’s infiltration by lymphocytes, plasma cells and macrophages. There are just a few cases of coincidence of this two pathologies described in the literature.

Objective: We present a patient with coincidence of germinoma and lympho-
cytic hypophysitis. 9-year-old boy presented polydypsia, poliuria and head-
aches that lasted for 2 years. Neurological and ophthalmological examinations were normal. Wasospesin test confirmed central diabetes insipidus, DDAVP treatment was introduced. TSH, free thyroid hormones, ACTH, cortisol and IGF-1 levels were normal. Tumour markers, α-fetoprotein and HCG, both in serum and cerebral fluid were negative. Antithyroid and antidiareal autoanti-

~
~

PAO-182
StAR (= steriodogenic acute regulatory protein)
deficiency: case report

Ayla Guven1; Heyes Kirmizibekmez2; Ayse Nurcan Cebeci1; Berin Guculer1; Meltem Caglar2; Hamit Okur3
1Goztepe Educational and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey; 2Goztepe Educational and Research Hospital, Pathology, Istanbul, Turkey; 3Goztepe Educational and Research Hospital, Pediatric Surgery, Istanbul, Turkey

Introduction: Lipoid congenital adrenal hyperplasia is an autosomal recessive disease due to deficiency of StAR protein that transports cholesterol into the mitochondria for adrenal steroid synthesis. StAR is also essential for gonadal steroidogenesis and is encoded by a gene on chromosome 8p11.2.

Case: 6 month female patient was hospitalized for vomiting and lose in weight started at 4th month. She had severe hyponatraemia (Na: 108 mmol/L) and dehydration. She has been referred for persistent hyponatraemia and subsequently developed hyperkalemia. She was born at 33rd gestational week, birth weight was 1750 gr. Parents were second degree related, infant death or sexual development disorder was not described in family history. Physical inspections revealed paleness, vital findings were normal. Dehydration or hypopigmentation was not present. Height: 58 cm (10-25p), weight: 4 kg (< 3p), external genitalia seemed normal female and systemic examination findings were normal. Na: 130 mEq/L, K: 6.4 mEq/L, Glucose: 82 mg/dl, baseline ACTH was high, DHEA-S was normal. In classical ACTH stimulation test, mineralocorticoid, glucocorticoid and androgen precursors had not been increased. Significant hyperplasia of both adrenal glands observed in magnetic resonance imaging. Carotid type was 46 XY, t(4;9)(p16.6;p13.3) and a paternal translocation was determined.

Laparoscopic investigation showed intra-abdominal located testes, any Mullerian structure was not found. There was no increase in testosterone after three days of stimulation with hCG 1500 U/dose and gonadectomy was performed. She is still receiving hydrocortisone (14mg/m2/day) and fludrocorti-
sone (0.1 mg/day) treatments.

Result: StAR protein deficiency is the most severe and rare form of steroid biosynthesis disorders. Mineralocorticoids, glucocorticoids and androgens can not be synthesized and ACTH level is high. Normal DHEA levels helps for differentiating from 3 beta-hydroxysteroid dehydrogenase deficiency. Carotid type analysis and advanced investigations if needed should be performed.

Background: Cushing disease is the most common cause of hypercortisola-

Objective: The patient first presented at the age of 4,5 years with a rapid weight gain, growth arrest and symptoms of premature adrenarche. Clinical examination revealed central obesity, hirsutism, plethora, hypertension, psychological disturbances, puberty stage: A2, P2, testes 3 ml. Laboratory findings showed hypercortisolaemia (54.3 μg/dl in the morning, 39.2 μg/dl at midnight), hyperandrogenaemia, high level of ACTH (162, 375 pg/ml). CRH stimulation and Dexametasone suppression tests were performed, confirm-

~

PAO-183
A rare cases of early onset of Cushing disease

Agnieszka Lecka-Ambrozia; Elzbieta Moszczyńska;
Mieczysław Szalecki
The Children’s Memorial Health Institute, Department of Endocrinology and Diabetology, Warsaw, Poland

Background: Cushing disease is the most common cause of hypercortisolaemia in adults and children over 7 years of age, whereas in children under 7 years adrenal tumours predominate. We present a case of Cushing disease in a 5-year-old boy.

Objective: The patient first presented at the age of 4,5 years with a rapid weight gain, growth arrest and symptoms of premature adrenarche. Clinical examination revealed central obesity, hirsutism, plethora, hypertension, psychological disturbances, puberty stage: A2, P2, testes 3 ml. Laboratory findings showed hypercortisolaemia (54.3 μg/dl in the morning, 39.2 μg/dl at midnight), hyperandrogenaemia, high level of ACTH (162, 375 pg/ml). CRH stimulation and Dexametasone suppression tests were performed, confirm-

~

Conclusions:
The diagnosis of central diabetes insipidus with thickened pituitary stalk size 4x6 mm, absent of a posterior pituitary lobe and 5 mm pineal cyst. During 2,5-year observation growth velocity showed normal pituitary gland. Due to excessive clinical symptoms of hy
PAO-184

Different skeletal maturation patterns in patients with constitutional delay of growth (CDG) and growth hormone deficiency (GHD)
Sandra Barth; Stefan A. Wudy
Justus Liebig University, Division of Paediatric Endocrinology and Diabetology, Center of Child and Adolescent Medicine, Giessen, Germany

Background: The determination of bone age is one of the most important criteria to diagnose and work clinically with short stature.

Objective and hypotheses: The study aimed to identify disparities in the level of phalangeal bone (PH), metacarpal bone (MC), carpal bone (CP), and radius/ulna (RU) - development in patients with CDG or GHD.

Methods: Left hand radiographs of patients with CDG (bone age retardation > 1 yr; no organic diseases; family history of delayed growth and puberty) were compared with those of untreated GHD patients (maximum stimulated GH peak <3µg/l). In each patient PH, MC, RU, and CP bone age were calculated by the method of Greulich/Pyle.

Results: In the CDG cohort (13 males, 2 females, mean age 10.2 yr) bone age was retarded on average by 2.0 yr. Differences in the developmental stages of PH, MC, CP, and RU bone were identified as shown in table 1. Likewise, the GHD group (13 males, 2 females, mean age 5.71 yr) showed delayed bone maturation as revealed in table 1. GHD patients primarily carpal bone development was delayed, whereas in CDG patients the maturity of metacarpal bones was primarily delayed.

Conclusions: The pattern of bone maturation as assessed by left hand radiographs is different between patients with CDG and GHD. We suggest that the extreme delay in carpal bone maturation could be used as a marker for GHD in the assessment of short stature.

<table>
<thead>
<tr>
<th>Chronicological</th>
<th>PH Mean</th>
<th>MC Mean</th>
<th>CP Mean</th>
<th>RU Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>age Mean in yr</td>
<td>PH Mean in yr (delay in %)</td>
<td>MC Mean in yr (delay in %)</td>
<td>CP Mean in yr (delay in %)</td>
<td>RU Mean in yr (delay in %)</td>
</tr>
<tr>
<td>Patients with CDG</td>
<td>10.2</td>
<td>8.1 (21%)</td>
<td>7.4 (27%)</td>
<td>8.2 (20%)</td>
</tr>
<tr>
<td>Patients with GHD</td>
<td>5.7</td>
<td>4.8 (16%)</td>
<td>4.4 (23%)</td>
<td>3.5 (39%)</td>
</tr>
</tbody>
</table>

PAO-185

Abstract withdrawn.

PAO-186

Transsexualism in an African setting; case report
Olumide Jarrett1; Olayomi Esani1; Omolola Ayoola1
1University College Hospital, Paediatrics, Ibadan, Nigeria; 2University College Hospital, Psychiatry, Ibadan, Nigeria; 3Royal Manchester Children’s Hospital, Endocrine Science Research Group, Manchester, United Kingdom

Background: Transsexualism is the condition in which a person with apparently normal somatic sexual differentiation of one gender is convinced that he or she is actually a member of the opposite gender. It is associated with an irresistible urge to be and live in that gender hormonally, anatomically and psychosocially. The patient has persistent discomfort with his or her sex and a sense of inappropriateness in the gender role of that sex. It occurs in all societies and cultures however it is a rare occurrence in Africa.

Objective: We describe a case of Male-to-Female Transsexual who presented at the paediatric endocrine clinic of the University College Hospital.

Case report: EA is a 27 year old male who presented with the desire for sex reassignment surgery. He has already stated wearing female clothes, cosmetics and jewellery. He also changed his name to a female one and moved to another town. Physical examination revealed an individual with Tanner stage I for breast and a well developed normal male external genitalia with a solitary right testis. Hormonal profile revealed normal testosterone (31.2nmol/l, normal values 15 – 40nmol/l) and low estradiol levels (0.4nmol/l). He is awaiting laparoscopy and other investigations which have largely been delayed as a result of lack of funds to pay for them. He is being co-managed with the Psychiatry and Surgical teams.

Conclusions: Transsexualism is a rare condition and it is often marginalized even in developed economy. This report exposes the socio-cultural and religious influences associated with management. The dilemma it causes to the immediate family and relatives which has not been highlighted in previous reports is also described. The financial implication of management in this part of the world could also be frustrating to the individual. To our knowledge, this is the first case reported in Nigeria.

PAO-187

An unusual presentation in an adolescent with parathyroid adenoma: tendinitis
Selim Kurtoglu1; Leyla Akin1; Salih Ozgöcmert1; Mustafa Kendirci1; Nilfan Solmaz2; Sena Oncu3
1Erciyes University Faculty of Medicine, Pediatric Endocrinology, Kayseri, Turkey; 2Erciyes University Faculty of Medicine, Physical Therapy and Rehabilitation, Kayseri, Turkey; 3Erciyes University Faculty of Medicine, Pediatrics, Kayseri, Turkey

Background: Primary hyperparathyroidism (PHPT) in children and adolescents is a rare condition. PHPT is usually sporadic and caused by parathyroid adenomas. Patients may present with bone pain, proximal myopathy, bony deformities, fractures, renal calculi, neck swelling or acute pancreatitis.

Case: We describe an unusual presentation for PHPT in a 15-year-old male patient. He presented with difficulty in walking due to swelling of the ankles bilaterally. Ultrasonography revealed intratendinous calcific nodules in both Achilles tendons. Serum biochemistry showed hypercalcaemia and hypophosphatemia. Serum parathormone level was found high (512 pg/ml N:4.5-36). Parathyroid scanning suggested parathyroid adenoma. Parathyroidectomy was performed and the diagnosis of parathyroid adenoma was confirmed histopathologically. The family history was negative for multiple endocrine neoplasm syndrome. The intervention was followed by normalization of phosphocalcic profile and improvement of signs and symptoms of the patient.

Conclusion: We suggest that hyperparathyroidism should be kept in mind in the differential diagnosis of tendopathies.

PAO-188

Trend in body height distribution and short stature prevalence among children and adolescents aged from 6 to 18 years in two districts of Shanghai
Mingyin Zhang1; Feihong Luo1; Shuxian Shen1; Hong Xia1; Yuezhen Tu1; Fengxia Guo1; Tingting Huang1; Dingji Zhu1; Zhuhui Zhao1; Rong Ye2; Ruoqiang Cheng1; Xiaojing Li3
1Children's Hospital, Fudan University, Department of Endocrinology and Metabolism, Shanghai, China; 2Public Health Bureau, Minhang District, Shanghai, China; 3Center for Disease Control and Prevention, Minhang District, Shanghai, China

Background: It is unclear how is the trend of height distribution and short stature prevalence change among children and adolescents in Shanghai.

Objective: The aim of this survey was to establish baseline data on the trend in body height distribution and short stature prevalence among children and adolescents in Shanghai.

Methods: We selected two districts in Shanghai in 2003, randomly, one in urban area and the other in suburb area. All students in the primary schools, junior and senior high schools of the two districts were screened in 2003 and 2008. The main variables we studied were the subjects’ height, age, sex. We analysed the body height distribution and the prevalence of short stature.

Results: (1) Body heights were significantly higher in boys than that in girls. (2) Compared with data in 2003, the mean height of 2008 was higher. (3) In the past 5 years, the overall increments were 0.09-4.03cm (Urban male), 0.57-2.55cm (Rural male), 0.42-3.76cm (Urban female) and 0.04-1.81cm (Rural female) for stature. (4) The prevalence of short stature was significantly higher in urban district than in suburb area (2003:X2=139.73, p<0.01; 2008:X2=241.82, p<0.01).
LEOPARD syndrome: clinical characteristics and molecular study
Claudia Heredia1; Lidia Castro-Feijoo1; Emilia Balboa1; Jesús Barreiro1; Paloma Cabanas2; Isabel Martinez2; Francisco Barros1; Manuel Pombo1
1Hospital de Santiago de Compostela, Universidad de Santiago de Compostela, Unidad de Endocrinología Pediatrica, Crecimiento y Adolescencia, Santiago de Compostela, Spain; 2Fundación Publica Galega de Medicina Xenomica, Ciberer, Medicina Molecular, Santiago de Compostela, Spain; 3Hospital de Santiago de Compostela, Cardiología Pediatrica, Santiago de Compostela, Spain

Background: LEOPARD syndrome (LS) is an autosomal dominant disorder and features overlap closely with those observed in Noonan syndrome (NS). PTPN11, BRAF and RAFI are genes known to be associated with LS. The characteristics are including lentigines and cardiac defects.

Methods: Three patients were diagnosed with LS and required the presence of lentigines at least one of the cardinal features outlined byVoron et al. We made a mutational analysis: Cyclic sequencing was performed after PCR amplification of all the encode regions and the exon/intron boundaries of PTPN11.

Results: There were two female (2.5years and 7.3years) and one male patient (13.4years). Phenotypically, the two girls are typical facies of NS; in all patients we found pterigium colli and ocular hypertelorism. Cardiac anomalies we observed low-set ears, high palatal arch and epicanthal folds; in two patients we found valvar aortic insufficiency. Phenotypically, the two girls are typical facies of NS; in all patients we found pterigium colli and ocular hypertelorism. Cardiac anomalies we observed low-set ears, high palatal arch and epicanthal folds; in two patients we found valvar aortic insufficiency. The most patients we found pterigium colli and ocular hypertelorism. Cardiac anomalies we observed low-set ears, high palatal arch and epicanthal folds; in two patients we found valvar aortic insufficiency. The most patients we found pterigium colli and ocular hypertelorism. Cardiac anomalies we observed low-set ears, high palatal arch and epicanthal folds; in two patients we found valvar aortic insufficiency. The most patients we found pterigium colli and ocular hypertelorism. Cardiac anomalies we observed low-set ears, high palatal arch and epicanthal folds; in two patients we found valvar aortic insufficiency.
Background: Generalised Arterial Calcification of Infancy (GACI) is a severe autosomal recessive disorder characterized by calcification and stenosis of large and medium sized arteries. Although many affected children die in early infancy approximately 34% children would be expected to survive beyond infancy. Inactivating mutations of the Ectonucleotide Pyrophosphatase/Phosphodiesterase -1 (ENPP-1) gene have been implicated in many cases of GACI and more recently, in causation of hypophosphataemic rickets. Case report: A female baby was born of on-consanguineous Caucasian parents, at 29 weeks of gestation with evidence of GACI on antenatal scans. She died within 24 hours of birth secondary of congestive cardiac failure. Her female sibling was born at 31 weeks of gestation and was diagnosed antenatally to have complex congenital heart disease including hypoplastic left ventricle, double outlet right ventricle, arterio-pulmonary window and idiopathic arterial calcification. A postnatal scan confirmed these findings. Due to very poor prognosis of this condition, after extensive discussion with parents and paediatric cardiologist it was decided not to actively treat her cardiac condition. Molecular analysis of the ENPP1 gene showed two novel nonsense mutations on Exon1 (c. DelGC 190/191, p. A64A fsX11) and Exon21 (c. 2230 ACG > TGG, p. Q744X). At two and half years of age she started showing evidence of phosphaturia and hypophosphataemia. Discussion: Within last 20 years, anecdotal GACI cases of survival beyond infancy with spontaneous regression of calcification have been reported. The factors which lead to survival beyond infancy are poorly understood but hypophosphataemia and treatment with bisphosphonates was associated with survival in a large retrospective study. The presence of a novel mutation in our case is unlikely to explain the association with complex CHD but this is the first reported case of such association. In our case, the long term outcome and survival could be affected by pulmonary hypertension, despite bisphosphonate treatment.

Conclusions: Since it is a rare disease, the number of patients is low, so that further investigations are needed with larger series and long-term follow-up.
Effectiveness of gonadotropin-releasing hormone analogue treatment in children with central precocious puberty with respect to bone age acceleration before the therapy

Irena Bobeff1; Diana Bobeff2; Joanna Smyczynska3; Barbara Pińiewska-Slarki4; Maciej Hilczer5; Andrzej Lewinski6
1Polish Mother’s Memorial Hospital - Research Institute, Department of Endocrinology and Metabolic Diseases, Lodz, Poland; 2Medical University of Lodz, Medical Faculty, Lodz, Poland; 3Medical University of Lodz, Department of Pediatric Endocrinology, Lodz, Poland

Background: Central precocious puberty (CPP) is defined as the onset of puberty in girls and boys before the age of 8 and 9 respectively. It has a higher incidence in girls. Bone age is almost always advanced. The treatment of choice is long term depot gonadotropin-releasing hormone analogue ( GnRHa). The goal of mentioned therapy is to inhibit pubertal development and improve the height prognosis.

Objective and hypotheses: The aim of this research was to evaluate the influence of GnRHa therapy in children with CPP on the height prognosis depending on pretreatment bone age.

Methods: The group of 62 patients with diagnosed CPP was enrolled in the study: 48 girls and 14 boys. Patients were treated with GnRHa analogues depot – triptorelin 3.75 mg. For all the patients, the following pre- and post treatment parameters have been calculated and expressed as SDS: height, predicted adult height (PAH), bone age/chronological age (BA/CA) and bone age/height age (BA/HA). Patients were divided in two groups. Group A comprised those children who began their treatment with BA advanced or slightly advanced in relation with CA and HA. Group B gathered those patients whose BA was definitely advanced with respect to CA and HA.

Results: Height prognosis improvement was observed in group B (in children whose BA before treatment was definitely advanced with respect to CA and HA). There was no height prognosis improvement noticed in the group A (which was characterized by consistent or only slightly elevated BA). The results are presented in the Table 1 for BA/CA and in the Table 2 for BA/HA.

Conclusions: The therapy with GnRHa proved to be effective in improving height prognosis only in children with advanced BA.
Two cases report of Turner syndrome associated with metabolic syndrome

Ying Zhang; Rui Min Chen; Xiang Quan Lin; Xiaohong Yang
Fuzhou Children’s Hospital of Fujian, Department of Endocrinology, Fuzhou, China

Background: Turner syndrome (TS) occurs in approximately one in 2500 female births and is characterized by short stature and sex hormone deficiency. However, it is becoming increasingly evident that patients with TS are also susceptible to a range disorders.

Method: We present two patients with metabolic syndrome (MS).

Results: Case 1, A 13.3ys female patient, karyotype was 45,X/46,XY, height 127.3cm (~4.95SD), weight 32.7kg, shield thorax, several pyramids on her face, no puberty signs. Elevation of hepatic enzymes (ALT 60 U/L), TG 5.89 mmol/L, CHOL 6.12 mmol/L, HDL:1.06 mmol/L, fasting blood glucose, insulin, HbA1C, GH peak of GH stimulating test, LH, FSH, TPO, Tg antibodies are presented in Table 1, T3, T4, TSH were normal, BA: 10y, Ultrasonography: small uterus and ovaries were not detected, fatty liver, MRI: pituitary gland dysplasia, partial empty sella turcica. She also suffered epilepsy since 6 months-old. Diagnosis: TS, MS, adipositas, diabetes mellitus (DM), hyperlipidemia, growth hormone deficiency (GHD), hashimoto thyroditis, epilepsy. Case 2, A 16.5ys female patient, karyotype was 45,XO, height 134cm (~4.76SD), weight 40.5kg, short neck, micrognathia, shield thorax, cubitus valgus, no puberty signs. Elevation of hepatic enzymes (ALT:170 U/L, AST:101 U/L), TG: 5.42 mmol/L, CHOL: 4.58 mmol/L, HDL: 1.14 mmol/L, fasting blood glucose, insulin, HbA1C, GH peak of GH stimulating test, LH, FSH, TPO and Tg antibodies are presented in Table 1. T3, T4, TSH were normal, BA: 14y, Ultrasound: small uterus and ovaries could not be detected, fatty Liver; Saddle area MRI showed normal. Diagnosis: TS, MS, adipositas, DM, hyperlipidemia, GHD.

Conclusions: It appears that β cell dysfunction or insufficiency response to glucose is intrinsic to TS and is at the core of the high DM risk, excess weight and an abnormal lipid profile, in particular excess triglyceride levels, worsened insulin sensitivity. So to detect and interfere with these disorders earlier are significant for TS patients.

First results from the screening for congenital adrenal hyperplasia in Bulgaria

Antonietta Kostova1; Iva Stoeva2; Radoslava Emilova2
University Pediatric Hospital, Screening and functional endocrine diagnosis, Sofia, Bulgaria

Background: Congenital adrenal hyperplasia (CAH) is difficult to diagnose and potentially life-threatening in the neonatal period.

Objective and hypotheses: The objective of the present study is to analyze the first results from the novel Bulgarian neonatal screening (NS) for CAH for the period April 2010 - March 2011.

Methods: The level of 17-OH-Progesterone (17-OHP) in dried blood spot was assessed in all Bulgarian newborns (n=74 133). Until the end of 2010 we used only the cut-off value of 30 nmol/l for full-term infants at age 3-5 days. We began to apply the ISNS referent values since the beginning of 2011.

Results: An increased levels of 17-OHP were found in 637 cases (recall rate 0.85%). On a second assessment the results were confirmed in 410 cases (recall rate 0.55%). Most of the babies were preterm. Only 52 of them (12.6 %) had birth weight ≥ 2500 g. and 47 (11.5 %) were born after the 36 week of gestation. The diagnosis classic CAH was confirmed in 7 children. Estimated prevalence for the country - 9.4:100 000. The treatment was started at average age 15.6 ± 8.3days). Three of the children with CAH were preterm (birth weight < 2500 g and gestational age < 36 gestational week).

Conclusions: The first data on CAH (classical forms) prevalence for the Bulgarian population obtained by NS do not differ significantly from the published data. The results show the importance of NS for the early diagnosis and initiation of treatment. Constant improvement of the existing screening logistic is possible during expansion of the screening programs.
POA-201

The medium and short-term effects of sinusoidal and vertical vibratory training on the musculoskeletal and endocrine system in healthy men

Musab Elmantaser1; Martin McMillan1; Sheila Khanna1; Karen Smith1; S. Faisal Ahmed1
1University of Glasgow, Department of Child Health, Royal Hospital for Sick Children, Glasgow, United Kingdom; 2Royal Infirmary, Clinical Biochemistry, Glasgow, United Kingdom

Introduction: The underlying mechanisms that explain the beneficial effect of whole body vibration (WBV) on bone health are unclear.

Aim: To compare the immediate and medium term effects of WBV using the Galileo platform (sinusoidal WBV) and the Juvent platform (v WBV) on muscle function, endocrine status and markers of bone turnover.

Material and method: 10 healthy men (6-2:4; randomized into two groups; the first group stood on the sWBV and the second group stood on vWBV 3times/week/2months. The measurements were performed at five timepoints(T) over 4 months. T0(1 month pre-WBV), T1(1st day of exercise), T2(1month WBV), T3(2month WBV) and T4(1month post-WBV). T1, T2 and T3 consisted of four sampling times 60mins before WBV and 5-30-60mins post WBV. Each participant had anthropometry, assessment of body composition by Tanita and assessment of muscle function by measurement of serum markers of bone turnover, glucose, IGF-1, cortisol.

Results: There were no significant changes in anthropometry, body composition or muscle function in the two groups at the end of the study period. The change in creatine kinase following exercise was similar in both groups. Both vibration platforms were associated with an immediate decrease(p=0.001) in cortisol following the exercise, but there was no difference in the decrement between the two devices. In the medium term, sWBV was associated with a reduction in median serum cortisol from 333 nmol/l(247,442) to 269 nmol/l (192,322)(p=0.04) whereas there were no significant changes in the vWBV group. Serum CTX, a marker of bone resorption fell significantly after 2months in the sWBV group from a median of 0.42ng/ml(0.3,0.87) to 0.29ng/ml(0.2,0.4)(p=0.03).

Conclusion: WBV is associated with a fall in endogenous cortisol and a reduction in bone resorption particularly in those subjects who were exposed to sinusoidal vibration. Longer-term comparative studies are required to further investigate the effect on bone.

POA-202

An interesting case of delayed puberty associated with neurofibromatosis type 1 and hamartoma

Fiorella Gulluzzo; Perla Scalini; Maria Luisa Vetran; Cristina Manoni; Salvatore Seminara
University of Florence, Department of Sciences for Woman and Child's Health, Florence, Italy

Background: Neurofibromatosis type 1 (NF1) is one of the most common neurogenetic disorder. Complications are quite variable however the most frequent are optic pathway tumors (glioma), short stature and precocious puberty.

Objective and hypotheses: We report the case of a 14 yr old boy that occurred, with delayed puberty.

Method: Clinical and laboratory investigations.

Results: Clinical history revealed a previous neurosurgical treatment for a ventricular hydrocephalus caused by a midbrain hamartoma, at the age of 12 yrs. The family history was negative. Upon examination, patient’s weight was 47.6 kg (~25th centile), height was 154.7 cm (~25th centile) significantly below his genetic target (186 ± 7 cm) and he exhibited a decrease in growth rate. Tanning stage was G1 PH1, testis 2-3 mL. Blood glucose levels were elevated more than 30 mg/dl with IV glucose. He was diagnosed as CHI. Diazoxide, somatostatin were started and later nifedipine were increased to maximum doses 15 mg/kg/min. During hypoglycemia (glucose: 5 mg/dL) blood ketone was negative, ammonia level was normal, insulin:400 ul/mL, c-peptide:2.65 ng/mL. Blood glucose levels were elevated more than 30 mg/dl with IV glucose. He was diagnosed as CHI. Diazoxide, somatostatin were started and later nifedipine and uncooked corn starch were added to the therapy. The doses of the diazoxide, somatostatin and nifedipine were increased to maximum doses according to levels of blood glucose. Glucose infusion stopped after total enteral nutrition was tolerated. During follow up, in generally his blood glucose levels were within normal limits. Although hypoglycemia was seldom detected, his neurological status never improved. The patient was found homozygous for a novel mutation (Q392H) in ABBC8 gene. His parents were heterozygous for this mutation. The patient died due to respiratory failure at 4 months of life.

Conclusions: In CHI patients, genotype-phenotype correlations are unclear. In our case hypoglycemia was detected at the second day of life and severe medical treatment was started in emergency. Although, severe hypoglycemia was seldom, his neurological status did not improve. We hypothesized that, cerebral damage of hyperinsulinemic hypoglycemia might start in utero period due to severely affected phenotype by the novel mutation.

POA-204

Hypercalciuria and renal function and in children affected by osteogenesis imperfecta

Francesco Dorigi1; Elena Monti1; Grazia Morandi1; Evelina Maimen1; Milena Brugnara1; Paolo Cavazar1; Rossella Gaudenti2; Antoniazzi Franco2
1Pediatric Clinic, Department of Life and Reproduction Sciences, Verona, Italy; 2Pediatric Clinic, Department of Life and Reproduction, Verona, Italy

Background: Osteogenesis Imperfecta (OI) is an heterogeneous group of inherited disorders of connective tissue characterized by bone fragility, reduced bone mass, laxity of ligaments, blue sclera and different levels of low stature. Hypercalciuria is a condition characterized by an increased urinary calcium without hypercalcemia. It is characterized by an urinary calcium excretion ~4mg/kg/die or urinary Ca/Cr ratio ~0.21. The relation between hypercalciuria and OI had been already analyzed in several studies.

Objective: The aim of this study is to observe the incidence of hypercalciuria and logical age therefore we excluded constitutional delay of growth and puberty. On suspicion of NF1 we also carried out: dermatological examination, which revealed signs compatible with NF1; ophthalmological exam, which showed one Lisch’s nodule in the anterior segment of right eye. MRI revealed a small midbrain hamartoma, normal morphology and amplitude of ventricles and pericerebral spaces, minimum herniation of the cerebellar tonsils and no areas of pathological impregnation.

Conclusions: This case is interesting for the association of hamartoma and NF1 with delayed puberty, when usually both diseases are associated with precocious puberty.
Myxedematous coma due to secondary hypothyroidism with panhypopituitarism

Leyla Telhan1; Nihal Hatipoglu2; Mehmet Boyraz2; Onder Kilicarslan1; Derya Girgin1
1Sisli Etfal Training and Research Hospital, Pediatric Intensive Care Unit, Istanbul, Turkey; 2Sisli Etfal Training and Research Hospital, Pediatric Endocrinology, Istanbul, Turkey

Introduction: Cranioopharyngiomas (CP) are rare brain tumors in children. The tumor itself or its subsequent surgical treatment causes the most common multiple hormone deficiency and replacement is frequently necessary. Myxedema coma (MC) is a rare, but often fatal endocrine emergency. The majority of cases occur in primary hypothyroidism but in central origin is extremely rare. We report the case of a patient with panhypopituitarism due to a craniopharyngioma surgery, who developed myxedema coma due to pituitary hypothyroidism.

Case: A 12-year-old girl with loss of consciousness was admitted to a nearby hospital. She was transferred to our hospital for further hormonal evaluation and treatment. Her medical history was learned that she took multiple hormone replacement for two years because of CP had been operated, but took no medicine for the last three weeks. On physical examination; she was unconscious, hypotensive, bradycardic and hypothermic. Oxygen saturation was 75% without administration of supplemental oxygen. She had pretibial, non-pitting edema. Peripheral blood tests detected decrease in hemoglobin, serum sodium, potassium, calcium levels. All of the pituitary hormone levels was demonstrated as decreased. A thyroid function test reported undetectable levels of both freeT4(<0.67ng/dL), freeT3(<0.67pg/ml), TSH(>00.002 IU/ml). Magnetic resonance imaging of the pituitary gland revealed an empty sella. We initiated replacement of electrolytes and erythrocyte then adrenocortical hormone replacement therapy, followed by oral administration of levothyroxine at an initial dose of 600 mcg. As a result, the patient’s awareness level gradually improved. Following this, dosages were reduced. Our final diagnosis for the patient was MC due to central hypothyroidism together with panhypopituitarism.

Conclusion: We suggested that panhypopituitarism together with stress could rapidly cause MC in children. The reason of this case presentation is that MC is a rare case of secondary hypothyroidism with panhypopituitarism.

Menstrual cycle in adolescence and its relationship with parameters of metabolic syndrome

Isabel Bouzas1; Claudia Braga1; Lenora Lead1; Maria Cristina Kuschnir1; Daniela Rodeiro1
1UERJ, NESA, Rio de Janeiro, Brazil; 2UERJ, Endocrinol, Rio de Janeiro, Brazil

Background: Clinical evaluation of adolescents should include an assessment of the menstrual cycle (MC), with emphasis on changes in the pattern of the cycle that can represent the first sign of a systemic and evolutive disease as the metabolic syndrome (MS), whose clinical manifestation can occur only in adulthood.

Objective and hypotheses: The valuation of changes in the pattern of CM may be the opportunity for early diagnosis and initiation of preventive and effective actions.Open objective: Evaluate the menstrual cycle in adolescence and its relationship with parameters of MS.

Methods: Observational, comparative and transversal-cut study with 59 female adolescents aged between 12 and 19 and presence of at least one of factors: Overweight/Obesity. All of adolescents underwent a clinical evaluation with anthropometric and laboratorial data, composed of Fasting Glucose, Total Cholesterol, HDL-Cholesterol, Triglycerides, Oral Glucose Tolerance Test (Glcose 120) and Fasting insulin and Insulin post OGTT (insulin 120), Follicle- Stimulating-Hormone (FSH), Luteinizing Hormone (LH), Total Testosterone (TT), Androstenedione. Two groups were created. G-1 adolescents with irregular cycles, and G-2 with regular cycles.

Results: 59 adolescents evaluated, 36 formed G-1, and 23 formed G-2. In statistical analysis it was observed :G-1 presented: Waist/Height (p=0,009), Waist (p=0,026), Fasting Insulin (p=0,009), Glucose 120 (p=0,002) , insulin 120 (p = 0,0001), HOMA-IR (p = 0,0008), Triglycerides (p = 0,013), MS (p=0,0001) and POS (p=0,0001) greater and QUICK (p=0,008), G/I (p=0,002) HDL (p = 0,001) lower than G-2.9 0% of G-1 presented irregularity since menstruation began.

Conclusions: We believe that greater knowledge about the correlation between changes in menstrual cycle in adolescents and variables related to metabolic risk in this age group is very useful for an early screening that will enable the prevention of MS and related diseases.
**PAO-208**

**An audit of the use of DDAVP for central DI at a single institution**

Esiete Ikazoboh; Valtia Tziaraer; Mehul Dattani  
UCL Institute of Child Health, Developmental Endocrinology Research  
Group, London, United Kingdom

**Background:** The use of DDAVP in childhood DI is currently non-evidence based.  
**Objective:** We audited the use of DDAVP in patients with central DI diagnosed between January 2000, and December 2010. 32 patients with a history of DI were identified; 4 were excluded: DDAVP had been discontinued in 3, and a diagnosis of central DI was uncertain in one.  
**Population and methods:** Diagnoses of the 28 (11 males) included patients were: Septo-optic dysplasia (SOD)-n=11; Crianiopharyngioma (CP)-n=7; Holoprosencephaly (HPE)-n=3; Langerhans Cells Histiocytosis (LCH)-n=3; Others-n=5.  
Medical records were retrospectively reviewed.  
**Results:** The median age at diagnosis was 1.38 years (range: 0 – 13.84; N=23), with a mean duration of follow up of 26 (0 – 130) months. 64% were ACTH deficient. The mean daily dose of DDAVP required (N=25) was 226.36 (9.46 – 1019.40) mcg/m². Patients with CP and LCH required higher doses (375.85mcg/m² {mean age=9.6years} and 341.04mcg/m² {7.41years} respectively) whilst patients with SOD and HPE required lower doses (141.24mcg/m² {mean age=5.1years}; 70.78mcg/m² {6.6years} respectively). All patients were on oral preparations except for one who received intranasal DDAVP. Eight patients were on a twice daily dose whilst 20 were on a thrice daily dose at last follow up; 12.5% of children under 7 years were on a thrice daily dose whilst the proportion was higher (55%) in children over seven. 17 patients had relevant tests performed in the last 6 months, and 8 in the last year; data were unavailable in three. Mean plasma Na+ concentration (N=26) was 138.4 (131 – 155) mmol/l. 20 patients had paired urine and plasma osmolalities checked in the last year. No adverse events related to DDAVP use were identified.  
**Conclusion:** Doses of DDAVP in our population vary according to age and underlying condition. In this high risk cohort, 89% of our patients had relevant tests over the past year and had no adverse events.

**PAO-210**

**Coagulation-factor deficiencies and abnormal bleeding in Noonan’s syndrome**

Gabriella Gamba1; Francesca Marabotto2; Laura Losa1; Gabriele Rutfi1; Luisa Strocchio1; Arianna Zoroli1; Mariangela Cisternino2  
1University of Pavia, Department of Internal Medicine - IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; 2University of Pavia, Department of Pediatrics - IRCCS Fondazione Policlinico San Matteo, Pavia, Italy

**Background:** Noonan syndrome (NS) is a congenital autosomal disorder, characterized by dysmorphic facies, congenital heart defects, short stature and other anomalies including coagulation abnormalities not fully studied so far.  
**Objective and hypotheses:** The aim of this study was to evaluate phenotypic features, gene mutations and coagulation parameters in a cohort of NS patients.  
**Method:** We studied 19 NS patients (10 M, 9 F), 12 probands and 7 first degree relatives, we found in 7/19 a mutation of PTPN11, in 8 of SOS1 and in 1 case of SOS1/Raf1, the remaining 3 cases were mutation-negative.  
**Results:** A positive history for abnormal bleeding was found in 9 patients (47%), a prolonged PTT in 5 cases (26%), coagulation factors deficiency in 9 patients (47%) and abnormal platelet aggregation in 8 cases (44%); the coagulation abnormalities were more frequent in patients with a history of abnormal bleeding and in 6 cases (60%) without clinical evidence of bleeding disorders. The coagulation abnormalities were reported both in patients with or without a mutation and were not correlated with a mutation of a specific gene. Important differences in haemostatic status were found between probands and their relatives: the former showed coagulation abnormalities in the majority of the cases while the latter showed a history of bleeding diathesis, but normal laboratory hematological findings. The coagulation abnormalities were more frequent in patients with heart defects; however, a history of bleeding diathesis was detected in patients without cardiopathy.  
**Conclusions:** A high frequency of coagulation abnormalities was found in NS. These abnormalities do not seem to be related with the patients’ genotype. The heart defects should not be the only cause of the haemostatic disorders. The bleeding disorders, as well as the other phenotypic NS features, tend to decrease with age. Our advice is to screen patients with NS for bleeding diathesis to avoid bleedings and post-operative complications.

**PAO-209**

**Effect of urtica dioica leaves distillate on blood glucose of patients with type 1 diabetes**

Maryam Razzaghy-Azar; Hossein Zaree Aghamashadi  
Tehran University of Medical Sciences, H. Aliashgar Hospital, Tehran, Islamic Republic of Iran

**Background:** Urtica dioica is an edible plant that is traditionally used for its different effects including lowering of blood glucose.  
**Objective and hypotheses:** The aim of this study was to determine the glucose lowering effect of urtica dioica in patients with type 1 diabetes mellitus (T1DM).  
**Methods:** This phase one study is registered as the number “IRCT2010 08174585N1” and has ethical approval. It was done on 24 patients with T1DM aged 12 ± 2 years and duration of diabetes was more than one year. They had no chronic complication of diabetes or concomitant disorder. Distillate of urtica dioica leaves was prepared in the laboratory. Patients were divided into 8 groups of 3 subjects and were studied in 6 days. In the first 3 days, they did not receive the solution but in the second 3 days, they drank urtica distillate in the morning once daily while they were on usual insulin therapy. The carbohydrate counting of their foods were equal on these two periods. Their blood glucose was monitored by continuous glucose monitoring system (Medtronic USA) every 5 minutes in these 6 days. Total daily blood glucose and insulin compared by paired T test on these two periods (SPSS 12). The first group received 30 ml/M2 of the solution and the other groups received 15 ml/M2 more than the previous one up to 150 ml/M2.  
**Results:** Mean blood glucose in the second period and on day 6 were 201 ± 48.6 mg/dl and 194.75 ± 55 respectively that were significantly lower than first period (218 ± 50) (P=0.017, and 0.014 respectively). The total dose of insulin did not change during these periods.  
**Conclusions:** Urtica dioica leaves have a substance with blood glucose lowering effect in T1DM.

**PAO-211**

**Puberty as precipitating factor of type 2 diabetes. Prospective 5 years clinical and biological study**

Corina Paul; Puli Iulian Veilea; Ionela Tamasan; Oana Alexandra Veilea  
1University of Medicine and Pharmacy V.Babes, Clinic II Pediatrics, Timisoara, Romania; 2University of Medicine and Pharmacy V.Babes, Department of Parodontology, Timisoara, Romania

**Aim:** The relation between puberty and the onset of type 2 diabetes in obese children.

**Material and method:** Within 2006-2010, we studied 95 children with primary obesity. We monitored: family history of DM, clinical signs of insulin resistance (obesity, acanthosis nigricans), biologically we assessed the OGTT, lipids metabolism, Hba1C, HOMA index every six months.  
**Results and discussions:** At diagnosis 38 cases presented mild obesity, 32 cases medium obesity while 25 cases were severely obese. Neither one presented clinical symptoms of diabetes. We found positive family history of type 1 and/or type 2 DM in 12 cases. At the first visit, fasting blood glucose was normal in all cases; 18 cases were diagnosed as having impaired glucose tolerance and 1 case type 2 DM (with severe insulin resistance HOMA >5). Hba1c level was normal. In all cases we recommended hypocaloric diet. After 3 years of follow up 4 more cases (2 F, 2 M) pubertal age, were diagnosed as type 2 DM. Anti GAD 65 and ICA were negative in the 5 children with type 2 DM. The metabolic desequilibrium was confirmed by the increased level of Hba1c in all 5 cases. 4 of these 5 children had positive family history for DM (3- type 2 and 1- type 1 DM). In 4 cases we initiated therapy with Metformin 2 x 500 mg/ day. After 3 months of therapy Hba1c levels decreased significantly. In the 5th case, with severe insulin resistance Hba1c normalized with diet. At the time of diagnosis 3 of 5 cases with type 2 DM had normal weight (for age, height and sex), puberty being considered the precipitating factor for
the onset of diabetes.

Conclusions: Not only obesity, as a factor of insulin resistance, favours the occurrence of type 2 DM but also puberty precipitates its onset.

PAO-212
Ovarian function in cystic fibrosis patients
Dania Sánchez-Garvín; Raquel Corripio-Collado; Jacobo Pérez-Sánchez; Ramon Nosás Cuervo
Hospital de Sabadell, Corporación Universitaria Parc Tauli, Paediatrics, Sabadell, Spain

Background: A lower reproductive capacity in women with cystic fibrosis (CF) has been associated with delayed puberty and amenorrhea.

Objective and hypotheses: To evaluate ovarian function in women with CF, regarding their clinical and nutritional status.

Methods: Cross-sectional study in women (3 years post-menarche) with CF controlled in our hospital. Data of menarche and menstrual cycles were collected by telephone survey. Anthropometric and spirometric data were obtained by medical history review. Blood samples were taken 3-5 days post-menstruation and after 21 days. The biochemical and hormonal parameters measured were glucose, insulin, HOMA, HbA1c, follicular estradiol (E), FSH, LH, luteal progesterone (P), total testosterone (T), androstenedione (A4), DHEA-S, SHBG, and free androgen index (FAI). Results are expressed by mean values and ranges.

Results: We studied 8 patients aged 22.1 years (15-33). Their BMI was 20.5 (18.3-23.6) and their body fat percentage was 26.4% (20.4%-33%). Mean age at menarche was 13.2 years (11-15). They had menstrual cycles every 28.3 days (21-35), lasting 5.1 days (1-7). Oligo (amenorrhea was found in 2 cases (number 5 and 6). We detected an impaired lung function (FEV1 <80%) in 3 cases (number 3, 5 and 6). One case presented CF-related diabetes (number 6) and impaired fasting glucose in 3 cases (number 4, 6 and 7) with HOMA normal ranges.

Conclusions: None had delayed puberty. We detected normal ovarian function in women with CF, according to their clinical and nutritional status.

PAO-214
Evaluation of 1218 oral glucose tolerance tests in children and adolescents
Andreas Schuster; Jennifer Krueger; Judith Großé-Sudhues; Annette Richter-Urruhr
Endokrinologikum Ruhr, Pediatric Endocrinology, Bochum, Germany

Background: In our outpatient department we evaluated 1218 oral glucose tolerance tests (oGTT) for impaired glucose tolerance (IGT), impaired fasting glucose (IFG), insulin resistance syndrome (IRS) and Type 2 Diabetes (T2D).

Objective and hypotheses: The indication for oGTT was obesity (n=1052), small for gestational age (SGA) (n=36), SHOX- Gen deficien/ Ullrich Turner Syndrome (UTS) (n=55) and Prader Willi Syndrome (n=25) before or during growth hormone therapy, as well as IRS at follow up (n=39) and risk factors for disturbance of the glucose homeostasis (n=48).

Methods: All subjects underwent in our ambula two hour oGTT (1,75g glucose per kilogram bodyweight, maximum 75g). Following parameters were measured/collected: fasting-, 1- and 2 hour glucose and –insulin, HbA1c, height, weight, body mass index.

Results: The older the children the percentage of impaired fasting glucose and impaired glucose tolerance were rising up from about 12% -35%. We detected Type 2 Diabetes in children between eight to ten years in one percent, between 10-13 years in three cases and in group older than 13 years of age in 2,1 percent. All patients were obese. The percentage of insulin resistance defined as a fasting insulin greater than 15mU/L and/or a peak insulin greater than 150mU/L (S. Ten, J.Clin. Endocrinol. Metab. 200489:2526-2539) was as higher as older the patient evaluated. The HOMA IR >2,5 climbed up from 28% in the younger prepubertal group to 80% in the older subjects. The highest risk factor to develop impaired glucose tolerance, insulin resistance and Type 2 Diabetes was obesity in pubertal children.

Conclusion: In obese children change in lifestyle has to begin before onset of puberty. Performance of OGTT is important to detected insulin resistance as major risk factor to develop Type 2 Diabetes. Insulin and glucose results of non obese children differ from obese children.
at the Centre for the prevention, treatment and rehabilitation of obesity in children in the period from 27/07/2008 to 03/10/2010. Hospitalisation lasted 21 days.

Results: After the multidisciplinary treatment, the average reduction in body mass (p<0.05) in all adolescents was 5.92 ± 2.71 kg. During the 21-day hospitalisation, the average BMI was reduced by -2.12 ± 0.31 in all examinees, and the BMI z-score was considerably lower (p<0.05) in all examinees -1.65 ± 0.23, the waist circumference was reduced by -7.85 ± 3.01. Hypertension was observed in 28% of adolescents. Two factors of metabolic syndrome were present in 27.6%, and metabolic syndrome was present in 18.3% of the examinees. The disorder in sugar transport was observed in 8.9% of the examinees.

Conclusions: The effects of the ‘Cigotica’ programme are very encouraging and they show that the multidisciplinary approach directed towards the reduction in energetic intake, education, change of lifestyle and habits related to nutrition and physical activity, leads to a considerable reduction in body mass, improvement in blood pressure laboratory analyses, aerobic capacities and self-confidence in obese adolescents.

PAO-216
Prevalence of cryptorchism, retractile testis and orchiopexy in children
Shakhhrizada Sultanova
Endocrinology, Paediatric-endocrinology, Tashkent, Uzbekistan

Background: Cryptorchism represents the most common congenital defect of the male urogenital system. It may be an important cause for male infertili ty. Very variable figures on the incidence of cryptorchism have been described in different type of studies.

Objective: The aim of the present study was establish the prevalence of the abnormality in Uzbekistan population living in the Tashkent city and Tashkent region.

Patients/methods: In total there were surveyed 3417 children and adolescents at the age from 3-14 years. The testis determination was carried out by palpation method.

Results: As a whole, the frequency of cryptorchism was 1.2% for boys between 3 years and 14 years. The frequency of pathology was 2.5% for those of between 3 and 6 years, retractile testis was 5.2%, there were no cases of orchidopexy 0.75% was at the age between 7-10 years; orchidopexy was 0.35% and retractile testis was 0.15%; the frequency of pure cryptorchidism drops more than 3.3 times and retractile testis does 7 times to the puberty age.

Conclusion: The prevalence of cryptorchism and the mean age of orchiope xy are high among schoolchildren aged 10-12. The prevalence of cryptorchism differs significantly from the prevalence reported fifteen years ago. Is it was show prevalence of cryptorchism, on Uzbek population correlates with those of foreign sources.

PAO-217
Cushing syndrome due to adrenocortical carcinoma in an infant
Emine Diliek1; Vesseli Oz2; Didem Bezen1; Mustafa Inan1; Fulya Ozyay1; Filiz Tunuculer1
1Trakya University School of Medicine, Pediatric Endocrinology, Edirne, Turkey; 2Trakya University School of Medicine, Department of Pediatric Surgery, Edirne, Turkey; *Trakya University School of Medicine, Department of Pathology, Edirne, Turkey

Background: Adrenocortical tumors are the most common cause of endogenous Cushing syndrome in infancy and early childhood. We present an infant with Cushing syndrome due to adrenocortical carcinoma.

Case: A 15 month-old female child was referred to the hospital with a history of progressively increasing weight gain, appetite, terminal hair growth on the back and limbs but arrested growth rate since 4 months. There was no history of oral intake and topical application of steroids. Physical examination revealed weight of 9 kg (25p), length of 69.5 cm (3-10p), blood pressure 80/40 mmHg, cushingoid features with moon face and facial plethora. Rest of the physical examination was unremarkable. She had no clinorhegomy. Serum assays confirmed hypercortisolemia with loss of diurnal variation for cortisol secretion (8 am: 27.05 µg/dl, 03 pm: 21.64 µg/dl, 11 pm: 22.63 µg/dl) and a concomitantly suppressed ACTH level<5 pg/mL. DHEA-S<15 µg/dl (5-57), androstenedione [0.9µg/ml (0.8-5)], total testosterone [<0.1ng/dl (0.1-1.3)] were normal. Abdominal ultrasound showed 30x40 mm intra-abdominal mass arising from the left adrenal gland. Magnetic resonance imaging also detected a solid mass sized 40x45 mm in the left adrenal gland. She was operated on left adrenalecтомy under perioperative glucocorticoid coverage. Histopathological examination confirmed adrenocortical carcinoma. She was discharged 20 days after surgery on hydrocortisone 4 mg/day. She is doing well on hydrocortisone and has not shown any sign of disease recurrence during follow up.

Conclusions: Although Cushing syndrome is rarely seen in infants, the pediatricians should take it into consideration in cases presenting with rapidly weight gain and decreasing growth rate in infancy.

PAO-218
Do children with growth hormone deficiency diagnosed on the strength of one growth hormone stimulation test grow better than patients diagnosed on the strength of two stimulation tests on GH replacement therapy?
Sumeela Nayak, Ali Ng; Swati Upadrashta; Urmil Das; Poonam Dharmaraj, Joanne Blair; Mohammed Didi Aldef Hey Childrens Hospital, Paediatric Endocrinology, Liverpool, United Kingdom

Background: A recent consensus statement recommends the use of two growth hormone (GH) stimulation tests for the diagnosis of GH Deficiency (IGHD) in childhood. Some clinicians have used a single GH stimulation test because of the high frequency of distress that such tests cause children and the lack of a strong evidence base to the recommendation, while others have followed the recommendation.

Objective: To compare the change in height (Ht) Standard deviation score during the first year of GH treatment in subjects diagnosed with Idiopathic Isolated GHD (IGHD) following one GH stimulation test (GHST) to those diagnosed following two GHSTs.

Methods: A retrospective case note review of all patients diagnosed with IIGHD recorded in the UK between 2003 and 2009. Patients were categorised in to those who had 1 test (Group1) and two tests (Group 2). Height at diagnosis, 3-8 months and 9-15 months after starting treatment with GH was identified. Ht SDS at baseline and change in Ht SDS (ΔHt SDS) at each time point during treatment was compared using the Mann Whitney U test.

Results: 19 patients were studied. Results are summarised in table 1. Data presented as median(range). Table 1. Ht SDS at diagnosis and ΔHt SDS for patients at the three time points during treatment with GH.

<table>
<thead>
<tr>
<th>Group 1 [n=12]</th>
<th>Group 2 [n=7]</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ht SDS at diagnosis</td>
<td>-2.7 (-0.9 to 4.5)</td>
<td>-2.5 (-1.9 to -3.5)</td>
</tr>
<tr>
<td>ΔHt SDS 3-8 months</td>
<td>0.2 (0.1 to 0.4)</td>
<td>0.5 (0.3 to 0.8)</td>
</tr>
<tr>
<td>ΔHt SDS 9-15 months</td>
<td>0.3 (-0.1 to 0.8)</td>
<td>0.3 (0.1 to 0.8)</td>
</tr>
</tbody>
</table>

Conclusions: Patients with IIGHD diagnosed on the strength of one and two GHST show no difference in the growth response in the first year when on optimal GH replacement therapy.

PAO-219
Prevalence of metabolic syndrome (IDF 2007 criteria) in obese children and adolescents
Didem Bezen1; Emine Diliek1; Filiz Tunuculer1; Necdet Su1
1Trakya University School of Medicine, Pediatric Endocrinology, Edirne, Turkey; *Trakya University School of Medicine, Biostatistics, Edirne, Turkey

Background: Metabolic syndrome (MS) frequency is increased in proportion to the increasing prevalence of obesity in children and adolescents.

Objective and hypotheses: This retrospective study was performed to de-
LDL-C levels were found to be similar between two groups.

level was significantly lower in MS group when compared to non-MS group.

factors; fasting blood glucose levels, insulin resistance, levels of total chole-

14 of them having impaired glucose tolerance (IGT). There was no silent type
in 17,6% of patients; 21 of them having impaired fasting glucose (IFG) and

demia 20%, low HDL-C 48,5%. Impaired glucose metabolism was identified

involved. Investigations to assess the reliability of these assumptions are in

possible causes of this failure are unclear: the genetic alteration, the poten-

- hormonal inhibition. To our knowledge, similar cases are not reported. The

in presence of a good compliance. At 2 years and 2 months the treatment

of the pubertal development (basal LH 4.3 mU/ml, testosterone 6.27 ng/ml),

development delay and seizures, so at the age of 2 years he started antiepileptic

is based on

Background: The treatment of central precocious puberty (CPP) is based on

Objective and hypotheses: Our aim is to describe the case of a children with

Population: The boy came to our attention at age 6 years. Neurological ex

Conclusions: In our patient the treatment with LHRH-a failed to induce hormonal inhibition. To our knowledge, similar cases are not reported. The possible causes of this failure are unclear: the genetic alteration, the poten-

tial alteration of pharmacokinetic of LHRH-a and the cerebropancreatitis may be involved. Investigations to assess the reliability of these assumptions are in progress.

Results: The treatment with LHRH-a did not permit an adequate inhibition

The overall prevalence of MS in our study was 38% with no inter-

difference. Mean age was 12,7±1,62 years. Eighty nine percent (n=176) of

level was significantly lower in MS group when compared to non-MS.

Conclusions: MS prevalence at diagnosis is high (38%) in obese children. When cardiovascular risk factors are considered, the increase in the MS fre-
gency gets more important for the future of children.

PAO-220

Central precocious puberty unresponsive to LHRH analogue treatment in a patient with chromosomal anomaly and cerebropancreatitis

Alessandra di Lascio1; Silvia Laura Carla Meroni1; Elena Grechi1; Gianni Russo1; Maria Pia Guarneri1; Stefano D’Amigo1; Giuseppe Chiumello1

1San Raffaele Scientific Institute, Department of Pediatrics, Milan, Italy;
2C. Besta Neurologic Scientific Institute, Department of Neurology, Milan, Italy

Background: The treatment of central precocious puberty (CPP) is based on LHRH analogue (LHRH-a) with a good hormonal inhibition.

Objective and hypotheses: Our aim is to describe the case of a children with chromosomal alteration, cerebropancreatitis and CPP, who does not respond to the treatment with LHRH-a.

Population: The children, born at 38 gestational weeks, showed hypospadias, microcephaly and some dysmorphic notes. He presented a neuropsychic de-

velopment delay and seizures, so at the age of 2 years he started antiepileptic treatment. The karyotype was 46XY, the array CGH showed [del(1)(q41)] and [del(7)(q36.1q36.3)]. At 6 months of age he developed pubic hair and then increase in testicular (5 ml) and penile size. The hormonal investigations (1 months 7 months) showed the activation of hypothalamic-pituitary-gonadal axis (LH peak 18.3 mU/ml, testosterone 1.94 ng/ml), normal adrenal function and advancement of the bone age, suggestive for CPP. The NMR did not demon-

strate anomaly of the brain and the hypotalamic-pituitary region. He started treatment with LHRH-a.

Results: The treatment with LHRH-a did not permit an adequate inhibition of the hypothalamic-pituitary-gonadal axis and it also caused an advancement of the pubertal development (basal LH 4.3 mU/ml, testosterone 6.27 ng/ml), in presence of a good compliance. At 2 years and 2 months the treatment with LHRH-a was stopped and the treatment with letrozole and cyproterone acetate was started.

Conclusions: In our patient the treatment with LHRH-a failed to induce hormonal inhibition. To our knowledge, similar cases are not reported. The possible causes of this failure are unclear: the genetic alteration, the poten-
tial alteration of pharmacokinetic of LHRH-a and the cerebropancreatitis may be involved. Investigations to assess the reliability of these assumptions are in progress.

PAO-222

A rare cause of precocious puberty: β-hCG secreting tumor

Silvia Laura Carla Meroni1; Alessandra di Lascio1; Matilde Ferrario1; Gianni Russo1; Maura Massimino1; Giuseppe Chiumello1

1San Raffaele Scientific Institute, Department of Pediatrics, Milan, Italy;
2Sant’Anna Hospital, Department of Pediatrics, Como, Italy; 3National Scientific Tumor Institute, Department of Pediatrics, Milan, Italy

Background: Beta human chorionic gonadotropin (β-hCG) secreting tu-
mours are a recognized cause of precocious puberty (PP), almost exclusively in boys. These tumours may occur in gonads, liver, retroperitoneum and me-
diastinum or within the central nervous system (CNS).

Objective and hypotheses: We present one case of PP due to β-hCG secreting tumour, whose site was difficult to determine.

Population: The boy came to our attention at age 6 years. Neurological ex-

amination was normal. Physical examination showed scrotal hair, enlarged penile and testes (4 mL) size and gynecomastia. Hormonal test revealed suppressed levels of gonadotropins at LHRH test (FSH peak 0.6 mU/mL, LH peak 0.5 mU/mL), increased testosterone 3.47 ng/mL), normal adrenal function, prolactin and α-fetoprotein and slightly higher β-hCG (6.8 U/L; nv 0-5 U/L).

Results: Hormonal picture was compatible with gonadotropin-independent PP due to β-hCG secreting tumour. To determine its site testicular and abdom-

inal ultrasound, thoracic CT, abdominal and CNS NMR were performed. These studies didn’t reveal any suspicious lesion, with the exception of a cys-
tic-like aspect of pineal gland. A lumbar puncture was performed and revealed slightly higher β-hCG (11.3 U/L). The abnormal cerebrospinal fluid (CSF)/serum ratio of β-hCG was consistent with a CNS germ cell tumour. Although the tumour was not clearly identified, he underwent four courses of multi-agent chemotherapy (bleomycin, etopos-

dis and cisplatin) and ventricular radiotherapy. β-hCG and testosterone values fell to within the normal range after the first course, indicating significant re-
gression of the tumour. Nowadays the clinical and hormonal picture is stable.

Conclusions: Congenital adrenal hyperplasia (CAH) is an autosomal rece-
sive condition with significant consequences if not correctly diagnosed and treated. We have reviewed the patients with CAH presenting in Northern Irl-

and 9 years old (10%); 4 years old (16%); 15 years old (10%); 5 years old (25%); 8 years old (7%); 2 years old (10%); 1 year old (5%).


e remain normal. Physical examination showed scrotal hair, enlarged penile and testes (4 mL) size and gynecomastia. Hormonal test revealed suppressed levels of gonadotropins at LHRH test (FSH peak 0.6 mU/mL, LH peak 0.5 mU/mL), increased testosterone 3.47 ng/mL), normal adrenal function, prolactin and α-fetoprotein and slightly higher β-hCG (6.8 U/L; nv 0-5 U/L).

Results: Hormonal picture was compatible with gonadotropin-independent PP due to β-hCG secreting tumour. To determine its site testicular and abdom-

inal ultrasound, thoracic CT, abdominal and CNS NMR were performed. These studies didn’t reveal any suspicious lesion, with the exception of a cys-
tic-like aspect of pineal gland. A lumbar puncture was performed and revealed slightly higher β-hCG (11.3 U/L). The abnormal cerebrospinal fluid (CSF)/serum ratio of β-hCG was consistent with a CNS germ cell tumour. Although the tumour was not clearly identified, he underwent four courses of multi-agent chemotherapy (bleomycin, etopos-

dis and cisplatin) and ventricular radiotherapy. β-hCG and testosterone values fell to within the normal range after the first course, indicating significant re-
gression of the tumour. Nowadays the clinical and hormonal picture is stable.
The aim of this case report is to show how is females and the lack of genital ambiguity in the males.

Methods: One month-old male infant was admitted to our hospital for further evaluation of a bleeding after vaccination. He was born vaginally at 38 gestational weeks to a 23 year-old primagravid mother, with a birth weight of 2550g. It was learned that his mother had Graves disease for 2 years and did not take propylthiourasil regularly during pregnancy. Physical examination revealed weight of 3100g (3p), height of 51 cm (3p), head circumference of 34 cm (<3p, -2,2SD), prominent eyes and 2x2cm hematoma at left inguinal region. The other physical findings were unremarkable. Laboratory studies revealed weight of 3100g (3p), height of 51 cm (3p), head circumference of 34 cm (<3p, -2,2SD), prominent eyes and 2x2cm hematoma at left inguinal region. The other physical findings were unremarkable. Laboratory studies showed normal hematological and coagulation parameters but mildly elevated transaminases (ALT 74IU/l, AST 55IU/l) and conjugated bilirubin (3.8 mg/dl). Blood and urine culture were negative as were titers for toxoplasmosis, rubella, CMV, herpes, hepatitis B and C. Metabolic screening tests were negative. Thyroid function tests revealed that the infant was suffering from NT (free T4 2.5 mg/dl (0.63-2.3), free T3 4.9 pg/ml (1.8-4.2), TSH 0.17 mIU/ml (0.4-8.6) and TSAb 54U/l (0-9)). We decided to follow up him without treatment, because he had only biochemical thyrotoxicosis but not clinical. After 2 months, his conjugated hyperbilirubinemia level resolved as well as transaminases (ALT 74IU/l, AST 55IU/l) and conjugated bilirubin (3.8 mg/dl levels). Blood and urine culture were negative as were titers for toxoplasmosis, rubella, CMV, herpes, hepatitis B and C. Metabolic screening tests were negative. Thyroid function tests revealed that the infant was suffering from NT (free T4 2.5 mg/dl (0.63-2.3), free T3 4.9 pg/ml (1.8-4.2), TSH 0.17 mIU/ml (0.4-8.6) and TSAb 54U/l (0-9)). We decided to follow up him without treatment, because he had only biochemical thyrotoxicosis but not clinical. After 2 months, his conjugated hyperbilirubinemia level resolved as well as thyroid hormone levels returned to the normal range.

Conclusions: We suggest that as infants born from mothers with Graves may develop different clinical signs, they should be followed up carefully and closely after birth.

Conjoined hyperbilirubinemia caused by neonatal thyrotoxicosis in an infant

Dagdem Bezen1; Filiz Tutunculer2; Emine Dilok1; Betul Orhaner2
1Trakya University School of Medicine, Pediatric Endocrinology, Edirne, Turkey; 2Trakya University School School of Medicine, Pediatric Endocrinolgy, Edirne, Turkey.

Background: Neonatal thyrotoxicosis (NT) caused by maternal Graves disease is a rare disorder. In the newborn, characteristic signs and symptoms include tachycardia, irritability, poor weight gain, and prominent eyes. Rarely, infants with NT present with thrombocytopenia, jaundice and hepatosplenomegaly. We report an infant with hemorrhagic diathesis and conjoined hyperbilirubinemia, who was diagnosed with NT due to maternal Graves disease.

Case: One month-old male infant was admitted to our hospital for further evaluation of a bleeding after vaccination. He was born vaginally at 38 gestational weeks to a 23 year-old primagravid mother, with a birth weight of 2550g. It was learned that his mother had Graves disease for 2 years and did not take propylthiourasil regularly during pregnancy. Physical examination revealed weight of 3100g (3p), height of 51 cm (3p), head circumference of 34 cm (<3p, -2,2SD), prominent eyes and 2x2cm hematoma at left inguinal region. The other physical findings were unremarkable. Laboratory studies showed normal hematological and coagulation parameters but mildly elevated transaminases (ALT 74IU/l, AST 55IU/l) and conjugated bilirubin (3.8 mg/dl). Blood and urine culture were negative as were titers for toxoplasmosis, rubella, CMV, herpes, hepatitis B and C. Metabolic screening tests were negative. Thyroid function tests revealed that the infant was suffering from NT (free T4 2.5 mg/dl (0.63-2.3), free T3 4.9 pg/ml (1.8-4.2), TSH 0.17 mIU/ml (0.4-8.6) and TSAb 54U/l (0-9)). We decided to follow up him without treatment, because he had only biochemical thyrotoxicosis but not clinical. After 2 months, his conjugated hyperbilirubinemia level resolved as well as thyroid hormone levels returned to the normal range.

Conclusions: We suggest that as infants born from mothers with Graves may develop different clinical signs, they should be followed up carefully and closely after birth.

Auxometric and biohormonal data of patients with Turner syndrome undergoing treatment with Somatropin

Camelia Procopie1; Cristiana Dumitrescu2; Juliana Ghierlan3; Nina Dumitriu2; Andra Carageaheorgheopol1; Florin Alexiu1
1“C.I. Parhon” Institute of Endocrinology, Pediatric Endocrinology, Bucharest, Romania; 2“M.S. Curie” Children’s Hospital, Pediatric Endocrinology, Bucharest, Romania; 3“C.I. Parhon” Institute of Endocrinology, Hormonology Laboratory, Bucharest, Romania; 4AORN A.

Background: 95% of Turner syndrome patients are known to have a final adult height 20 cm below the median parental height. It has been proven that these patients respond to rhGH treatment, despite the fact that they are not GH deficient.

Objective and hypotheses: Analysis of the effects of Somatropinum therapy on the growth of Turner Syndrome patients and identification of the parameters that influence growth.

Methods: We analyzed a group of 30 patients with Turner syndrome who were treated in our board between 2002 and 2010. We measured and calculated: height, median parental height, growth velocity under treatment, bone age, IGF-I, predicted adult height without treatment, predicted final height when study was carried out.

Results: Mean age was 8,4 yrs (4,5 - 14 yrs); mean initial height was -3,18 SD below normal and 0,12 SD when compared to other girls with Turner syndrome of the same age; the mean period of treatment was 3.26 yrs (-1,7 yrs) and the mean dosage was 0,327 mg/kg/week (0,27-0,42); growth velocity per year of treatment averaged at 7,02 cm and growth velocity per year of bone maturation at 5,94 cm. Predicted adult height (PAH) without treatment had an average of 142,6 cm, while the predicted final height, when the study was carried out had an average 150,7 cm. Thus, the mean benefit of the therapy is 8,1 cm.

Conclusions: We analyzed the significant correlations between the height benefit of the therapy and a series of auxometrical parameters. Even if we noted that IGF-I rose to considerably higher levels during the therapy, this phenomenon did not correlate significantly with the gain of centimeters per year of treatment or per year of bone maturation, which leads us to believe we may encounter a certain degree of resistance to the action of IGF-I in some patients. Under treatment the patients recovered an average of 1,98 SD from the growth retardation compared to normal adult females and an average of 1,95 SD from the genetic target height.

Does Letrozole in boys and GnRHa in girls with idiopathic short stature (ISS), constitutional precocious puberty (CPP), or being born small for gestational age (SGA) improve their prospective adult height?

Andreas Krebs; Nicola Menzel; Thomas Kratzin; Natascha van der Werf-Grohmann; Cordula Roemer-Pergher; Karl Otfried Schwab
University Hospital of Freiburg, Department of Pediatrics, Freiburg, Germany

Objective and hypothesis: To investigate the hypothesis that Letrozole in boys and GnRHa (leuprolide acetate) in girls are able to improve the prospective adult height (PAH).

Method: We retrospectively compared growth data of girls with CPP (n= 14, intervention. A suitable psychological support has been offered to her parents, both during the diagnosis process and the surgical intervention.

Conclusions: Virilization occur of external genitalia, in absence of appreciable gonads and with genital feminine insides, has allowed to set clinical diagnosis of CAH before hormonal biochemical confirmation. Therapy was promptly started, preventing hydro-electrolytical imbalances. Clinical, hormonal and instrumental parameters monitoring, along with psychological parents support allowed to early manage this case successfully and to create the premises for a goood future therapeutic alliance.
confirm the results. In some patients, the adult height was reached and was higher than calculated by median 8.9 cm. One boy with ISS, treated with letrozole and growth hormone, had an improvement of adult height by only 1.9 cm. However, one boy born SGA, showed an improvement of adult height by 15 cm according to Bayley-Pinneau. A transient decrease of bone density, as measured by the DEXA method, was observed. A patient questionnaire revealed no other relevant side effects due to the treatment with both letrozole and GnRHa. Fig 1+2 show the reached gain of height.

Conclusions: Both medications seem to be able to improve the PAH. However, a small number of patients failed to improve the prospective adult height. In some patients, the adult height was reached and was higher than calculated before. Therefore, the therapy should be continuously supervised by a pediatric endocrinologist. Prospective controlled trials are necessary in future to confirm the results.

Results: Girls with CPP (n=4), treated with GnRHa, showed an improvement of their near final height or adult height in median by 6.2 cm. In girls born SGA (n=2), treated with GnRHa and growth hormone, the final height improved by median 8.9 cm. One boy with ISS, treated with letrozole, had an improvement of adult height by only 1.9 cm. However, one boy born SGA, showed an improvement of adult height by 15 cm according to Bayley-Pinneau. A transient decrease of bone density, as measured by the DEXA method, was observed. A patient questionnaire revealed no other relevant side effects due to the treatment with both letrozole and GnRHa. Fig 1+2 show the reached gain of height.

Conclusions: Both medications seem to be able to improve the PAH. However, a small number of patients failed to improve the prospective adult height. In some patients, the adult height was reached and was higher than calculated before. Therefore, the therapy should be continuously supervised by a pediatric endocrinologist. Prospective controlled trials are necessary in future to confirm the results.

Results: Girls with CPP (n=4), treated with GnRHa, showed an improvement of their near final height or adult height in median by 6.2 cm. In girls born SGA (n=2), treated with GnRHa and growth hormone, the final height improved by median 8.9 cm. One boy with ISS, treated with letrozole, had an improvement of adult height by only 1.9 cm. However, one boy born SGA, showed an improvement of adult height by 15 cm according to Bayley-Pinneau. A transient decrease of bone density, as measured by the DEXA method, was observed. A patient questionnaire revealed no other relevant side effects due to the treatment with both letrozole and GnRHa. Fig 1+2 show the reached gain of height.

Conclusions: Both medications seem to be able to improve the PAH. However, a small number of patients failed to improve the prospective adult height. In some patients, the adult height was reached and was higher than calculated before. Therefore, the therapy should be continuously supervised by a pediatric endocrinologist. Prospective controlled trials are necessary in future to confirm the results.

Results: Girls with CPP (n=4), treated with GnRHa, showed an improvement of their near final height or adult height in median by 6.2 cm. In girls born SGA (n=2), treated with GnRHa and growth hormone, the final height improved by median 8.9 cm. One boy with ISS, treated with letrozole, had an improvement of adult height by only 1.9 cm. However, one boy born SGA, showed an improvement of adult height by 15 cm according to Bayley-Pinneau. A transient decrease of bone density, as measured by the DEXA method, was observed. A patient questionnaire revealed no other relevant side effects due to the treatment with both letrozole and GnRHa. Fig 1+2 show the reached gain of height.

Conclusions: Both medications seem to be able to improve the PAH. However, a small number of patients failed to improve the prospective adult height. In some patients, the adult height was reached and was higher than calculated before. Therefore, the therapy should be continuously supervised by a pediatric endocrinologist. Prospective controlled trials are necessary in future to confirm the results.
The relation between skinfold thickness and leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers

Mustafa Kara1; Zerrin Ortak2; Hakan Doneray3; Behzat Ozkan4; Fatih Akcay3
1Ataturk University, Department of Pediatrics, Erzurum, Turkey; 2Ataturk University, Department of Biochemistry, Erzurum, Turkey

We aimed to investigate the relation between skinfold thickness and serum leptin, ghrelin, adiponectin and resistin levels in infants of diabetic mothers. The mother two were diagnosed as having gestational diabetes by an Oral Glucose Tolerance Test (OGTT) performed between 24-28 gestational weeks, and their babies were included into this study. Mean HbA1C level between diabetic and control mothers were not significantly different. Mean Body Mass Index (BMI), abdominal circumference, upper extremity circumference, and biceps skinfold thickness was not significantly different between infants of diabetic mother and control infants. However, mean subscapular ad triceps skinfold thickness was significantly lower in infants of diabetic mother. Mean leptin, ghrelin, adiponectin and resistin levels were also not significantly different between infants and diabetic mother and control infants. Our results indicates that early diagnosis of gestational diabetes and control by appropriate diet or insulin treatment may be effective in protection of fetuses of diabetic mother from the negative effects of gestational diabetes.

Background: Type 1 diabetes mellitus (T1DM) is the most common endocrine problem in childhood, with increasing worldwide incidence. The risk of developing diabetic ketoacidosis (DKA) is higher in children because of non-specific and non-classical signs and symptoms.
PAO-232
Correlation of childhood obesity with obesity at late adolescence and young adulthood

Aim: The aim of this study is to answer the question whether an obese child becomes an obese adolescent and/or obese young adult.

Methods: It’s a follow-up study of obese children followed in our department for the time period 1997-2006. We contacted 234 (109 M) of them during the last trimester of 2010, and they were asked to answer a semi-structured questionnaire. The questionnaire included questions regarding sociodemographic data of the family, current height and body weight of the index case, factors that in their opinion affect weight control. At present 141 cases were contacted, from them 43 were not available because of address change, 3 refused to participate and 22 were excluded because of young age (< 16 yrs old). The response rate is 96.6%. To analyze the data we used descriptive statistics.

Results: The two sexes were equally represented in both the childhood sample (46.5% M and 53.4% F) and the follow-up sample (46.7% M, 53.3% F). Of this cohort of obese children, at follow-up, 24.7% were obese, 32.6% were overweight and 42.7% were of normal weight. M than half, 52.8% were overweight and obese at follow-up. Examining the sexes separately, 7.9% of the men were obese and 22.5% were overweight whereas 16.9% of men were obese and 10.1% were overweight.

Conclusions: These data, based on this particular sample of obese children, that they were investigated and received dietary counseling in a tertiary center, suggest that more than half of this cohort have body mass index higher than normal, at young adulthood. Furthermore we conclude that obesity is more prevalent in men, whereas overweight is more prevalent in women. The limitations of the present study is the relative small sample size (the study is ongoing) and the absence of control group in order to assess whether early intervention has a positive effect on long term weight control.

PAO-234
Pseudohypoparathyroidism: monogenic obesity and tall stature

Background and aim: Obesity is a common feature in patients with type 1a pseudohypoparathyroidism (PHP) and affected patients typically also have short stature. We describe a infant with PHP who developed morbid obesity with tall stature in early infancy.

Methods: 6 months female infant with history of abnormal weight gain and increased appetite was referred for endocrinological evaluation. She was born 38 week gestation with birth weight 4500 gram and rapid weight gain at 1 month. She was only breastfed from birth. Frequently nursed due to crying 3kg/last 1 month. Prenatal history unremarkable. No vitamin D taken by mother during pregnancy or child after birth. On physical examination at 6 months of age length was 70cm (1.4SD) weight was 13 kg (4.8SD) and head circumference was 48>(SD). She had no dysmorphic feature but she had a hard subcutaneous nodule in her lumbar area and umbilical hernia. Laboratory investigation showed the following values: serum calcium: 6.8 mg/dL (8.6-10mg/dL.), phosphorus: 7.6mg/dL (4.2-7mg/dL.), magnesium: 3.7 mg/dL (1.6-2.6mg/dL.), alkaline phosphatase: 333 U/L (145-420U/L), parathyroid hormone:400 pg/ml (9.6pg/ml), albumin: 3.7 mg/dl (4.5mg/dl), 25(OH)D: 55 nmol/l (15-80nmol/l), thyrotropin: 6.87 mU/ml (0.5-5.2mU/ml), free thyroxin: 0.69 ng/dl (0.8-1.8ng/dl), cortisool: 2.65 ug/dl (4.2-7ug/dl), cortisol: 12.9 pg/mL (10-60), leptin: 23 ng/mL. Excessive weight gain, mild hypothyroidism and increased parathyroid hormone and decreased serum calcium suggested a diagnosis of Pseudohypoparathyroidism type 1a.

Conclusion: Hypothalamic G-protein coupled melanocortin receptor may mediate the central effects of leptin. GNAS mutation result in underactivity of MCR4 It explains the obese, hyperphagic and tall stature phenotype and suggest that the genetic mutations which underlie PHP may be a more common cause of severe obesity.

PAO-235
Clinical evaluation of short children referred by school screening: an analysis of 2589 children according to the WHO norms of 2007

Background: An isolated delay in growth can reveal a treatable pathology. A school inquiry was launched. A prospective study was made during the school year 2008/2009 in the north of Tunisia.

Objective and hypotheses: To determine the prevalence of stunting growth and the etiologies.

Methods: All school children 5 to 8 years old: 2589 children have benefitted from a school screening. Infants with short stature (heights< -2DS) have been identified for exploration. Exploration included: a detailed medical history, nutritional inquiry, physical examination and successive tests, according to institutional delay or endocrine causes. The screening for stunting growth in 5 to 8 year old children would allow treatment resulting in a more effective, and improved height development.

Conclusions: The majority of short stature in our region is due to either constitutional delay or endocrine causes. The screening for stunting growth in 5 to 8 year old children would allow treatment resulting in a more effective, and improved height development.
PAO-236
Graves' disease management with antithyroid drug (ATD) therapy - retrospective analysis of 35 children
Paweł Matusik1; Martyna Lopataek1; Anna Gronna1; Agnieszka Bargiel ska1; Aleksandra Januszek-Tzcziakowska1; Ewa Malecka-Tendera1
1Medical University of Silesia, Department of Paediatrics, Endocrinology and Diabetes, Katowice, Poland; 2Medical University of Silesia, Scientific Society of Students, Katowice, Poland

Background: Graves' disease is the most common cause of thyrotoxicosis in children, which can have many negative effects on both physical and psychological development. Antithyroid drug (ATD) therapy is recommended as the initial treatment but still exist many controversies concerning optimal duration of ATD therapy.

Objective and hypotheses: The aim of our study was the retrospective evaluation of ATD therapy in children with Graves' disease.

Methods: The medical history of 35 children (29 girls) in mean age of GD diagnosis 12.1 years was analyzed. Total duration of treatment, time to initial remission, number of relapses, way of ATD therapy discontinuation and block and replace treatment were taken into consideration.

Results: Mean time of observation was 2.5 yrs (max. 5.83 yrs.). The initial hormonal remission was achieved in 30 (85.7%) children. Mean ATD therapy duration for hormonal remission was 4 months. Only in 14 (34.3%) discontinuation of ATD was possible and mean time free from ATD was 6 months. Mean number of relapses 2.42 was observed. In 34.3% of children ATD dose reduction was fast (by 50% during a weeks), 34.3% of children had prolong ATD low dose therapy (form 1.25 to 2.5 mg/d for several months), in 54.3% of children combination of L-thyroxine with ATD was used. No differences concerning time of initial remission, time and number of relapses depending on way of ATD dosage was found. 5 children from that group were qualified to radioiodine therapy.

Conclusions: ATD therapy in children is effective way to achieve initial clinical and hormonal remission in GD thyrotoxicosis but longer permanent remission (after ATD discontinuation) than 6 months is unusual. The late outcome of ATD therapy seems to have no relationship to way and duration of dosage.

PAO-238
Final height in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Suley Keiko Kohara1; Tatadzwa Masaya2; Paul Dimmr1; Neil Wright1; Jerry Wales2
1‘UNIVILLE’, Pediatrics, Joinville, Brazil; 2Sheffield Children's Hospital, Endocrinology, Sheffield, United Kingdom

Background: Achievement of optimal growth is one of the major problems in the management of children affected by congenital adrenal hyperplasia (CAH) due to 21-hydroxilase deficiency (21-OHD). The current literature reports that patients with classic CAH often do not achieve their target height (TH) and that they are obese. Glucocorticoid replacement is vital for preventing adrenal crisis and reducing androgen excess, but results in growth inhibition when administered in larger doses. If the androgens are not supressed, there is advancement of bone age with premature fusion of the epiphyses and ultimate short stature.

Aim: The aim of this study was to evaluate final height (FH) of patients with the classic form of 21-OHD and compare to TH.

Methods: We reviewed the growth charts of patients with CAH who had attained FH.

Results: We evaluated 14 patients who had attained FH. 7 salt-wasting (SW) and 7 simple virilizing (SV). Five patients were male. Mean age at onset of treatment was 2.6y. Target height was available in twelve patients and mean TH-SDS was -0.15±1.1. Mean FH-SDS was -0.58±1.24. Corrected FH (FH-SDS – TH-SDS) was -0.66. All the patients were treated with hydrocortisone. Two patients were overweight at FH. The last bone age done at a mean chronological age of 13 years were advanced more than 1 year in 6 patients.

Conclusions: We concluded that mean FH of our CAH patients was within normal range, but in 8 patients was below the genetic target, as reported in the literature. Only one patient was obese.

PAO-239
Response of C-peptide/ insulin during a mixed meal test in combination with repaglinide to identify the diabetes type and the option for oral treatment
Dieumud Simm1; Henk-Jan Veeze; Henk-Jan Aanstoot2
1Diabetology, National Center of Diabetes in Children and Young Adults, Diabetology, Rotterdam, Netherlands

Background: The aetiology and type of diabetes is not always clear in young diabetes patients. While clinical features, autoimmune antibodies (IC, GAD, IA2 and insulin) as well as molecular diagnostics for Mody 1 – 6 help to distinguish diabetes forms, a subgroup remains without a certain diagnosis.

Objective and hypotheses: For such cases we aimed to develop a method to evaluate β-cell function and subsequent options of treatment by repaglinide, a short acting insulin secretagogue (maximum plasma concentration within 0.5 – 1h, half life 1 h) which also stimulates early insulin secretion and is thus suitable to be combined with a β-cell provocation. A mixed meal test combined with incremental dosages of repaglinide was previously applied by Lawrence S. Coma et al. to show the effectiveness of the medication in type 2 diabetes.

Methods: Seven patients with unclear aetiology of diabetes and 1 healthy control person underwent after an overnight fasting period a MMMT with Sustacal 6 ml/kg (max.: 360 ml) ingested in combination with repaglinide 1 mg directly before the meal intake. Glucose, insulin and c-peptide were determined after fasting and 30, 60, 90, 120, 150 minutes after test start, i.e. repaglinide medication and start meal intake.

Results: In this pilot study we identified five patients who responded with sufficient insulin release to change medication from insulin to repaglinide.

Conclusions: We conclude that this test identifies individuals with repa-
Incidence and clinical characteristics of the new cases of type 1 diabetes in Galicia, Spain
Claudia Heredia1; Jesús Barreiro1; Aurora Pavón1; Pablo Lázaro2; José Luis Chamorro3; Pablo Fariña5; María Mercedes Rodicio4; Alicia Cepedano1; Maravilla Santos1; Inês Quintela2; Cordo Lourdes2; Paloma Cabanas5; María José Pita1; Marían Rodríguez1; 1Hospital of Santiago of Compostela, University of Santiago de Compostela, Unidad de Endocrinología Pediátrica, Creceimiento y Adolescencia, Santiago de Compostela, Spain; 2Hospital Provincial de Pontevedra, Pediatría, Pontevedra, Spain; 3Hospital Infantil Teresa Herrera, Pediatría, A Coruña, Spain; 4Hospital Xeral-Cies, Pediatría, Vigo, Spain; 5Hospital Cristal Piñor, Pediatría, Ourense, Spain; 6Hospital Da Costa, Pediatría, Burla, Spain; 7Hospital Xeral Calde, Pediatría, Lugo, Spain; 8Hospital Arquitecto Marcide, Pediatría, Ferrol, Spain; 9Hospital Virxe da Xunqueira, Pediatría, Cee, Spain; 10Hospital Comarcal Montforte, Pediatría, Monforte, Spain; 11Hospital del Barbanza, Pediatría, Riveira, Spain

Objective: Studying the epidemiology of childhood-onset type 1 diabetes (DM1) less than 15 years of age in hospitals of Galicia during the period 2001-2010.

Methods: We identify new cases with DM1 criteria diagnosed by a pediatrician in Galicia Autonomous Community from January 2001 to December 2010 and conducted a data collection protocol to hospitalization include age, prior to the debut diabetic symptoms, duration, associated autoimmune disease, family history and biochemical parameters at diagnosis.

Results: We identified 559 subjects with childhood-onset DM1 during 2001-2010 and distributed by sex: 44.3% females and 55.6% males. The annual incidence rate was 17.2/100,000/year (range: 15.0-19.4); younger than 5 years were 151 children (21.7% from 8 months to 4.9 years); 179 (32%) were 5-9.9 years and between 10-14.9 years were 224 patients (40.8%). Nineteen patients (3.3%) had celiac disease, 15 patients (2.68%) autoimmune thyroiditis (6 subjects hypothyroidism) and 72.7% of patients tested positive for at least one autoantibody (insulin autoantibody, GAD antibody or insulinoma-associated protein 2 (IA2). In relation to family history: 31 children have a first-degree relative with DM1 and 16 with DM2. The debut diabetic symptoms are shown in table 1.

<table>
<thead>
<tr>
<th>Insulin requirements (U/Kg/d)</th>
<th>Before change</th>
<th>After change</th>
<th>Mean of differences</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)</td>
<td>Before change</td>
<td>After change</td>
<td>Mean of differences</td>
<td>p 1st</td>
</tr>
<tr>
<td>0-4.9 years</td>
<td>11.2 ± 0.23</td>
<td>11.1 ± 0.27</td>
<td>-0.01 ± 0.19</td>
<td>NS</td>
</tr>
<tr>
<td>5-9.9 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-14.9 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusions: The incidence peak was found in the 10 to 14 years age-group and a third of the children was diagnosed with DKA. The 0-4.9 years group was diagnosed in less time and with lower values of HbA1c. The most common symptoms were polydipsia, polyuria and weight loss. The incidence remained stable over the 10 years.

Use of 70/30 premixed insulin in DM1 pediatric patients with a basal bolus regimen with multiple snacks
Marta Ferrer-Lozano; Mercedes Rodríguez-Rigual; Gracia M. Lou-Francés; Maria D. Cañas-Redondo; Jose I. Perales-Martínez; Sofia Congost-Marín
Children’s University Miguel Servet Hospital, Paediatric Diabetes and Endocrinology, Zaragoza, Spain

Background: Metabolic control is related with the number of short-acting analogs bolus administered, as we reported in a previous study [3 bolus (n=33) HbA1c: 8.54+/–0.8; And ≥4 bolus (n=73) HbA1c: 7.52+/–0.8; p<0.001]. In our country, children have 4-5 meals/d, with midmorning and midafternoon snacks. Some of them, especially adolescents, refuse to receive more bolus/d, and have snacks without insulin. In these patients a premixed 70/30 insulin at breakfast and/or lunch could better satisfy insulin requirements, improving glycemie profile and HbA1c.

Methods: 28 DM1 patients with a basal-bolus regimen, 3 short-acting analogs/d and poor metabolic control were proposed to change to 70/30 premixed insulin at breakfast and/or lunch. 21 patients were included.

Results: Mean age +/- DS: 15.14+/–2.49 years (range 9-17). Diabetes evolution: 9,5%, 19 pubertal (90,5%).

Disorder of sex development (DSD) is a congenital condition in which development of chromosomal, gonadal, or anatomic sex is atypical. The prevalence of DSD is about 1% among live births and about 0.1-0.2% present with marked genital ambiguity. In most developing countries, the exact incidence is not known. This is because some cases are missed at delivery, which is mainly by traditional birth attendants and amongst clinicians, poor awareness is a major challenge.

Objective and hypotheses: To analyze the characteristics of a regimen using a premixed insulin 70(aspartic)/30(NPH), related to insulin requirements (U/kg/d), time of the injection and its effect on metabolic control.

Methods: 28 DM1 patients with a basal-bolus regimen, 3 short-acting analogs/d and poor metabolic control were proposed to change to 70/30 premixed insulin at breakfast and/or lunch. 21 patients were included.

Results: Mean age +/- DS: 15.14+/–2.49 years (range 9-17). Diabetes evolution: 9,5%, 19 pubertal (90,5%).
Results: Of 62 children seen with various endocrine disorders during the study period, 4 (6.4%) had ambiguous external genitalia. Their ages at presentation ranged from 8days to 16 years. The commonest initial clinical diagnosis was congenital adrenal hyperplasia. Confirmatory diagnosis was not done in any of the patients due to financial constraint and non availability of facilities for performing the investigations in our centre. Three (75%) were lost to follow up while one patient died from chronic renal failure. Reasons for default were religious (2/50%), financial constraints in investigations (4/100%), lack of diagnostic tools (3/50%), and unwillingness to continue follow up (2/50%).

Conclusions: There is still delay in diagnosis of children with ambiguous external genitalia in our environment. Lack of diagnostic facilities, belief in spiritual attacks and high cost of confirmatory test have led to high rate of loss to follow up.

PAO-243
The TRH test identifies hypothalamic defects of the thyroid axis in children with euthyroid state
Ana de la Puente Arévalo1; Julio Guerrero-Fernández; R Mora1; Jose Maria Iturzaeta; R. Gómez; Antonio Buño; Maria Antonia Molina; Isabel González Casado; Ricardo Gracia Bouthelier; Jose Carlos Moreno1
1La Paz University Hospital, Pediatric Endocrinology, Madrid, Spain; 2La Paz University Hospital, Biochemistry and Clinical Analysis, Madrid, Spain; 3La Paz University Hospital, Molecular Thyroid Laboratory, ING EMM-Institute for Medical and Molecular Genetics, Madrid, Spain

Background: Congenital Central Hypothyroidism (CCH) has a prevalence of 1/16.000 neonates. 40% of cases are isolated pituitary or hypothalamic deficiencies. CCH is not screened for in Europe where TSH is mainly used as screening. Besides, it is not routine to discriminate between secondary or tertiary CCH using the TRH test. Pituitary CH is due to TSHB and TRHR genes mutations, while hypothalamic CH remains genetically "orphan". 

Objective and hypotheses: To test the discriminative capacity of the TRH test in the etiology of CCH.

Methods: After 7 µg/kg TRH, TSH and PRL were determined at -15, 0, 15, 30, 60, 120 and 180 min. and FreeT4 and TotalT3 at 0 and 180 min. We analyzed TSH peak, its return to basal levels and dynamics of TSH increase (ratios 15’/0’ and 30’/0’) and fall (ratios 30’/60’ and 180’/0’) upon Van Tijn. The test was performed in: 1. A 20 month old girl with postnatal progressive and severe growth retardation (-3.7 SD weight and height), hyperplagia and reduced TSH related to her FT4 (TSH 1.2 mU/L, FT4 0.92 ng/dl). 2. A 12 year old boy with hypothyremia-brachidactyly-sweating crises and sporadic hyperthyrotropinemias (TSH 5.4-8 mU/L) and 3. An 11 year old boy with high hyperthyropenia (TSH 9.82 mU/L) and hyperglycemia (109 mg/dl) (TRH defect suspect).

Results: Patients 1 and 2 had type 3 TSH response (hypothalamic defect) with 15’/0’ ratios of 23.8 and 9.1 (N<6.5) respectively, without return to basal TSH after 3 h. (180’/0’ ratios of 2.87 and 1.7). Patient 3 had type 0 response (thryroid defect) with 15’/0’ and 180’/0’ ratios of 4.6 and 0.8, respectively.

Conclusions: The 180 min. TRH test identifies hypothalamic defects of the thyroid axis even in the biochemically euthyroid state. Tertiary hypothyroidism can present as mild TSH elevation or as TSH decreases (even within normal values) relative to FT4 levels.

PAO-244
Type 1 diabetes mellitus in schools - monitoring of current practice
Cristina Matei1; Nadeem Abdullahi2
1Norfolk and Norwich Hospital, Paediatrics, Newmarket, United Kingdom; 2Addenbrooke’s hospital, Paediatrics, Cambridge, United Kingdom

Background: It has been shown that by improving diabetes control, the rate of complications later in life is reduced. In the recent years, there is more interest in multiple injection therapy and continuous subcutaneous infusions compared to the conventional twice daily regimes.

Objective: We wanted to establish the level of support in school for children and young people with diabetes in our area.

Methods: We prospectively collected questionnaires, anonimised from parents or patients attending paediatric diabetes outpatient clinics over 2 months period, (July-September 2010). Our questionnaires included: who does blood glucose testing?, what insulin regimes children are on?, who does the insulin injection in school? and the patient’s views about different aspects of education and understanding of school staff of diabetes.

Results: We had a total of 78 questionnaires completed and returned. Most children had insulin given in school (44 out of total 78) In the overall sample, most injections were done by the children or young people with supervision from school staff. Who does blood glucose test? 7 school staff 7 you/your child 7 your child 62 your child/school staff 3 Total 77 However, when we analysed the data by ages it appeared that in the young children (less than 8 years), all (7) had the insulin given by school staff (4) or parents (2).

Conclusions: We concluded that even in some schools there continues to be fear of managing diabetes. The main problem continues to be the administration of insulin in the young age group, who are most vulnerable group. However, insulin is only a part of the complex assistance children with diabetes need in school. We believe that our efforts should concentrate in improving schools’ understanding of diabetes and education in management of this condition.

PAO-245
Variation of the heart rhythm in children with type 1 diabetes mellitus-preliminary report
Aleksander Basiak; Julieta Nocen-Bohusz; Beata Wikiera; Anna Noczyńska
University of Medicine in Wroclaw, Endocrinology and Diabetology for Children and Adolescents, Wroclaw, Poland

Background: In very early stage of diabetes type 1, we may observed symptoms of autonomic neuropathy, which unfavorably effect on course of diabetes type 1. Especially sense have complications which are connected with heart-vascular system. In adults the complications may increase risk of death because of cardiac complications.

Aim: Early detection neuropathy in diabetes type 1 with different time of going the IDDM.

Methods: In both groups were done 24 Holter electrocardiography examination. Mean value of diabetes type 1 was 7.1+/−3.7 y and level of the Hba1c was 9.2%+/−2. We analyzed patients with good and bad compensation of diabetes type 1. We observed children 19 with diabetes type 1 (11 girl and 8 boys)-mean age 14,12+/−4,32 y. Control group was consist of 11 girls and 8 boys mean age 14,02+/−2,8 y.

Results: Mean value of all parameters of variation of the heart rhythm were lower than in healthy group and it was correlate with duration of diabetes type 1.

Conclusions: Indirect symptoms of diabetic autonomic neuropathy, which disturb adaptation of the heart rhythm, may observed in very early stage of diabetes type 1. Preliminary results indicate, that is necessary to do 24h electrocardiography examination in patients with diabetes type 1.
A case of short stature due to phosphatediabetes

Ekaterine Kvaratskeli1; Maia Rekhviashvili2; David Metreveli2; Medea Tsanava5; Rolf Peter Willig1
1Center for Endocrinology, Metabolism, Nutrition, Pediatric Endocrinology, Tbilisi, Georgia; 2Center for Endocrinology, Metabolism, Nutrition, Pediatric Endocrinology, Tbilisi, Georgia; 3Tbilisi State Medical University, Pediatric Nephrology, Tbilisi, Georgia; 4Endokrinologikum Hamburg, Pediatric Endocrinology, Hamburg, Germany

**Background:** Primary hypophosphatemic rickets is a rare disorder caused by inborn defect of renal tubular reabsorption and usually manifested in childhood and infancy with stunted growth and deformities of lower limbs.

**Objective and hypotheses:** The female patient from healthy parents, born without complications at term, normal weight and length. Psychomotor development until the age of 2 years was normal. Since the age of 2 years deformation of legs and difficulties with walking have been observed.

**Methods:** The patient was consulted by Pediatric Orthopedist, Nephrologists and Endocrinologist. The blood biochemical findings revealed normal pH, normal calcium (Ca2+), potassium (K+), sodium (Na+) concentrations, very low phosphate (P)- with markedly elevated alkaline phosphatase (AP)- and slightly elevated parathyroid hormone (PTH)-concentration; urine test indicated impaired tubular function: mild glucosuria, proteinuria, erythrocituria and markedly increased phosphaturia. Phosphate tubular reabsorption (PTR) was 52%, phosphate clearance/creatinine clearance 0.52, renal threshold phosphate concentration (TmP/GFR) 0.25mmol/l. Genetic tests results not available yet.

**Results:** The diagnosis of phosphate diabetes made on the basis of clinical-laboratory data. The therapy with Inorganic phosphate (100mg/kg/d) and 1,25(OH)2VitD 50-60ng/kg/d had been started. Childs walking abilities improved with treatment, the deformation of legs decreased, but O-legs and other skeletal deformations are still remarkable. Auxological parameters are not satisfactory. Physical growth is below the normal range (height SDS -3, 84); the patient’s predicted height less than target height. Biochemical monitoring performed regularly under the treatment, serum phosphate remains below normal, serum AP is still elevated.

**Conclusion:** This case is in line with other publications and indicates the difficulty to achieve normal phosphate levels and normal growth without an additional treatment with growth hormone.

PAO-247

Particularities of diabetes mellitus type 1 according to gender, date of birth, onset of disease and complications

Vira Yakovenko1; Galina Solovyova2
1Crimean State Medical University, Periatric Department, Simferopol, Ukraine; 2Ukrainian Children Specialized Hospital “OHMATDIT”, Endocrinology, Kyiv, Ukraine

**Background:** Diabetes Mellitus (DM) is one of the hardest diseases and is not only a medical, but social problem. DM takes the third place on mobility and mortality in developed countries. Children and adolescent make 8 to 10% of all patients with diabetes. One out of 500 children or one out of 200 adolescent has diabetes.

**Objective and hypotheses:** The aim of the study was to investigate particularities of DM1 according to gender, date of birth, onset of disease and complications.

**Methods:** 397 children from 0 to 18 years of age with diagnose DM1 were discovered according to standard medical protocols for this pathology.

**Results:**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Total %</th>
<th>Boys %</th>
<th>Girls %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic retinopathy</td>
<td>31.8</td>
<td>50.8</td>
<td>49.2</td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>34.6</td>
<td>46.7</td>
<td>53.3</td>
</tr>
<tr>
<td>Diabetic angiopathy of the lower extremities</td>
<td>14.4</td>
<td>49.1</td>
<td>50.9</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>27.0</td>
<td>51.4</td>
<td>48.6</td>
</tr>
<tr>
<td>Central neuropathy</td>
<td>2.0</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Chiaropathy</td>
<td>5.6</td>
<td>54.5</td>
<td>45.5</td>
</tr>
<tr>
<td>Mauriac syndrome</td>
<td>0.5</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

**Conclusions:** There is practically the same prevalence of onset of DM in all age groups among boys, with an increase in number of cases at 8 and 12 years of age in girls, and decrease at the age of 15 to 17 years. Children born in spring and summer months have higher risk of developing DM1. The onset of the DM1 usually occurs in autumn and winter months. Most commonly children develop nephropathy, retinopathy, and peripheral neuropathy, 1/3 of all patient would have these complications. Gender is not a risk factor for chronic complications’ development in DM1. Though girls seem to develop diabetic nephropathy more frequently than boys, but have lower risk of chiariotopathy and Mauriac syndrome.
tremors, and fluctuating mental status. Her thyroid function studies revealed a Free T3 of 747 pg/dl, Free T4 of 4.8 ng/dl, and TSH of <0.01 uu/ml. She was started on Methimazole, Propranolol, and Potassium Iodide for thyroid storm. Antibody testing revealed anti-TPO of 1355.5 iu/ml, anti-thyroglobulin of 291.8 iu/ml, and TSI of 335% baseline. She was diagnosed with Grave’s disease and continued treatment with Methimazole and Propranolol.

**Conclusions:** Graves’ disease accounts for 10-15% of all childhood thyroid disorders, with incidence ranging from 0.1-3.0 in 100,000 children. Approximately 1-2% of patients with hyperthyroidism progress to thyroid storm when physiologically stressed. To our knowledge cases of asymptomatic Grave’s disease with initial presentation of thyroid storm in pediatric patients are not commonly reported.

**Complication of subcutaneous fat necrosis of the newborn**

**Nazanin Hazhir; Robabeh Ghergherehchi**
Tabriz University of Medical Sciences, Students’ Research Committee, Tabriz, Islamic Republic of Iran

**Background:** Subcutaneous Fat Necrosis (SCFN) of the newborn is uncommon, self-limited disorder that occurs in full term infant who experienced a perinatal distress in the first weeks of life. It can be complicated by life threatening hypercalcemia and other rare complication such as hypoglycemia, thrombocytopenia, hypertriglyceridermia, anemia and fever. SCFN with hypercalcemia frequently has been reported.

**Methods:** We recorded risk factors concerning the mother, pregnancy and delivery, clinical aspects of SCFN and early and late outcomes.

**Results:** The child was born at term. Lesions appeared on the 22th day of life. Delivery was complicated by meconium aspiration. Complications were hypoglycemia, hypercalcemia, nephrocalcinosis, dyslipidemia, thrombocytopenia and fever.

**Conclusions:** Physicians caring for infants with subcutaneous fat necrosis of the newborn should be aware of the above associations in order to provide prompt and appropriate treatment to prevent associated, undesirable sequelae.

Figure 1: The erythematous subcutaneous nodular plaque on the middle of the back and arm.

**Nutritional status in PKU patients in Mazandaran province: is it acceptable or not?**

**Peiman Esragh1; Ali Abbaskhanian2; Sahar Taghavi3**
1Mashhad University of Medicine, Pediatric Endocrinology, Mashhad, Islamic Republic of Iran; 2Sari University of Medicine, Pediatric Neurology, Sari, Islamic Republic of Iran; 3University of Pharmacy, Biotechnology, Mashhad, Islamic Republic of Iran

**Background:** Phenylketonuria is one of the most frequent metabolic diseases which is transmitted as autosomal recessive pattern. Appropriate diet with restricted phenylalanine is the base of treatment, so special formulas and diet replace phenylalanine containing foods. Limited native studies exist about the results of such treatment means protein limitation and replacing an expensive and unavailable foods. This study was designed to evaluate nutritional status the calorie, protein, carbohydrate and fat of patients’ diet and iron storage and iron deficiency anemia in PKU patients.

**Objective and hypothesis:** This is a cross sectional study which evaluated all of the PKU patients in Mazandaran province during 2009-2010 in metabolic clinics in Babol and Sari. Nutritional status was evaluated according to 72 hours diet recall sheet which is the method for recording nutrients eaten within 3 days. Nutritional and demographic information was studied according to questionnaire and blood sampling results and iron deficiency anemia.

**Results:** Twenty one PKU patients were studied which 7 ones (33.3%) were female and 14 ones (66.7%) were male with mean age of 7.26±6.64 years. Iron deficiency and iron deficiency anemia was present in respectively in 10 (47.1%) and 6 patients (28.6%). Five patients (23.8%) were underweight and 4 patients (19%) were short stature.

**Conclusion:** Energy, protein, carbohydrate, fat and iron deficiency was significant in patients; According to the price of special foods in our country, families cannot prepare enough foods. So, attention to nutritional demands in PKU patients to reduce malnutrition and iron deficiency is critical.